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Abstract

In this project, the aim was to achieve two important objectives and solve some challenges that
the pharmaceutical industry is facing. It will be shown that the NRTL-SAC (Non-random Two
Liquid Segment Activity Coefficient) model can best predict the solubility of different
pharmaceutical and chemical components in pure and mixed solvents by comparing the results
with the well-known model of the UNIFAC. The four parameters that are used in the NRTLSAC model will be found through nonlinear parameter estimation technique. This project also
covers the VLE, LLE, and VLLE phase behaviour calculations using the mentioned models to
verify their applicability in industries that use solvents as their main process materials (such as
pharmaceutical processes). It will be explained that the NRTL-SAC model is efficient and less
complex than the UNIFAC model when dealing with multi-component systems of solvents. The
solvent screening process is then modeled using a novel method of modeling and optimization
which resulted in a significant change in the objective functions from single to binary solvent
combinations. The proposed method shows the efficient selection of single, binary, and ternary
solvent systems with the optimal crystallization operating conditions to achieve the desired
objectives. However, the change from binary to ternary system of solvents did not have a
significant effect on the performance functions. The study on the crystallization process of a
polymorphic transformation phenomenon is another part of the project which was modeled and
optimized. The novel method of modeling for polymorphic transformation of L-glutamic acid
enabled us to develop an optimal control strategy of the system consisting of a variety of process
conditions (such as seeded and un-seeded crystallization). The outcome of this part of the project
gives a detailed understanding of polymorphic transformation systems with optimal conditions
that can be implemented for such processes. Finally some useful experimental work that has
been done in the area of nucleation and polymorphic transformation of L-glutamic acid using a
powerful spectroscopic probe (Lasentec FBRM) will be explained. The nucleation detection and
the change from metastable polymorph to the stable one can be performed using the in-situ
FBRM which was used in this project.
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Chapter 1

Introduction

1

This chapter provides a brief overview of the materials that will be discussed in detail in the
next chapters of this thesis. In this chapter, the project subject with its explanation is first
demonstrated briefly and then, the main challenges that the industry is dealing with will be
mentioned. The questions that were raised in this field directed us in performing different
sections of the project. The objective(s) that will be addressed in each chapter with a brief
description of the methods and procedures are discussed in subsequent paragraphs.
One of the main unit operations in the chemical industry, especially in the pharmaceutical
industry is the crystallization. In the pharmaceutical and chemical industry, the development of a
drug or chemical compound with desirable characteristics is of prime significance. In achieving
this objective, the choice of a proper solvent for crystallization, operating condition, and design
parameters is very important to lead to better separation and purification, lower cost, and better
product quality. The solids that are produced in a crystallization unit will affect the downstream
unit processes, such as filtration and drying [1]. Solution crystallization is widely used in
chemical and pharmaceutical industry during final and intermediate parts of purification and
separation processes [2]. The chemical synthesis of a drug molecule often involves several
synthetic steps in series and each step contains many unit operations. Each unit which is involved
in the production of a specific pharmaceutical product has some challenges regarding the method
of operation to reach to the optimal performance in production. A schematic diagram of a general
pharmaceutical process for a solid active pharmaceutical ingredient (API) synthesis and
development to the final product is shown in Figure 1-1.
In the current project, we will focus on the product development and the crystallization
process. These two stages of drug production have significant effect on the performance of other
unit operations downstream of the crystallization process. In developing a specific
pharmaceutical product, there are many issues that the researchers have to deal with. Some
examples include the physico-chemical properties of the potential component under study, such
as potency, solubility, pKa, lipophilicity, metabolic stability, absorption, etc [2]. The drug
candidate should have the best characteristic in terms of the mentioned properties. Traditionally,
the task of selection of the potential component that has all the desirable properties was timeintensive and very expensive.

2

Figure 1-1. Schematic diagram of typical processes that involved in the pharmaceutical
manufacturing
Since the amount of the component under study at early stages of the development is low and
often expensive, the researchers had to manage the experimental work so as to minimize the loss,
and therefore, a few data could be found. This problem is more significant when the solubility of
the candidate drug has to be examined in several solvents and their mixtures [3]. Several
pharmaceutical companies have implemented high-throughput screening to profile compounds in
terms of properties such as solubility [4]. Although this method is helpful in identification of the
early failures in development without spending resources on clinical trials, it needs proper
amount of solvent(s) and pharmaceutical components, which is often expensive. The mentioned
reasons directed us to build a comprehensive algorithm which can overcome those problems in
an efficient and accurate way. The following are the main questions that need to be addressed in
the synthesis and development of a pharmaceutical product:
1. How to predict the solubility of a chemical or pharmaceutical in pure and mixed
solvent(s) at different operating temperatures and solvent compositions?
3

2. What solvent or mixture of solvents will result in a favorable operation of crystallization
of a given chemical component?
3. How to comprehensively model a solvent screening process for a specific pharmaceutical
component?
4. Which conditions (temperature and solvent composition) can optimize the production of
an API?
5. What thermodynamic model(s) to pick to investigate all the possible behaviors affecting
the process, such as the vapor-liquid (VLE), liquid-liquid (LLE), and solid-liquid
equilibrium (SLE)?
Chapters 2-4 cover all the details about the above questions.
As it is mentioned before, measuring physical properties of the new discovered drugs is timeconsuming and expensive. Therefore, the need to have a reliable and accurate method of finding
the solubility of pharmaceutical compounds in solvents or solvent mixtures is beneficial. This
subject is completely discussed and addressed in chapter 2. The method that is picked for
modeling the solubility should have the least dependency on experimental data and provide
accurate predictions. As a result, applying different predictive thermodynamic models and
comparing them to find which method can result in accurate solubility prediction is desirable.
The outcome of this part of the project can help the researchers in the pharmaceutical industry
and more generally, in the particulate and fine chemical industry, to understand the behaviour of
the solids in suspensions and their solubility in different pure and mixed solvents. The
bioavailability of a pharmaceutical compound depends heavily on its solubility and dissolution
rate in the blood stream. Having an accurate predictive model describing these properties, results
in less dependency on the process measurement, saves time, and cost. In order to address this
objective, we applied the predictive methods of the UNIFAC and a recent developed model, the
NRTL-SAC, to predict the phase behaviour of solid-liquid, vapor-liquid, liquid-liquid systems,
and solubility prediction of different pharmaceuticals. Three model compounds were selected to
study and experiments were performed to characterize and measure the solubility of the
compounds in different pure and mixed solvents. The measured data and predicted values are
compared using two predictive models.

4

The process of selecting the right solvent combination for a crystallization process is
referred to as solvent screening. Normally, the solvent screening is done with high-throughput
experiments at different operating conditions. This process is very time-intensive and costly.
Having the knowledge of the phase behaviour of different solvent compositions helps one to
select the proper operating conditions for the best production performance. If the operating
temperature for the crystallization process is out of the safe range (i.e., the starting crystallization
temperature exceeds the solute’s melting point or solvent mixture’s bubble point temperature),
there will be a failure in the process operation that leads to loss of valuable products and time. As
a result, prior to designing an optimized process for production of a pharmaceutical, we have to
ensure that the operating conditions will meet the safe and reliable behaviour of the production
unit. Chapter 3 discusses the phase behaviour of different solvents that are used in
pharmaceutical industries. The equilibrium condition of a variety of binary, ternary, and
quaternary combinations of solvents at various operating conditions (pressure and temperature)
will be modeled and verified. The use of a powerful method to predict different solvent
compositions within a desirable accuracy is not only helpful to the pharmaceutical industry, but
also to other common chemical processes. We developed a preliminary software program to
model the phase behaviour of the solvent combinations using the new robust model of NRTLSAC.
After finding the best operating conditions for each combination of solvents, the production
rate of the crystallization process has to be calculated. By comparing the production rates at
different combinations of solvents, one can pick a solvent or a solvent mixture which results in
the maximum production rate. It should be noted that in addition to the production rate, other
important objective functions can be studied (e.g., the minimum mass of solvent usage). At this
stage of process design, a non-linear programming should be used in which the linear and nonlinear constraints are included. The nonlinear constraint originates from the phase equilibrium
calculations. It is worth noting that the crystallization process in general, can be run by three
methods: cooling, antisolvent addition, and evaporation, or a combination thereof. For the
current study, we examined the case of cooling and antisolvent crystallization process,
simultaneously. An optimization procedure was developed to examine all the possible
combinations of cooling and antisolvent crystallization based on different objective functions.
The procedure used to obtain the optimal process conditions is discussed in chapter 4. The
5

outcome of the proposed method in chapter 4 is helpful for preliminary studies of solvent
screening in picking the optimum solvent combination and also, finding the best operating
conditions of the process. It should be noted that the proposed algorithm is capable of handling
other related processes that are involved in the production of a chemical compound from solvent
mixture (such as reactive or extractive distillation).
After the drug is selected as a potential candidate for production in large scale, the necessary
processes for manufacturing the component have to be designed. The competition in the
pharmaceutical industry and on the other hand, the increase in demand by the society, has made
the industry focusing more on the efficiency of the manufacturing units [5]. The process
modeling and simulation is a powerful means to facilitate the task of moving from synthesizing
to large-scale manufacturing of a component. The solid form of a drug can have different
physical properties in terms of its crystalline shape. The most preferred crystalline shape is the
one which is thermodynamically stable. However, the stable form of the component may show
poor solubility and dissolution rate in the human body. The solubility and absorbance of a drug
in the body are the main parameters for the selection a suitable form (polymorph) of a
pharmaceutical component. In this case, other forms of that component (less stable forms) may
be selected for synthesis and development [6]. The separation of the crystals of different
polymorphic forms of a drug is a great challenge in industry [7]. Most of the studies in the field
of polymorphic crystallization are qualitative descriptions. The complexity of the quantitative
study of this process comes from the presence of different phenomena such as thermodynamics,
kinetics, reactor dynamics, and population balances [7-11]. This issue is more difficult to study
when other related phenomena such as agglomeration and breakage of the particles are also
present. The study on the dynamics and process modeling of polymorphic crystallization systems
has recently started and thus, there is a wide range of unsolved problems in this field. Therefore,
we investigated the polymorphic processes, their comprehensive modeling, and dynamic
optimization of such processes. The followings are the main questions that can be raised to be
addressed in this area of study:
1. Which method can be used to model a polymorphic crystallization process?
2. How to reduce the time of computation for modeling polymorphic transformation
processes?
6

3. How to minimize or maximize the production of a specific polymorph?
4. How to generate the particle size distribution of different polymorphs during and at the
end of a batch crystallization process?
5. How to implement the dynamic optimization procedure to model a polymorphic
transformation

process

in

different

conditions

(comprehensive

modeling

and

optimization)?
To answer all the above concerns, one needs to know the fundamentals of crystallization and
different effective parameters that influence the process performance. For example, the method
of implementing the cooling rate has to be studied to achieve the desirable product with optimum
crystal size distribution. Most of the newly discovered pharmaceuticals show different crystalline
forms in solid state that is called polymorphism. Depending on a method which is implemented
on the process, the product can have a mixture of polymorphs or just one form. From all of the
possible crystalline forms of a pharmaceutical component, a very few (in most cases one) of
those are bioavailable. Different polymorphs of a pharmaceutical component have different
properties in dissolving and absorbing by the body. It is important for the pharmaceutical
industry to produce as much desirable and bioavailable drug as possible to gain the highest
benefit. Chapter 5 discusses the conventional and optimal cooling profiles which can maximize
some objective functions that are currently used in industry for achieving the desirable product.
The polymorphic transformation process is studied in this chapter. The model component which
we studied was L-glutamic acid that has stable and metastable forms. A comprehensive modeling
of the process can be used effectively by the particulate industry that are facing complex
polymorphic systems and want to find the dynamic operating conditions that lead to their
desirable objectives [8, 11]. It will be shown that a method of moments (MoM) that is used for
performing the population and moments of particles cannot be applied for generation of particle
size distribution (PSD). In addition to the production rate of each polymorph and final average
size of the product, the size distribution of the particles that are produced at the end of the batch
is important. This will be more significant when designing filtration and particle transportation
systems since they are dependent on the size distribution of the solids that are processed. The
conventional method of generating PSD is the method of classes (MoC) which has been used to
model crystallization systems containing only one form of crystal. The main disadvantage of this
method is its time-demanding calculation. In our study, we have combined the method of classes
7

(MoC) with the method of moments (MoM) to: 1) reduce the CPU time and 2) generate PSD of
both stable and metastable polymorphs during the crystallization process. Although, there are a
few other methods for calculating PSD from the population balance equation (such as finite
element method), they are difficult to model. Our new proposed method (MoMC) generates the
PSD in a few seconds with the same accuracy of other methods . The mentioned method of
MoMC and all the related materials will be discussed in chapter 5. The outcome of chapter 5 can
be used effectively by the research centers of industries to study the effect of different
parameters in the size distribution of the polymorphs. The proposed MoMC method can also be
effectively used in real-time control of polymorphic transformation systems where the size
distribution has to be adjusted within a specified range.
We also have done several experiments to monitor the nucleation and polymorphic
transformation behaviour of L-glutamic acid with different cooling rates. The nucleation
behaviour of L-glutamic acid with different cooling and agitation rates will be discussed in
chapter 6. The development of the new methods of monitoring the crystal size distribution such
as Focused Beam Reflectance Method (FBRM) has made the online control of crystallization
systems more easily than before. At first, the use of FBRM probe in monitoring the onset of
nucleation is shown. Then, it is used for detecting the cloud and saturated points corresponding
to different solution concentrations. The automated method for doing such experiment will be
explained in chapter 6. Next, the FBRM technology will be incorporated in detecting the
polymorphic transformation of L-glutamic acid from its metastable form to stable during the
course of crystallization. The FRBM can qualitatively show the time and the size distribution of
polymorphic transformation of the particles. Finally, the use of XRPD as another tool for
polymorph detection in offline mode will be presented.
1.1. Project Outline
The project outline in schematic flowchart is shown in Figure 1-2. Based on this flowchart,
the whole project is divided into two phases: 1) development phase, in which the pharmaceutical
is discovered and developed and 2) production phase, in which the pharmaceutical component is
manufactured using different chemical and physical processes. In order to answer the previous
mentioned questions, we picked predictive thermodynamic models to verify their capability in
generating accurate and reliable data to be used for drug development. The most important part
8

of the pharmaceutical development is the solvent screening process. This is best studied and
modeled in our work. In order to get the comprehensive view of the solvent screening proess, we
needed to ensure the solvet(s) are operated within the safe and reliable process conditions.
Therefore, different phase behaviors of the solven(s) with the solids, such as VLE and VLLE
were studied in the development phase.
In the development phase, the polymorphic transformation of complex components using the
current and the novel method (which was developed in our work), were done. As most of the
pharmaceutical processes are performed in batch operation, the dynamic optimization procedure
was used to achieve two different important objectives.
The conclusion and future works of the stated projects will be discussed in chapter 7. The
program codes that were developed in Matlab environment are listed in the Appendix.

9

Figure 1-2. Project summary with the brief title of each section
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Chapter 2

Solubility Measurement and Prediction of Pharmaceutical and
Chemical Compounds in Pure and Mixed Solvents

A version of this chapter has been published as:
Ehsan Sheikholeslamzadeh and Sohrab Rohani “Solubility Prediction of Pharmaceutical and
Chemical Compounds in Pure and Mixed Solvents Using Predictive Models” Ind. Eng. Chem.
Res. 2011, 51, 464-473.
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2.1. Introduction
One of the main properties of the polymorphic compounds is their solubility difference in
solvents and solvent mixtures. With this important property, different polymorphs of a drug can
be separated by crystallization. In the synthesis of pharmaceuticals, there are many unit
operations and factors which affect the overall performance of the unit, such as the solvent
selection, operating temperature and supersaturation [1]. Empirical selection of solvents requires
extensive experimentation and high cost [2]. The predictive thermodynamic models can be a
good choice in estimation of the phase behaviour and solubility of drugs in different solvents and
solvent mixtures [3]. There have been many thermodynamic models for the prediction of the
phase behaviour of vapour-liquid and liquid-liquid systems, such as the Margules equation [4],
the Wilson equation [5], the Van Laar equation [6], the NRTL equation [7], and the UNIQUAC
equation [8]. These models can also be used for solid-liquid equilibrium behaviour. Generally,
the equations of activity coefficient for solubility prediction can be divided into the two
categories:
1. The correlative models, which require many experimental data at different conditions. In
some cases the data on ternary mixtures are also needed, such as for Wilson’s equation [5].
2. The group-contribution and predictive models, which only require the chemical structure of
the molecule and/or a few experimental data points to predict the phase behavior of the solid
in different solvents, such as the UNIFAC and NRTL-SAC models.
From the two above categories, the first one is not very useful for solubility prediction and
solvent screening purposes [1]. The main reason for this is the lack of experimental data for the
binary interaction parameters of the solute-solvent, solute-antisolvent, and solvent-antisolvent
systems. As an example, the activity coefficient from the Wilson’s equation of state is found
from [5]:
lnγ
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Where i and j refer to the compounds present in the solution. From the equation (2-1) it can be
interaction parameters (Λ# , Λ# , Λ and Λ##  which are temperature dependent. In addition,

seen that for obtaining the activity coefficient of a component 1 in a pure solvent 2, we need four

from equation (2-2) it is evident that for calculating the value of the binary interaction
parameters, additional experimental data, such as molar volume is needed. Other models which
belong to the first category have the same limitations as Wilson’s method. Matsuda et al. [9]
used the Wilson’s model to predict the solubility of Salicylic acid, Benzocaine, Acetanilide,
Phenacetin in water mixed with different co-solvents. They referred to several literatures in order
to get the parameters for Wilson’s equation. For pure parameters they used the Tassios method
[10] followed by using DECHEMA VLE collection [11]. In addition, they had to consider some
assumptions which led to some errors in prediction (i.e., they used the simplified method to find
the interaction parameters, or the molar volumes were estimated using the group contribution
method) which led to some errors in prediction.
From the second category, the universal functional activity coefficient (UNIFAC) model is one
of the well-developed ones. This model is basically used for prediction of the phase behaviour of
non-electrolytic and non-ideal systems. This model was first introduced by Fredenslund et al. in
1975 [12]. They used the UNIFAC model to predict the solubility of Naphthalene, Anthracene
and Phenanthrene in various solvents and their mixtures. They showed the applicability of the
UNIFAC model in prediction of the phase behaviour of solutes in solvents. After that some
modifications have been made on the original form of the UNIFAC model in order to make the
prediction better [13]. Sheikhzadeh et al. [14] used the UNIFAC and its modified form in
predicting the solubility of the two forms of Buspirone-hydrochloride in isopropanol and its
mixture with water. They concluded that the modified UNIFAC forms are not suitable for
prediction of highly soluble drugs. Gracin and coworkers [15] studied the solubility of a wide
variety of chemical compounds in water and some organic solvents. Although they obtained
some reasonable predictions for a few chemicals, but the model was not proper for solvent
screening purposes. They used some known group parameters in UNIFAC method for complex
and unknown groups. In addition, because of the dependency of the property of some functional
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groups on the rest of the molecule, they concluded that the UNIFAC was not a suitable method
for crystallization process design and solvent screening. Kan et al. [16] used the UNIFAC
method for solubility prediction of some compounds from alkanes, alkyl benzenes, alkenes, and
benzenes. The solubility of 11 out of 14 compounds was best predicted by UNIFAC model in
their study. The chlorinated alkenes, phthalates, and long-chain alkanes were not predicted well.
The NRTL-SAC model was first introduced by Chen et al. [17] in 2004. This model was
proposed in order to compensate the weakness of the UNIFAC in predicting the solubility of
complex chemical molecules with functional groups that had not been studied for the UNIFAC
parameters. Also, in some cases the UNIFAC group addition rule becomes invalid [18]. One of
the main advantages of NRTL-SAC model in comparison to the other predictive methods is its
ability to predict organic electrolyte systems [17]. The UNIFAC method identifies the molecule
in terms of its functional groups, while the NRTL-SAC model divides the whole surface of the
molecule to four segments. Each compound can have three conceptual segments [17],
hydrophobic, hydrophilic, and polar with four segment numbers. Hydrophobic segment (X)
accounts for the molecular surfaces that do not tend to form a hydrogen bond, such as hexane.
The polar segment (Y- and Y+) does not belong to the hydrophobic nor hydrophilic segment.
The polar attractive segment (Y-) shows attractive interaction with hydrophilic segment, while
the polar repulsive segment (Y+) has repulsive characteristic with hydrophilic segment.
Hydrophilic segment (Z) contributes to the part of the molecule which tends to form a hydrogen
bond, such as water.
The four segments are identified in terms of the interactions between the molecules in the
solution which is expressed in the phase equilibrium experimental data. Chen et al. [17] selected
water as a reference for hydrophilic segment, acetonitrile as a reference for polar segment, and
hexane as a reference for hydrophobic segment.
In order to predict the solubility of a chemical in a solvent or a mixture of solvents, one should
know the segment numbers for solute and solvent(s). Chen et al. has studied extensive data of
liquid-liquid equilibrium (LLE) and vapor-liquid equilibrium (VLE) for many solvents. Based
on the reference solvents (water, acetonitrile, and hexane), they found the optimized values of
segment numbers for other common solvents. Many solvents have only one or two segment
numbers that are significant compared to the other segment numbers. Up to now, there are 62
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common solvents which their segment numbers have been adjusted and tabulated for calculation
of the phase behaviour [17].
2.2. Thermodynamic theory and modeling
For a solid in equilibrium with itself in a solution, there is a thermodynamic relation [18]:

f( T, P, x+ 

)
f( T, P

2

3


)
Where f( T, P denotes fugacity of component i in solid phase and f( T, P, x+  represents the

fugacity in the liquid phase. The procedure to get the equation (2-5) from fundamental relations
of thermodynamics is explained.
With plugging in the proper definitions in equation (2-3), we get:
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Where f ) and f  are the fugacity of pure component i in solid and liquid states, respectively. In
order to find the ratio of the two fugacities, we need to include all the thermodynamic processes
that are needed to start from solid and reach to the liquid state. The three processes are shown in
Figure (2-14). Path A in this Figure shows the changing from process conditions to the state
where the solid starts melting. Path B shows the melting process at constant temperature and
pressure. Path C indicates the change of conditions from melting to the process state. The sum of
the three paths will give us the whole change from solid to liquid state of a pure component.
From the fundamental rules in thermodynamics, we have:
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And the Gibbs energy change is related to change of enthalpy and entropy:
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Figure 2-1. Schematic diagram for finding the fugacity change from solid to liquid state of a
pure substance
From Figure (2-1), the whole change in enthalpy is found from:
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If we neglect the terms including change in the heat capacity (because of the large value of heat
of fusion compared to the heat capacities), then we will get to the equation (2-5).
After some mathematical calculations we get to the following equation:
f 
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Where f  and f ) are the pure fugacities of the liquid and solid state of the component i and ∆CQ

is the heat capacity change during the phase transition from solid to liquid. With applying the
side of equation (2-4) can be neglected, because of the magnitude of ∆CQ compared to ∆H@A) , and
two assumptions the equation (2-4) can be further simplified: (1) the second term in the right-

(2) The triple-point temperature, Tt, can be substituted by melting-point temperature, Tm, at

regular pressures. After considering the two assumptions, the equation (2-4) will be simplified:
lnx)
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Where the index s refers to the solid phase, ∆H@A) is the heat of fusion, and TU is the melting

point. Equation (2-11) is used in prediction of the solubility of a solid in a solvent. For an ideal
solution, γ)

1 and therefore, the Van’t-Hoff equation will be derived. To predict the solubility

of a real solution, we need the physical properties of the solid (∆H@A) and TU that can be obtained
using thermal methods, such as DSC and TGA) and a proper model describing γ) .

2.2.1. Universal Functional Activity Coefficient model (UNIFAC)
The group-contribution models divide the contribution of the activity coefficient to two parts:
•

Combinatorial part. This part includes the contribution of the chemical structure and the
size (volume and surface of the molecule) of the compound.

•

Residual part. This part includes the contribution of the group size and binary interaction
between pairs of the functional groups.

With the above definition, the total activity of a component in the solution is the sum of the two
parts:
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In which γ is the activity coefficient of component i in the solution, γ 9 is the combinatorial part

and γ V is the residual part. Up to this point all of the group contribution and activity coefficient

methods (i.e. NRTL-SAC) are the same, but the method in which the activities are calculated is
different. In the UNIFAC model the combinatorial part for the component i is found from the
following equation [12]:
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z is the coordination number and is taken to be 10. In equation (2-13), ]+ is the segment fraction
and ^+ is the area fraction of component i and is related to the mole fraction of the species i in the
mixture:
X
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qi and ri are the pure component surface area and volumes (Van der Waals), respectively. These
parameters are not temperature dependent and are only functions of chemical structure of a
functional group. In the UNIFAC model for every functional group there is a unique value for
surface area and volume that can be found in common texts and handbooks [18]. The first step in
modeling the UNIFAC for a specific binary or ternary system is to break down the chemical
structure of a molecule into the basic functional groups. As it is suggested in thermodynamic
textbooks [19], the optimum way of breaking down is the one which results in the minimum
number of sub-groups with each sub-group having the maximum replicates. The qi and ri can be
found from equations (2-17 and 2-18):
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v  is the number of sub-group k in component i. The residual part of the UNIFAC is found from
the below equation:
lnγ V
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In equation (2-19) Γ is the residual activity coefficient of sub-group k in the mixture and Γ  is

that value in a pure solution of the component i. This term is added so when the mole fraction
approaches unity, the term lnγ V tends to zero (γ V 1 1). The residual activity coefficient of sub-

group k in a solution is given by:
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Equation (2-19) is also applicable to the case of Γ  , in which the parameters of the right-hand
side of the equation are written based on the pure component i. ^d is the area fraction of the

functional group m in the mixture:
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XU is the mole fraction of sub-group m in the mixture. ψU is the group interaction parameter

between groups n and m and is dependent on the temperature:
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The group interaction parameter ijd is found from the large sets of VLE and LLE data in the

literature which are tabulated for many sub-groups. It is worth noting that aU k aU . There are
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some modifications to the original UNIFAC equation in order to make the model robust for some
complex systems. In the UNIFAC-DM method, the modification is made on the combinatorial
part:
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is defined as:
2

24

The algorithm for finding the solute solubility in the mixture of ternary solution (solvent/cosolvent/solute) is shown in Figure 2-2. The algorithm starts with known values, such as the
physical properties of the solute. After making an initial guess for the solubility, the program
obtains the activity coefficients and the new solubility is found and is compared with the old
value and the calculations are repeated to converge to a unique value for solubility. This
procedure is done for all of the experimental data points.

21

Figure 2-2. The algorithm of converging to the solubility of a ternary system using UNIFAC
model
2.2.2. Non-random Two-liquid Segment Activity Coefficient (NRTL-SAC)
According to Chen et al. [17], the NRTL-SAC model is based on the derivation of the original
NRTL model for polymers. From equation (2-6) the activity coefficient is made up of two terms,
combinatorial and residual. Like the UNIFAC model, the activity coefficients must be generated
in order to obtain the solubility. In the NRTL-SAC model, the combinatorial part is calculated by
equation (2-19):
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Where xi is the mole fraction of component i, rm,i is the number of segment m, ri is the total
segment number in component i (r1 refers to the value of X, r2 refers to Y-, r3 refers to Y+, and r4
refers to Z), and q is the segment mole fraction in the mixture. The residual term is defined as:
lnγ V
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In equation (2-28) there are two terms, lnΓU >W and lnΓU >W, which are the activity coefficients of
segment m in solution and component i, respectively.

The two mentioned terms are found using the equations (2-29 and 2-30):
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∑ x G,U

U′

∑ x,> G,U τ,U

∑ x,> G,U

∑ x G,U′ τ,U′

xU′ GU,U′
rτ ′
∑ x G,U′ U,U

U′

xU′ ,> GU,U′
rτ ′
∑ x,> G,U′ U,U

∑ x G,U′

s

∑ x,> G,U′ τ,U′
∑ x,> G,U′

2
s
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2
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In the two above equations l refers to component and j, k, m, and t′ refer to the segments in each

component. xj,l is the segment-based mole fraction of segment species j in component l only. The

mole fractions of segments in the whole solution and in components are defined as below:
x

x,>

∑> x> r,>
∑ ∑ x r,
r,>
∑ r,>

2

2
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G, and τ, are the local binary values which can be related to each other based on NRTL non-

random parameter α , and are shown by their values in Table 2-1. G, and τ, have the

following relation:
G,

euαJ,vτJ,v

2
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Therefore, from fixed values of τ, and α, one can find G,. The segment numbers for the

common solvents can be found from the literature [20]. After putting the values of segments for

solvents and initial guess values for the solute segments, the written code for NRTL-SAC starts
solving for the mole fractions at saturation for all of the species in the solution (see Figure 2-3).

Figure 2-3. Algorithm flowchart for parameter estimation using NRTL-SAC model
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The only thing here which is different from the UNIFAC model is the parameter estimation loop.
This part of the model (which has a separate Matlab code) uses a few experimental data in order
to fit the model output to the experimental data. After optimizing the process and finding the four
segment numbers for the solute (which were unknown initially), the values can be set for that
compound and be used for further predictions. For the NRTL-SAC models, we used the
lsqnonlin routine of the Maltab software which is suitable for solving the nonlinear least-squares
problems. The algorithm for solving the least-squares is based on interior-reflective Newton
method [21]. After finding the adjustable parameters for the selected solutes, we used the model
equation to predict the solubility of the compound in pure/mixed solvents. For UNIFAC model
there is no need to find the adjustable parameters. The average relative deviation (ARD) for the
whole data is calculated for each case in order to find which model best describes the system:
ARD

1
N



z

x U=?{> x {m<
z
x {m<

2
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Where N is the total number of data points. The dependency of the binary parameters in the
NRTL-SAC model for the segments to temperature is ignored. The values of the binary
interactions for the segments are shown in Table 2-1.
Table 2-1. NRTL binary interaction constants for conceptual segments
Segment (1)

X

X

Y-

Y+

X

Segment (2)

Y-

Z

Z

Z

Y+

1.643

6.547

-2.000

2.000

1.643

1.834

10.949

1.787

1.787

1.834

0.2

0.2

0.3

0.3

0.2

α#

τ#

τ#

α#

For binary parameters between the two segments, Chen et al. [17] did the following:
1. For binary interaction between hydrophobic (X) and hydrophilic (Z), they used the
experimental data of LLE for hexane-water system. The values of both parameters are high,
stating the strong repulsive nature of the two segments.
2. The values for binary segment interaction between hydrophobic (X) and polar (Y) segments
were determined from LLE data of the hexane-acetonitrile mixture.
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3. The binary interaction between polar (Y) and hydrophilic (Z) segments were found from the
vapour-liquid equilibrium (VLE) data available in the literature for acetonitrile-water system.
4. The value of α for the liquid-liquid mixtures was set to 0.2 and for vapour-liquid mixtures
was set to 0.3.
5. The interaction between polar attractive (Y-) and polar repulsive (Y+) segments in the
mixture was assumed to be ideal and the binary interactions were set to zero.
2.3. Materials and methods
2.3.1. Model compounds
The model compounds for our study are: 3-pentadecylphenol [22], lovastatin [23, 24] and
valsartan [25, 26]. 3-Pentadecylphenol with the chemical formula of C21H36O, and molecular
weight of 304.51 is the product of catalytic hydrogenation of cardanol. Its main usage is in
agriculture industry as an emulsifier and coating material. The chemical structure of this
compound is shown in Figure 2-4. It has a phenolic head and a linear alkyne group. Because of
having a long hydrocarbon chain, and near straight shape of the molecule, one can consider the
molecule as if it does not have a benzene ring. This assumption can be reasonable because the
benzene ring has a non-polar characteristic and has a minor effect on non-ideality of the solution.
The dimensions are shown in Figure 2-4. The sizes of bonds are calculated form ChemDoodle
software, version 3.3.1. From this Figure, the length of the hydrocarbon chain is about 29.53 

and that of the benzene-ring is 4.73 . This means that about 16% of the volume of the molecule

is occupied by the benzene-ring, which is non-polar and the other part of molecule is mostly the
alkyl chain.

Figure 2-4. The chemical structure of 3-pentadecylphenol in compact form (right) and the length
of bonds in Angstrom () (left)
The solubility of this compound was studied in six pure solvents, ethanol, 1-butanol, toluene,
acetone, tetrachloromethane, and ethyl acetate [22]. The authors used a laser detector in order to
26

find the point of saturation. In the study by Mao et al. [22] they used the Wilson’s equation to get
the adjustable parameters for every solute-solvent system. They did not do any prediction of the
solubility, but only fitted the experimental data to the Wilson’s model and derived the values of
binary interactions for the system. We also conducted solubility measurements of this compound
in pure and mixed solvents. The material and the experimental procedure will be discussed in the
next section. In our study we used the UNIFAC and the NRTL-SAC model to predict the
solubility of the compound and compared it with the experimental data.
Lovastatin is a drug that belongs to a group of compounds that lower the lipids of the body,
called statins [23]. There are other statins approved in many countries, like simvastatin and
fluvastatin. The chemical name of this drug is (butanoic acid 2-methyl-1,2,3,7,8,8a-hexahydro3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl) ethyl]-1-naphalenyl ester) with
the chemical formula of C24H36O5 and molecular weight of 404.54. The chemical structure of
this drug is represented in Figure 2-5. There are two main studies that have been reported on the
solubility of this compound [23, 24].

Figure 2-5. Chemical structure of lovastatin
In the study by Gyabaah et al. [24] the solubility of lovastatin in a group of acetate- solvents was
measured. The solvents were ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, secbutyl acetate, isobutyl acetate, tert-butyl acetate, and 2-butanone. All of the solublities were
measured in the range of 285-313K. In their study they used the NRTL model to find the binary
interaction parameters for solute-solvent mixtures. In another study the solubility of lovastatin in
six alcohols was measured [23]. It was found that in alcohol groups the solubility of lovastatin
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increases from ethanol to 1-butanol and then decreases as the carbon chain length increases. This
can be rationalized by the solute-solvent interactions.
Valsartan with the chemical formula of C24H29N5O3 and chemical name (S)-N-(1-carboxy-2methyl-l-yl)-N-pentnoyl-N-[2’-(1H-tetrazol-5-yl) biphenyl-4-yl methyl]-amine, is used orally for
the treatment of hypertension [37]. The chemical structure of valsartan is illustrated in Figure 26.

Figure 2-6. Chemical structure of valsartan
This drug is extracted from the product mixture by ethyl acetate at the end of the production
process, because of its high solubility [25]. However, some problems such as poor yield, slow
filtration, and long-time drying are the results of recrystallization with ethyl acetate. For solving
this problem hexane has been used as an antisolvent in order to overcome those problems. Liu et
al. [26] found the solubility of the mixture of ethyl acetate + hexane at different molar ratios over
the temperature range of 278.15 to 313.15K. The synthetic method was used to obtain the
solubility of valsartan in the solvent mixture. In another study the solubility of valsartan in six
different solvents: methyl acetate, n-butyl acetate, acetonitrile, N,N-dimethylformamide,
dichloromethane, and chloroform over the temperature range of 278.15 to 313.15K, was
measured [25]. The melting point temperature, heat of fusion, and entropy change of melting of
the three mentioned model compounds are given in Table 2-2.
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Table 2-2. Physical properties of the model compounds used for thermodynamic modeling and
prediction
Compound

3-pentadecylphenol,

Melting point

Heat

of

[K]

[J/mol]

fusion

Entropy

of

fusion

[J/mol-K]

322.35

38092

118.14

Lovastatin, [23, 24]

445.50

43136

96.86

Valsartan, [25, 26]

380.65

31647

84.97

[22]

2.3.2. Experimental setup and procedure
The solubility of 3-pentadecylphenol in isopropyl alcohol and the mixture of isopropyl alcohol
and water were measured. 3-Pentadeclyphenol (90% purity) was purchased from Sigma Aldrich.
The compound was recrystallized for purification with ethanol [22]. A specified amount of 3pentadecyphenol was dissolved in ethanol in 50oC. After reaching to the desired temperature the
solution was filtered by filter paper (VWR, Grade 410, qualitative). The clear solution was again
maintained at that temperature for 1 hour. Then the solution was cooled with cooling rate of
0.2oC/min until reaching to 20oC. The solution was kept at that temperature for 1 hour. The
precipitated solids were filtered and dried. In order to identify its purity we used the differential
scanning calorimetry (DSC) analysis (DSC, Mettler Toledo, Chicago, IL). The sample was put in
a 40µl aluminum crucible with a hole in the cap to allow venting. The heating rate was 0.5oC/min
in the temperature range of 20oC to 120oC. The DSC curve and the obtained melting temperature
were compared to those of the purified compound. The results showed good purity of the sample
and effective experimental procedure.
After getting the purified compound, it was used for determining the solubility in IPA (isopropyl
alcohol) solvent. The gravitational method was used to obtain the solubility data. At first, a
known amount of 3-pentadecylphenol was dissolved in 50ml of IPA solvent at 40oC. The
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solution was prepared in 250ml Bellco jacketed vessel (Vinelean, NJ). A bath circulator (Julabo,
Germany) was used for heating and cooling. A Teflon-coated thermocouple was used for reading
the temperature in the flask. For mixing a top-mounted electromagnetically stirrer was employed.
After complete dissolution of all of the particles in the solvent, the temperature was cooled down
to a specified temperature to get the data of solubility. The solution was kept at constant
temperature for 1 hour. A membrane disk filter (VWR, Mississauga, ON) with 0.45µm was used
in order to filter the impurities from the sample solution. The clear saturated solution was kept in
closed weighted vials. The vial with solution was weighed and transferred to the oven (at 60oC)
for 1 day. The weight of solute and solvent were recorded for every sample. The mentioned
experimental procedure was repeated three times for each temperature to increase the reliability.
The replicates at every temperature were averaged and the standard deviation was calculated for
data analysis. In addition to the single solvent experimentation, we used solvent mixtures. Water
was selected as an antisolvent because 3-pentadecylphenol is sparingly soluble in water, but
fairly soluble in IPA. The solubility of 3-pentadecylphenol was measured at different solvent
volume fractions.
2.3.2.1. Characterization methods
2.3.2.1.1. X-ray powder diffraction (XRPD)
X-ray powder diffraction was conducted by XRPD equipment (Rigaku, Miniflex) with CuKα
radiation. The scan angle was between 5o-40o with the step angle of 0.05o.
2.3.2.1.2. Differential scanning calorimetry (DSC)
Thermal analysis was conducted by differential scanning calorimetry (DSC, Mettler Toledo,
Chicago, IL). The sample of 3-5mg was prepared in a covered 40µl aluminum crucible with a
hole in the lid to allow venting. The heating rate of 1oC/min was employed and the temperature
range was set from 20oC to 120oC. The N2 flow was used on the crucible with a rate of
100ml/min. The calibration was performed using indium.
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2.4. Results and discussion
2.4.1. Solubility prediction of 3-pentadecylphenol.
In order to model the solubility of 3-pentadecylphenol using the UNIFAC model, the chemical
structure of the solute was broken down to functional groups. For 3-pentadecylphenol, the alkyl
chain length is much longer than the benzene-ring. The prediction was based on the two
functional group arrangements: (1) structure with benzene ring and (2) structure without benzene
ring. We found some functional groups that each have one or more replicates in the structure.
The functional groups for two conditions are shown in Table 2-3. The results of characterization
using XRPD and DSC instruments are shown is Figure 2-7.
Table 2-3. Functional groups that are defined in UNIFAC and their replication in two different
structures of 3-pentadecylphenol
Sub-group

Condition I (with benzene

Condition II (without benzene

ring)

ring)

ACOH

1

0

ACCH2

1

0

ACCH

4

0

CH3

1

1

OH

0

1

CH2

13

14

The solubility of 3-pentadecylphenol in the solvents was calculated using the algorithm which is
shown in Figure 2-2. The results of the prediction using UNIFAC are shown in Figures 2-8 and
2-8. For the NRTL-SAC model the estimation using two solvents are shown in Figure 2-8 and
the prediction is shown for other solvents in Figures (2-9 and 2-10). Except for butanol and
ethanol, for which the two conditions (with and without benzene ring) have nearly the same
prediction, for other four solvents, there is a big difference between the solubility predictions for
the two conditions. For acetone, with the inclusion of the benzene ring, the prediction is very
well. For ethyl acetate, tetrachloromethane and to some extent toluene, the assumption of no
benzene ring shows better prediction. The reason for the different behaviour in the two proposed
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structure, is mainly due to the electron-rich nature of the benzene ring. When the benzene ring is
present, the electron cloud on the ring helps to interact better with some polar solvents, such as
acetone. On the other hand, when we assume no benzene ring in the structure, the molecule will
be an alcohol with long alkyl chain, which has OH group at the terminal of the structure and
makes it easier to interact with non-polar or less polar solvents, such as tetrachloromethane.
XRPD for 3-pentadecylphenol
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Figure 2-7. Characterization of re-crystallized 3-pentadecylphenol with DSC (left) and XRPD
(right)
For the NRTL-SAC model prediction, we need to find the four segment numbers for the
chemical compound, and then use the segment values to predict the solubility of the compound
in other solvents. We selected 1-butanol and acetone for parameter estimation and optimized the
values of segment numbers which are shown in Table 2-4.

Table 2-4. Optimized segment numbers for the model compounds using the NRTL-SAC method
Component

X (Hydrophobic)

Y- (Polar attractive)

Y+ (Polar repulsive)

Z (Hydrophilic)

3-pentadecylphenol

0.674

0.000

0.571

0.398

Lovastatin

1.175

0.000

0.548

0.882

Valsartan

0.000

0.946

0.000

0.539
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Using the obtained segment numbers for the compound, the NRTL-SAC model predicted
solubility in other solvents (Figures 2-9 and 2-10). It can be seen from the results that except for
toluene, the solubility in other three solvents were predicted satisfactorily. For all of the four
solvents, the NRTL-SAC model resulted in better prediction compared to the UNIFAC. As it is
evident from Table 2-5 the polar attractive segment is zero, which implies the molecule has a
repulsive nature against polar solvent, due to the electron-rich part of benzene ring. As it was
mentioned previously, about 84% of the total volume of the molecule is occupied by the alkyl
group, and the remaining is the phenolic part. This makes the molecule to have a good
interaction with other polar solvents. For non-polar solvents (such as toluene) the interaction is
not the same. That is why the prediction for toluene has some deviation from the experimental
results.
Table 2-5. Experimental solubility of 3-pentadecylphenol in pure IPA and its mixtures with
water (the mean values with their standard deviation)
Temperature

15

20

25

30

35

Pure IPA

0.7072 ± 0.0631

0.9436 ± 0.0804

1.4109 ± 0.1233

2.2355 ± 0.1011

3.8502 ± 0.4150

80vol.% IPA

0.7635 ± 0.0659

0.9755 ± 0.1213

1.6026 ± 0.1519

2.3653 ± 0.2608

4.4036 ± 0.2307

50vol.% IPA

0.2302 ± 0.0286

0.3980 ± 0.0419

0.6704 ± 0.0681

1.2739 ± 0.1396

3.1857 ± 0.2867

20vol.% IPA

0.0152 ± 0.0040

0.0188 ± 0.0031

0.0235 ± 0.0045

0.0273 ± 0.0028

0.0329 ± 0.0037

[oC]

For a system of IPA-water we see that with the addition of water to the pure IPA, the solubility
increases to a certain value at constant temperature. With more addition of water to the mixture
the solubility decreases and approaches zero as the volume fraction of water goes to unity in the
mixture. The maximum value of solubility is predicted by the NRTL-SAC (Figure 2-10).
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Figure 2-8. Experimental points of the solubility of 3-pentadecylphenol in two solvents and their
curve of estimation using NRTL-SAC model. The curves of UNFAC are also shown here for
comparison
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Figure 2-9. Experimental and predicted solubilities for 3-pentadecylphenol in solvents using UNIFAC and NRTL-SAC models
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Figure 2-10. Experimental and predicted values of the solubility data of 3-pentadecylphenol in
IPA-water mixture at different temperatures
2.4.2. Solubility prediction of lovastatin. From the chemical structure of lovastatin, the
functional groups in the UNIFAC model are listed in Table 2-6. The experimental data were
obtained from literature [23]. The functional groups are shown schematically in Figure 2-11.
Using the obtained group functions and their replicates in the chemical structure, we modeled the
thermodynamic equilibrium of lovastatin in alcohol and acetate group solvents.
Table 2-6. Functional groups that have been used in modeling with the UNIFAC model
Sub-group

Number of replicates

CH3

4

CH2

6

CH

6

C=C

2

CH-O

1

C-O-C

2

COCH3

2
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From the acetate group we selected methyl acetate and ethyl acetate for estimation of the NRTLSAC segment numbers. We made three ways of modeling the solubility of lovastatin in solvents:
•

Parameter estimation with two solvents from alcohol group only and solubility prediction
for all the remaining solvents

•

Parameter estimation with two solvents from acetate group only and prediction of
solubility for the remaining solvents

•

Parameter estimation with two solvents from alcohol and two solvents from acetate group
and solubility prediction for other remaining solvents.

Also we selected ethanol and 1-pentanol from alcohol group for alcohol estimation. After finding
the segment numbers from a few set of solvents, we predicted the solubility of lovastatin in other
remaining solvents. Finally, all alcohol and acetate solvents were put in one group and again the
estimation was repeated with the same compounds as before. After optimizing the adjustable
parameters using four solvents, the solubility for the remaining eight solvents were predicted.
The summary of the methods are shown in Table 2-7. For the first estimation (method I) we
selected two alcohols from the set of 5 alcohols in ref. [23]. Our selection was based on the alkyl
chain in order to consider the effect of its length on the parameter estimation. Therefore, we used
ethanol and 1-pentanol for parameter estimation. With the adjusted value for segment numbers
that were generated for alcohol group, we then predicted the solubility of lovastatin in remaining
three alcohols.

Figure 2-11. Schematic view of functional groups presented in lovastatin
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In Figure 2-12 the experimental data for four selected solvents with the predicted curves for the
NRTL-SAC and UNIFAC are shown. From those four curves, one is for the UNIFAC prediction
method, and the rest are for the NRTL-SAC model. The curve of “NRTL-SAC” results in the
best prediction of the data. Other methods are also shown for comparison. The next possible way
of estimation (method II) can be on the acetate group. In this group there are six acetate solvents
plus acetone as a basic solvent [24]. Two solvents were selected from the group (methyl- and
ethyl- acetate). By having their experimental values for these solvents the error between the
experimental and estimated values were minimized. The segment numbers that are generated
here were used to predict the solubility of lovastatin in the remaining 5 solvents. The final part
for estimation (method III) deals with four solvents from both the alcohols and acetate groups.
The solvents that were selected are the ones mentioned in method I and II. In this case, the
estimation is made by minimizing the error between the experimental and estimated solubility of
48 data point. For all of the three cases the ARD (average relative deviation) was calculated in
order to compare the three methods, qualitatively. The results and summary of the ARD are
shown in Table 2-7. The values of optimized segment numbers for each method are shown in
Table 2-8.
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Figure 2-12. Experimental data with the predictions of solubility in four selected solvents using three methods of the NRTL-SAC and
the UNIFAC method, experimental data from ref. [24]
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Table 2-7. Average relative deviation for the UNIFAC and NRTL-SAC in three methods
Method

%ARD based on

%ARD based on

%ARD considering

alcohol solvents

acetate solvents

both alcohol and
acetate solvents

NRTL-SAC (method III)

0.1946

0.1658

0.2401

NRTL-SAC (method II)

0.4980

0.1305

0.3306

NRTL-SAC (method I)

0.4735

0.4841

0.3499

UNIFAC

0.4795

0.7064

0.6153

Table 2-8. Optimized segment numbers for each method used for NRTL-SAC model
Method

X (Hydrophobic)

Y- (Polar attractive)

Y+ (Polar repulsive)

Z (Hydrophilic)

I

0.820

0.366

0.484

0.277

II

1.154

0.001

0.831

1.393

III

1.175

0.000

0.548

0.882

Referring to Table 2-7 it can be seen that from the four methods of predicting the solubility,
method III is the best one which describes and predicts the solubility of lovastatin. The next is
NRTL-SAC which was based on estimation of the two acetate solvents (method II). The
UNIFAC method has the highest average deviation from the experimental values. In Table 2-7 in
the second column, the ARD is based on only the deviation of predicted from experimental
solubility of alcohols. The prediction by the UNIFAC model and the method I (which was based
on parameter estimation of alcohols only) are nearly the same. However the minimum average
deviation in this column is for the method III. In column three the ARD is based on the acetate
solvent data. The method II has the lowest deviation which shows the selection of methyl- and
ethyl- acetate from the acetate solvents was satisfactory. From Table 2-8 it is evident that the
values of hydrophobic and polar attractive segments are very near to those of the method II
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(acetate estimation). However, this behaviour is different for polar repulsive and hydrophilic
segments, which are nearly the arithmetic average of the methods I and II. The method III was
the optimum one to minimize the total average deviation and hence best describes the solubility
of lovastatin in alcohols and acetate solvents. Finally it can be understood from the results that
the UNIFAC method was not able to predict the solubility data as well as the NTRL-SAC.
2.4.3. Solubility prediction of valsartan
For the solubility prediction of valsartan, we used the experimental data of Liu et al. [25, 26] to
estimate the adjustable parameters for NRTL-SAC. The chemical structure of valsartan is shown
in Figure 2-6. One group contains four nitrogen atoms in a pentagonal ring. To the best of our
knowledge and from the thermodynamic references and newly published articles, this group does
not have any UNIFAC parameter. This is one of the weaknesses that the UNIFAC model has in
face of newly complex chemical and pharmaceutical materials. In order to predict the pure
solvent solubility and solvent + antisolvent solubility, three solubility data sets were selected for
estimation and the remaining data were predicted using the adjusted segment numbers.
The solubility data in methyl acetate, DMF, and dichloromethane were used for parameter
estimation. After optimizing the model and obtaining the segment numbers, the solubility of nbutyl acetate and acetonitrile were predicted. The ARD for this prediction is 0.3843 which is
very good for prediction purposes. In the two graphs in Figure 2-13 the square points are the
coordination of the point that shows the experimental solubility (x-axis) and the prediction of the
solubility (y-axis). For the case of solvent mixture [26], the optimized segment numbers (Table
antisolvent, respectively. It is worth noting that if ~ is the mole fraction of the solute in the
2-4) was used to predict the solubility. Here the ethyl acetate and hexane is used as solvent and

solution, then with having the molar ratio (or mass ratio) of antisolvent to solvent, one can find

the mole fractions of the two solvents in the system. With the assumption that the molar ratio of
antisolvent to the solute-free solution is Mw, then the mole fractions of each species in the
mixture will be:
x
x
#

x
 n

mole fraction of solute
1 x 1 M  
M
x
1 M  #
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Figure 2-13. Predicted and experimental values of valsartan in two solvents: left: acetonitrile,
right: butyl acetate
Therefore, the mole fractions of all of the three compounds are functions of the solute mole
fraction, which is a function of the activity coefficient. As a result, for this type of calculation the
trial and error method have to be used to converge to a unique value of ~ . Having this included

in the modeling code, we started with the trial and error procedure to attain the solubility for each

antisolvent to solvent ratio over a range of temperature. Curves of solubility prediction for pure
ethyl acetate to the solution of up to the 49.44 mol%. ethyl acetate are illustrated in Figure 2-14.
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Figure 2-14. Solubility prediction of valsartan in three ethyl acetate + hexane mixtures for
different mole percent of ethyl acetate as a solvent
From the optimized segment numbers for valsartan we see that this drug does not have the
hydrophobic and polar-repulsive parts in its chemical structure. On the other hand, it has polar
attractive and hydrophilic segments, which can be rationalized by the carboxy group (COOH)
and also hydrogen head. Both Figures 2-13 and 2-14 show satisfactory prediction of the model at
different mixture ratios and temperatures. This shows the robustness of the NRTL-SAC model to
predict the ternary systems of solute-solvent-antisolvent.
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2.5. Conclusion
In this study we used two predictive methods for the phase behaviour of solid liquid equilibrium
(SLE) systems. There are many thermodynamic models which can describe the solubility of a
pharmaceutical or a chemical compound in a solvent or mixtures of solvents. However, the
correlative models have some restrictions such as the need to have a wide range of experimental
data in order to find the binary interaction parameters (i.e., Wilson). The UNIFAC model was
able to describe the solubility of the three selected solutes in the solvents with a reasonable
accuracy. We used some modifications in optimization of the adjustable parameters for NRTLSAC model. The NRTL-SAC showed a very good accuracy for pure solvent systems. Also, for
the mixture of solvents (in section 2.4.3) we were not able to use the UNIFAC model. Using a
few experimental data points for segment number estimation of the NRTL-SAC method allowed
us to predict the solubility in pure and also mixed solvents, successfully. For the case of solventantisolvent solubility prediction, 3-pentadecylphenol phase behaviour in the mixture of IPAwater was best predicted by the NRTL-SAC model. The maximum point of solubility was
predicted and verified by experimental data points. The NRTL-SAC predicted the solubility of
valsartan in a mixture of hexane and ethyl acetate, successfully.

2.6. References
1- P. B. Kokitkar, and E. Plocharczyk, Modeling drug molecule solubility to identify optimal
solvent systems for crystallization, Organic Process Research & Development, 2008, 12,
249.
2- W. Liu, L. Dang, S. Black, and H. Wei, Solubility of Carbamazepine (Form III) in Different
Solvents from (275 to 343) K, J. Chem. Eng. Data. 2008, 53, 2204.
3- C. Chen, P. A. Crafts, Correlation and prediction of drug molecule solubility in mixed
solvent systems with a Nonrandom two-liquid segment activity coefficient (NRTL-SAC)
model, Ind. Eng. Chem. Res. 2006, 45, 4816.
4- M. Margules, Uber die Zusammensetzung der gesattigten Dampfe von Mischungen,
Sitzungsber Akad. Wiss. Wien. Math. Naturw. Klasse, II, 1985.104, 1243.

44

5- G. M. Wilson, Vapor-liquid equilibirium. XI. A new expression for the excess free energy of
mixing, J. Am. Chem. Soc., 1964. 86, 127.
6- J. J. van Laar, Sechs Vortragen uber das thermodynamische Potential. (Six Lectures on the
Thermodynamic Potential). Braunschweig, Fried. Vieweg & Sohn, 1906.
7- H. Renon and J. M. Prausnitz, Local compositions in thermodynamic excess functions for
liquid mixtures, AIChE, 1968, 14, 135.
8- D. S. Abrams and J. M. Prausnitz, Statistical thermodynamics of liquid mixutres: A new
expression for the excess Gibbs energy of partly or completely miscible systems, AIChE,
1975, 21, 16.
9- H. Matsuda, K. Kaburagi, K. Kurihara, K. Tochigi, K. Tomono, Prediction of solubilities of
pharmaceutical compounds in water+co-solvent systems using an activity coefficient model,
Fluid Phase Equilibria, 2010, 290, 153.
10- D. Tassios, 62nd Annual meeting, American Institute of Chemical Engineers, Washington,
DC, 1969.
11- J. Gmehling and U. Onken, Vapor-liquid Equilibrium Data Colletction. DECHEMA,
Franckfurt/Main, 1977.
12- A. Fredenslund, R. L. Jones, J. M. Prausnitz. Group-contribution estimation of activity
coefficients in nonideal liquid mixtures, AIChE, 21, 1975, 1086-1099.
13- U. Weidlich, J. Gmehling, A modified UNIFAC model. 1. Prediction of VLE, hE, and γ∞ ,
Ind. Eng. Chem. Res., 1987, 26, 1372.
14- M. Sheikhzadeh, S. Rohani, M. Taffish, S. Murad, Solubility analysis of buspirone
hydrochloride polymorphs: Measurements and prediction, International Journal of
Pharmaceutics, 2007, 338, 55.
15- S. Gracin, T. Brinck, and A. C. Rasmuson, Prediction of Solid Organic Compounds in
Solvents by UNIFAC, Ind. Eng. Chem. Res. 2002, 41, 5114.
16- A. T. Kan and M. B. Tomson, UNIFAC Prediction of Aqueous and Nonaqueous Solubilities
of Chemicals with Environmental Interest, Environ. Sci. Technol. 1996, 30, 1369.
17- C. C. Chen, and Y. Song, Solubility modeling with a Nonrandom two-liquid segment
activity coefficient model, Ind. Eng. Chem. Res. 2004, 43, 8354.

45

18- J. M. Prausnitz, R. N. Lichtenthaler, E. G. de Azevedo, Molecular Thermodynamics of
Fluid-Phase Equilibria, Second edition, Prentice-Hall Inc., Engelwood Cliffs, N.J. 07632,
1986.
19- J. M. Smith, Hendrick C Van Ness, Michael Abbott, Introduction to Chemical Engineering
Thermodynamics, McGraw-Hill Science, Sixth edition, 2004.
20- C. C. Chen, Peter A. Crafts, Correlation and prediction of drug molecule solubility in mixed
solvent systems with a Nonrandom two-liquid segment activity coefficient (NRTL-SAC)
model, Ind. Eng. Chem. Res. 2006, 45, 4816.
21- Matlab software help documents, version 7.6.0.324 (R2008a).
22- Z. B. Mao, T. L. Luo, T.-B. Cui, Y. Wang, and Guo-Ji Liu, Solubility of 3-Pentadecylphenol
in Ethanol, 1-Butanol, Toluene, Acetone, Tetracholomethane, and Ethyl Acetate, J. Chem.
Eng. Data, 2010, 543.
23- J. Nti-Gyabaah, R. Chmielowski, V. Chan, Y.C. Chiew, Solubility of lovastatin in a family
of six alcohols: Ethanol, 1-propanol, 1-butanol, 1-propanol, 1-hexanol, and 1-octanol,
International Journal of Pharmaceutics, 2008, 359, 111.
24- J. Nti-Gyabaah, and Y. C. Chiew, Solubility of Lovastatin in Ethyl acetate, propyl acetate,
isopropyl acetate, butyl acetate, sec-butyl acetate, isobutyl acetate, tert-butyl acetate, and 2butanone, between (285 and 313)K, J. Chem. Eng. Data, 2008, 53. 2060.
25- Y. Liu, J.Wang, X. Wang, P. Liu, and F. Pang, Solubility of Valsartan in different organic
solvents and ethanol+water binary mixtures from (278.15 to 313.15) K, J. Chem. Eng. Data,
2009, 54, 986.
26- Y. Liu, J. Wang, X. Wang, and F. Pang, Solubility of Valsartan in Ethyl Acetate+Hexane
binary mixtures from (278.15 to 313.15)K, J. Chem. Eng. Data, 2009, 54, 986.
27- H. Qu, M. L. Kultanen, J. Kallas, Solubility and stability of anhydrate/hydrate in solvent
mixtures, International Journal of Pharmaceutics, 2006, 321, 101.
28- C. C. Chen and Y. Song, Extension of Nonrandom Two-Liquid Segment Activity
Coefficient Model for Electrolytes, Ind. Eng. Chem. Res. 2005, 44, 8909.
29- M. Mirmehrabi, S. Rohani, K.S.K. Murthy, B. Radatus, Solubility, dissolution rate and
phase transition studies of ranitidine hydrochloride tautomeric forms, International Journal
of Pharmaceutics, 2004, 282, 73.

46

30- A. Getsoian, R. M. Lodaya, A. C. Blackburn, One-solvent polymorph screen of
carbamazepine, International Journal of Pharmaceutics, 2008, 348, 3.
31- M. Trifkovich and S. Rohani, Polymorphic Generation through Solvent Selection: Ranitidine
Hydrochloride, Organic Process Research & Development, 2007, 11, 138.

47

Chapter 3

Vapour-Liquid and Vapour-Liquid-Liquid Equilibrium Modeling
for Binary, Ternary, and Quaternary Systems of Solvents

A version of this chapter has been published as:
Ehsan Sheikholeslamzadeh and Sohrab Rohani “Vapour-Liquid and Vapour-Liquid-Liquid
Equilibrium Modeling for Binary, Ternary, and Quaternary Systems of Solvents”, Fluid Phase
Equilibria, 333, 97-105.
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3.1. Introduction
Thermodynamic models have been used to aid chemical engineers in designing various chemical
and pharmaceutical processes. Although high-throughput solubility measurement techniques are
developing, they are time-demanding and expensive in finding the best operating conditions for a
specific process. This issue is more important when one deals with the crystallization of a
chemical compound in various solvents and their possible combinations. In this case, depending
on a solvent or solvent mixture, so many possible cases have to be tested in order to reach the
maximum solubility. In many applications where there are at least two phases in equilibrium
(such as crystallization process), the need to have an accurate thermodynamic model with less
dependency on experimental data is significant. Many thermodynamic models, such as Wilson
[1], Van Laar [2], NRTL [3], and UNIQUAC [4] have been used to help researchers design
chemical processes. The main disadvantage of these equations of state (EOS) is their dependency
on experimental data. For example, to predict the phase behaviour of a ternary vapour-liquid
equilibrium (VLE) system, one should have three sets of binary experimental data for all the
constituents of the system. Another problem dealing with the models based on the equation of
state is that the adjusted parameters are valid at a given pressure or temperature of the system. As
the total pressure and temperature of the system change, the fugacities in the vapour and liquid
phases can be changed, which may affect the mole fractions of species and other dependent
properties, such as bubble and dew point temperatures. One of the main advantages of predictive
models is that they do not require any experimental data on two, three, or more component
mixtures.
Since the universal functional activity coefficient (UNIFAC) model was proposed by
Fredenslund et al. [5], there have been much effort to find a model which can describe the phase
behaviour (i.e., vapour-liquid equilibrium) with no or limited experimentation. The UNIFAC
model is powerful in predicting vapour-liquid and liquid-liquid equilibrium systems with average
molecular weights of 100g/mol. However, when the molecular weight of a chemical species is in
the range of 200-600g/mol with complex chemical structure, the UNIFAC model and its
modifications fail to generate reasonable predictions [6].
Chen and Crafts [7] proposed a new predictive model, Non-random Two Liquid Segment
Activity Coefficient (NRTL-SAC) which is based on polymer NRTL model [8]. According to
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this model, four individual conceptual segments are assigned to each component, regardless of
its nature or chemical structure complexity. The segment numbers are unique for each
compound. According to the NRTL-SAC model, the molecule surface can have at least one or
more of the following segments:
•

Hydrophobic segment (x),

•

Polar-attractive segment (y-),

•

Polar-repulsive segment (y+) and

•

Hydrophilic segment (z)

A hydrophobic segment (X) does not form a hydrogen bond, such as heptane. A hydrophilic
segment (Z) contributes to the part of the molecule which tends to form a hydrogen bond, such as
methanol. The polar segments (Y- and Y+) do not belong to the hydrophobic nor hydrophilic
segment. The polar attractive segment (Y-) shows attractive interaction with hydrophilic
segment, while the polar repulsive segment (Y+) has repulsive characteristic with hydrophilic
segment, such as acetone. Depending on the nature and chemical structure of a molecule, the
contribution of the above four mentioned segments varies. Chen and Song have extracted the
numerical attributes of segments for common solvents. Therefore, for a given set of components,
one can calculate the phase behaviour of the mixture with using four parameters which are
constant and unique for each constituent of the solution. The segment numbers of most common
industrial solvents have been estimated and tabulated in the literature [6].
Recent works have been conducted on modeling phase equilibrium systems and finding segment
numbers for new components. Chen and Crafts [7] found the segment numbers for
acetaminophen, sulfadiazine, cimetidine, and sulfamerazine. Mota et al. [9] used this model to
adjust the segment numbers for allopurinol, furosemide, and budesonide. Sheikholeslamzadeh
and Rohani [10] used the NRTL-SAC and UNIFAC model to predict the solubility of 3pentadecylphenol, lovastatin, and valsartan in various solvents and their mixtures. They
concluded that the NRTL-SAC model can be used in many industrial applications and
pharmaceutical processes. The NRTL-SAC model has shown promising predictions and
applicability in many areas of interest. Ferreira and Pinho [11] have investigated the solubility of
flavonoids in pure solvents, experimentally and theoretically using the NRTL-SAC method.
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In order to ensure the predictive capability of a model in vapour-liquid equilibrium calculations
(specifically bubble point temperature prediction), different solvent mixtures should be
employed and the model predictions should be compared with the corresponding values from
other correlative models and experimental data.
Equations (3-1) and (3-2) are used to quantify the deviations of the suggested model predictions
from the experimental data:
•

Average Relative Deviation,

•

Average Absolute Deviation,

ARD

AAD
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Where x {m< and x W>W are experimental and theoretical mole fractions of a specific compound in
a solution, respectively. In a multiphase system at equilibrium, the fugacity of every compound
in each phase is equal to the corresponding value in other phases [3]:
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Nc is the total number of compounds present in the system. For a vapour-liquid-liquid
equilibrium system, equation (3-3) can be written in the following form:
x  γ α P )O

x  γ β P )O

y PO=O +

3

4

where x  , x  , and y are the mole fractions of component i in two liquid and vapour phases,

respectively. P )O is the vapor pressure of component i at an arbitrary temperature and total

pressure PO=O. + is the fugacity coefficient of component i in the vapour phase, which can be
equal to unity for low to moderate pressures (the studied cases in this work were at low

pressures). For VLLE systems, one can select an arbitrary phase as a reference for bubble point
or dew point calculations. For our study, we selected organic and aqueous liquid phases as
reference. The data on saturated pressure of the solvents have been found from the NIST
database [12]. The mathematical form of vapor pressure for a pure compound (Antoine equation)
is:
log P )O 
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B
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P bar¢, T K¢

The flash calculations were written in separate codes for every thermodynamic model. For the
UNIFAC model, the activity coefficient is temperature dependent, thus we had to build a
separate code for trial and error procedure. All the codes were written in the Matlab environment
and further details can be provided to the interested reader. The details of the procedure for
finding the bubble, dew, and flash calculations can be found elsewhere [13].
3.2. Theoretical background
3.2.1. Thermodynamic models
The mathematical description of the two thermodynamic models, UNIFAC and NRTL-SAC,
have been introduced in chapter 2. Therefore, we don't mention the details of how the models
predict the phase behaviour of the systems.
3.2.1.1. Phase behaviour calculations
3.2.1.2. Vapour-liquid equilibrium
In order to find the flash calculation of the systems containing vapour and liquid, we must start
from the equilibrium equation for the VLE system:
y φ
¥  PO=O

γ x P )O

3

6

Which y and x are the mole fractions of component i in vapour and liquid phases, respectively.

φ
¥  and γ denotes the deviation from ideal conditions for vapour and liquid phases, respectively.

Equation (3-6) is the basis for determining the bubble, dew, and flash calculations. The bubble
point pressure for a given temperature is found from:
PO=O
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3
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The procedure to find the bubble point temperature of a liquid solution at a given pressure is as
follows:
1. Estimate bubble temperature: T

2. Evaluation of Pi

sat

∑ x T )O

and γ at the given temperature
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4. Calculation of new bubble temperature by: T
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5. Evaluation of the new Pisat, calculation of yi, φ , γ , P )O , and finally T

3
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6. If the calculated T from step 5 and 4 are different the trial and error from step 1 should be
repeated.

3.2.1.3. Liquid-liquid equilibrium
For the systems exhibiting the liquid-liquid equilibrium behaviour, we use the fundamental
relation of equation (3-4). Thus:
x  γ α

x  γ β

3

10

γ α and γ β are generally the functions of mole fraction of constituents, temperature, and pressure.

Equation (3-10) is written for each of the species in the solution and solved for the system at
specific pressure and temperature of interest.
3.2.1.4. Vapour-liquid-liquid equilibrium

In order to investigate the existence of three phases in a system, equation (3-4) should be written
for each pain of phases and the results from each calculation should be re-corrected by the results
of other phases. In this study, we have selected both aqueous and organic phases for model
validation.
3.3. Test cases
3.3.1. VLE system of Toluene-Ethanol and Toluene-Isopropanol at different pressures
Ethanol, toluene, and isopropanol are common solvents used in large volumes in various
chemical and pharmaceutical industries. Also, they are used as an additive to other solvents to
promote their physical and/or chemical characteristics. Because of the formation of azeotrope for
toluene-ethanol and toluene-isopropanol systems, they are of great interest in azeotropic
distillation process design. According to a study by Stichlmair et al. [16], pressure swing
distillation process can be employed to overcome the azeotropic nature of the mixture. In order
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to have an accurate knowledge of vapour-liquid behaviour of these binary systems at different
temperatures and pressures and to simulate and optimize the unit operations, a reliable and
flexible thermodynamic model has to be used. In the work by Chen et al. [17], a recirculating
apparatus was used for VLE measurements of toluene-ethanol and toluene-isopropanol systems.
They found that the system was highly non-ideal and exhibited azeotropic behaviour. The VLE
data were extracted at four different pressures (101.3, 121.3, 161.3, and 201.3kPa) assuming that
the vapour phase can be treated as an ideal mixture. Chen et al. [17] also made use of Wilson,
NRTL, and UNIQUAC equations of state to fit the measured data with the experimental values
and found the interaction parameters, but did not predict the experimental data with the models.
In our study, we used the NRTL-SAC and UNIFAC models to predict these highly non-ideal
systems in liquid phase. Figure 3-1 compares the model prediction and the experimental data for
the systems. The NRTL-SAC model predicts the experimental data of bubble and dew point with
a reasonable accuracy. It is shown that UNIFAC model could anticipate the azeotrope formation
for all of the cases with respect to the mole fractions of ethanol, with close agreement with the
literature data. Because of this ability, the UNIFAC model can be used in simulation and
optimization of azeotropic distillation of these systems, effectively. On the other hand, the
NRTL-SAC model could not predict the azeotrope point for either of two systems.
The average relative deviation of two models for two solvents from the experimental data is
shown in Table 3-1. From this table, the average deviations of prediction from the experimental
value for vapour phase mole fractions with the use of the UNIFAC model are about one third of
the corresponding values from the NRTL-SAC model. Also, for bubble temperature deviations,
the ARD from the NRTL-SAC are three times larger than the UNIFAC model. It is worth noting
that the average relative deviations for both binary systems using NRTL-SAC model are nearly
the same. However, this is not the same when using the UNIFAC model. The deviation for the
system of toluene-ethanol is less than that of the toluene-isopropanol. It shows that the UNIFAC
can better predict the light alcohol systems than the heavier ones.
From the results that are shown in Table 3-1, two more conclusions can be drawn:
•

The ARD of the bubble point temperature for both models is small, which shows the
applicability of two methods for accurate bubble temperature calculations.
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•

At higher pressures, the ARD is generally increased. This is because of neglecting the
vapour phase fugacity coefficients which has been made in calculation. In spite of the
mentioned fact, the deviation is not that much to include a model to predict the vapour
phase fugacities for pressures up to 2 atm. For higher operating pressures (i.e., 5 atm and
above), the vapour phase should also be considered in evaluation of species’ fugacity
coefficients.

Table 3-1. Deviation of predictive model results from corresponding experimental values of
Chen et al. [17]
Thermodynamic
model

Pressure,

%ARD (equilibrium temperature and vapour-phase mole fractions)

[kPa]
System 1
Temperature,
[K]

NRTL-SAC

System 2

Ethanol

Toluene

Temperature,
[K]

2-Propanol

Toluene

101.3

0.46

5.14

9.81

0.41

4.91

7.19

201.3

0.64

7.63

9.72

0.66

7.76

9.77

101.3

0.10

1.08

3.15

0.22

2.04

3.87

201.3

0.27

2.03

3.47

0.36

3.43

5.40

UNIFAC
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Figure 3-1. Predicted and experimental results for systems (A) ethanol-toluene at 101.3kPa, (B) ethanol-toluene at 201.3kPa, (c)
isopropanol-toluene at 101.3kPa, and (D) isopropanol-toluene at 201.3kPa
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3.3.2. VLE data for binary and ternary systems of Ethanol-Water-Ethylene Glycol
Nowadays with increasing fossil fuel prices, the need to find alternative energy is so significant.
Ethanol is a promising candidate in blending with the fuel to increase its performance in burning
and decreasing air pollution by transportation vehicles. In addition to the environmental and
efficiency characteristics, the cost saving of blending ethanol is important. The performance of
the final fuel blend increases with an increase in the ethanol purity. It is shown that using glycols
can enhance the separation of ethanol from water (dehydration process) with consuming less
energy than conventional distillation processes [18]. In the work by Kamihama et al. [19], the
effect of adding glycol to the mixture of ethanol and water (hydrated alcohol) on separation
performance has been investigated.
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Figure 3-2. Txy diagram of VLE systems; (A) ethanol-water, (B) ethanol-ethylene glycol, and
(C) water-ethylene glycol all at 101.3kPa
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They conducted three main experiments on every pair of solvents from the ternary system of
ethanol-water-ethylene glycol. They concluded that ethylene glycol has an effect on separation
of ethanol and water beyond the azeotrope point. We have made use of two predictive models to
predict the experimental data of this system.
According to Figure 3-2 the UNIFAC model can predict the phase behaviour of ethanol-water
system well. The other two systems, specifically the case of water-ethylene glycol, were not
predicted satisfactorily. The NRTL-SAC, however, can give good results for all the binary
systems, especially for water-ethylene glycol. It should be noted that in the cases which there is
not an azeotrope point, the NRTL-SAC has the ability to predict the experimental points with the
same or even lower deviation from experimental points than the UNIFAC method (Figures 3-2B
and 3-2C). However, in the presence of the azeotrope point, the UNIFAC yields a better
prediction (Figure 3-2A). In order to have a quantitative assessment of the predictive ability of
two methods, we calculated the average relative deviation for three binary systems. As it is seen
from Table 3-2, the NRTL-SAC model can best predict the systems of water-ethylene glycol and
ethanol-ethylene glycol, while UNIFAC resulted in lower ARD for ethanol-water system.
Table 3-2. Absolute relative deviation (%ARD) of predicted and experimental vapour mole
fraction of components in each binary system

Model

System 1

System 2

System 3

Ethanol

Water

Water

Et. Glycol

Ethanol

Et. Glycol

NRTL-SAC

3.68

7.23

1.42

5.20

0.27

18.93

UNIFAC

1.22

2.19

3.58

12.17

0.37

23.94

Kamihama et al. [19] also performed the VLE measurements for ternary system of ethanolwater-ethylene glycol at 101.3kPa. They used the correlative models (such as UNIQUAC) to
find the binary parameters using three sets of binary data, and then predicted the ternary system.
For the NRTL-SAC model, we just used four conceptual segments of each solvent, which are
already found in the literature [6]. The NRTL-SAC model predicted the equilibrium of the
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ternary solvent system with a high degree of accuracy. This model could predict the vapour mole
fractions, as well as the equilibrium temperature. From Figure 3-3, except for ethylene glycol,
the mole fractions of ethanol and water in the vapour phase were predicted with nearly zero error
by the NRTL-SAC model. However, there were a few deviations for the results from the
UNIFAC model. The ethylene glycol vapour phase mole fraction for all of the experimental runs
were nearly zero and if we consider the contribution of inherent errors of experiments, the
NRLT-SAC model also described the behaviour of ethylene glycol in the vapour phase, well. As
it is evident from this figure, the NRTL-SAC could successfully anticipate the bubble and dew
points of the system. The results of the modeling showed that the NRTL-SAC predicts the data

W a te r v a p o r p h a s e m o le fra c tio n

E th a n o l v a p o r p h a s e m o le fra c tio n

with one third average relative deviation compared to the UNIFAC method.
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Figure 3-3. Vapour phase mole fractions of ethanol (top-left), water (top-right), ethylene glycol
(bottom-left), and saturated temperature of the solution (bottom-right) from experimental data
and theoretical models for the ternary system of ethanol-water-ethylene glycol
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3.3.3. Binary and ternary system of Diethyl Ether-Methanol-Butanol
In another study by Gao et al. [20], binary and ternary combinations of diethyl ether with
methanol and 1-butanol were examined in vapour and liquid phase equilibrium. This study is
mainly due to the importance of the presence of by-products (i.e., diethyl ether) during syngas
conversion to methanol. By adjusting binary interaction parameters, they could anticipate the
VLE behaviour of the three-component system.
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Figure 3-4. Three binary phase diagrams of (A) diethyl ether-methanol, (B) diethyl etherbutanol, and (C) methanol-butanol at 101.3kPa from experiment and models

Having a precise knowledge of the phase equilibria inside the syngas reactor will help the
engineer in efficient designing and optimizing the process. Even more, accurate design of the
downstream processes (such as distillation column) depends on thermodynamic equilibrium in
such systems. We examined the predictability of two models for the binary and ternary data [20].
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First, the binary data on every pair of the ternary system was modeled with both predictive
methods. The results of binary simulation are shown in Table 3-3 and Figure 3-4. Two main
conclusions which can be drawn from binary results are:
•

For system 1 which contains diethyl ether as one of the constituents, the NRTL-SAC
shows better performance in prediction, specifically saturation temperature. For this
system there is an azeotrope point near to diethyl ether unit mole fraction, which is also
predicted by the NRTL-SAC model.

•

For the second and third systems, the UNIFAC and NRTL-SAC show nearly the same
prediction.

Table 3-3. Binary solution deviation of model vs. experimental data for three pairs of Diethyl
ether-Methanol-Butanol (%ARD)

System 1

System 2

System 3

Model
Diethyl
ether

NRTL-

Methanol

Saturated

Diethyl

temperature

ether

Butanol

Saturated
temperature

Methanol

Butanol

Saturated
temperature

2.23

6.28

0.15

10.52

32.19

1.93

4.02

17.39

0.66

4.28

9.54

0.42

12.46

37.31

2.34

3.45

12.61

0.49

SAC

UNIFAC

In addition to the binary calculation, the ternary system was also studied. The numerical values
of absolute average deviation are shown in Table 3-4. The reason for adopting the AAD rather
than ARD for this system is to compare the results of Gao et al. [20] with our work. It is seen
from the table that the NRTL-SAC has a better accuracy in prediction in comparison with the
UNIFAC method. If the AAD of mole fractions of methanol and butanol are compared with the
UNIQUAC model, the ability of prediction of the NRTL-SAC model (with only four parameters)
will be obvious. The UNIFAC did not yield satisfactory results for this ternary system.
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Table 3-4. Average absolute deviation (%AAD) for predictive models and two correlative
models for a ternary system of Diethyl Ether-Methanol-Butanol
Model

Diethyl ether

Methanol

n-Butanol

NRTL-SAC

2.28

1.77

1.29

UNIFAC

5.33

4.13

1.21

UNIQUAC [20]

1.71

1.97

2.62

Wilson [20]

1.68

1.36

2.04

3.3.4. VLE and VLLE equilibrium of Water-Ethanol-Hexane-Toluene and Water-EthanolCyclohexane-Isooctane.
Generally the system of water-hydrocarbons is of importance, because they are mainly produced
and consumed in most oil and chemical industries. Pequenin et al. [21] used ethanol plus
hydrocarbon mixture (i.e., n-hexane and toluene) as a simulated gasoline. In the first study they
worked with the system of water-ethanol-cyclohexane-isooctane [21]. In the second work, they
performed experiments on ternary and quaternary systems of water-hexane-toluene and waterethanol-hexane-toluene, respectively [22]. Both studies were conducted under 101.3kPa total
pressure. For emulsification and preventing temperature fluctuations inside the solution, they
employed an ultrasound homogenizer. For each data point, they measured the boiling
temperature and mole fractions of the liquid phases and vapour phase of the system.
VLE data of Water-Hexane-Toluene. The study on the system of water-hexane-toluene
showed that in aqueous phase the mole fraction of water is nearly unit, while in the organic phase
hexane and toluene were the dominant parts of the phase. Since the aqueous phase was almost
pure water, this phase was not considered for equilibrium calculations. Therefore, we selected
the organic and vapour phase for our study. The mole fractions of the vapour phase and the
corresponding equilibrium solution temperatures with predicted values are shown in Figure 3-5.
As it is evident from the results, the bubble temperature of the four runs from the NRTL-SAC is
well predicted compared to the UNIFAC model. For water and hexane mole fraction in vapour
phase, the NRTL-SAC model could anticipate the phase behaviour with a higher degree of
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accuracy compared to the UNIFAC model. For toluene at low mole fractions, the NRTL-SAC
results are closer to their corresponding experimental values, while for higher mole fractions, the
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Figure 3-5. The results of prediction vs. experimental runs for VLE system of water-hexanetoluene; (A) bubble point temperature, (B) water, (C) hexane, and (D) toluene mole fraction in
vapour phase
VLLE system of Water-Ethanol-Hexane-Toluene (system 1) and Water-EthanolCyclohexane-Isooctane (system 2). For the VLLE system of quaternary compounds, we made
the calculation based on two methods:
•

VLLE prediction based on aqueous phase

•

VLLE prediction based on organic phase

As long as the equilibrium condition is maintained, the fugacity of the compounds in each pair of
phases should be equal (Equation (3-4)). Therefore, we first used aqueous phase as a base phase
to predict the data. After that, the organic phase was chosen as the reference phase for
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calculation. For quantitative analysis of the modelling procedure, the average relative deviation
for each of four mole fractions for the two systems is shown in Table 3-5. From this table, the
total average deviation for system 1 using NRTL-SAC model is 0.1003 and 0.1269 for organic
and aqueous phases, respectively. In case of the UNIFAC model, the average deviation for the
whole system 1 is 0.1269 and 0.1057 for organic and aqueous phase, respectively. According to
this result, the prediction performance for the two models is nearly the same. When the organic
phase is used for calculation, the NRTL-SAC gives better results.
Table 3-5. %ARD for the two quaternary systems of VLLE
%ARD (vapour-phase mole fractions) based on aqueous phase
Thermodynamic

System 1

model

NRTL-SAC

UNIFAC

System 2

Water

Ethanol

Hexane

Toluene

Water

Ethanol

Cyclohexane

Isooctane

6.07

3.94

8.93

5.95

9.53

8.29

10.19

10.31

4.29

5.04

12.48

8.71

10.10

10.23

9.59

11.60

%ARD (vapour-phase mole fractions) based on organic phase

System 1

NRTL-SAC

UNIFAC

System 2

Water

Ethanol

Hexane

Toluene

Water

Ethanol

Cyclohexane

Isooctane

3.40

3.19

4.67

1.60

9.50

9.32

6.67

12.69

12.04

4.94

6.72

1.09

6.32

4.76

2.44

10.44

According to the results depicted in Table 3-5, the NRTL-SAC model could predict the vapour
phase mole fractions of water, ethanol, and hexane with lower error compared to the UNIFAC
model. For the toluene prediction, the result depended on the method which the phase calculation
was based. If the aqueous phase was selected, then the error from NRTL-SAC model would be
lower, and for the organic phase, the UNIFAC would have the lower prediction error. The results
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Figure 3-6. Predicted and experimental phase mole fractions of three species in a quaternary system of VLLE, 1) system of WaterEthanol-Hexane-Toluene, prediction based on (A) organic phase and (B) aqueous phase, 2) system of Water-Ethanol-CyclohexaneIsooctane, prediction based on (C) organic phase and (D) aqueous phase
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of prediction are shown in Figure 3-6(A-B). The experimental and theoretical points are depicted
in triangles to show the mole fractions of the quaternary system. According to the Figure 3-6 the
two models could predict the quaternary system, except UNIFAC for the case of organic phase
base calculation. There is some deviation from experimental results for the UNIFAC when the
organic phase is selected as a base phase. We conclude that the NRTL-SAC can be a better
choice in VLLE calculation of this system, rather than the UNIFAC. From Table 3-5, we
conclude that the NRTL-SAC can be a better choice in VLLE calculation of this system
compared to the UNIFAC. For system 2 the total average deviation from NRTL-SAC model is
0.1056 and 0.1078 for organic and aqueous based calculation. The two deviations are nearly the
same, which confirms the liquid-liquid-vapour equilibrium condition in the system from the
NRTL-SAC model. The deviations obtained by the UNIFAC model were 0.0805 and 0.1141 for
organic and aqueous phase base, respectively. The two deviation values differ from each other,
illustrating that the UNIFAC model cannot verify the three phase formation, successfully. The
system of water-hexane-toluene and the quaternary system of it having methanol as the added
component were modeled by the two methods. For the ternary system, the bubble point was
perfectly verified using NRTL-SAC model, while the mole fractions of three compounds have a
few deviations from experimental values. For the two systems of quaternary solvents, depending
on selection of the aqueous or organic phase as a reference for calculation, the results were
different. If the aqueous phase was considered as a reference phase, the results from two models
showed large deviations, especially for UNIFAC model. However, when the organic phase was
selected as a reference phase, the results were much better than the former case. The main reason
for this behaviour can be the slight solubility of hydrocarbons in aqueous phase, while the most
portion of the hydrocarbons are in organic phase.
3.4. Conclusion
In this work, the applicability of two predictive activity coefficient based models was examined.
The experimental data of five different types of VLE and VLLE systems that are common in
industry were used for the evaluation. The NRTL-SAC and UNIFAC models were selected for
modeling the systems. In general, the NRTL-SAC model could predict all the binary systems,
except light alcohols in water and in aromatics. The accuracy of the NRTL-SAC model was
higher in ethylene glycol with alcohols and dimethyl ether with water. The NRTL-SAC model,
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also could best predict the ternary system of solvents. The UNIFAC model could accurately
predict the binary system of light alcohols with water and aromatic hydrocarbons. The ternary
systems, however, were modeled by the UNIFAC model with a less accuracy than the NRTLSAC model. For the quaternary systems, if the organic phase was selected as a reference phase,
the NRTL-SAC could give good results for water-ethanol-hexane-toluene, while the UNIFAC
gave better results for water-ethanol-cyclohexane-isooctane system. It can be concluded that
because of fewer parameters and ease of computation, the NRTL-SAC is a more powerful
method compared to the UNIFAC.
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Chapter 4

Optimal Solvent Screening for the Crystallization of Pharmaceutical
Compounds from Multi-Solvent Systems

A version of this chapter has been published as:
Ehsan Sheikholeslamzadeh and Sohrab Rohani “Solubility Prediction of Pharmaceutical and
Chemical Compounds in Pure and Mixed Solvents Using Predictive Models” Ind. Eng. Chem.
Res. 2011, 51, 464-473.
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4.1. Introduction
In the production of many pharmaceuticals and chemicals, the solvent selection for the
crystallization process is very important [1]. The solubility of an active pharmaceutical
ingredient (API) in a solvent or solvent mixture can affect the drug release and absorption in the
body and its transport in a living organism. The drug availability for experimental solubility
determination during the early stages of a new drug development is very restrictive [2]. In
addition, the difficulties in experimentation and inherent experimental errors are other
complexities. On the other hand, accurate thermodynamic models can provide guidelines for the
optimal selection of solvent combinations. Some thermodynamic methods, such as NRTL [3],
Wilson [4], UNIQUAC [5], and Van Laar [6] rely on huge experimental data. For systems of
ternary and quaternary solvents, the use of these models requires vast number of experimental
runs to determine the binary interaction parameters [7]. The predictive thermodynamic models
such as the UNIFAC [8], NRTL-SAC [2], and COSMO-SAC [9-10], require information on the
molecular structure of the solute and solvents. The UNIFAC model has shown a good predictive
ability for a wide range of VLE and LLE systems. However, it fails to deal with the systems in
which the molecules have complex and unknown functional groups [2]. The NRTL-SAC model
has been proposed by Chen and Song [2]. This model is derived from the polymer non-random
two-liquid model [11]. In this model the molecules of solute and solvent are characterized by
three segments; hydrophobic (X), hydrophilic (Z), and polar (Y). The polar segment itself is
divided to polar attractive (Y-) and polar repulsive (Y+). These conceptual segments are found
using some experimental data on VLE and LLE systems. The four conceptual segments assigned
to each molecule (solute or solvent) can be used as a descriptor of that molecule when used in
VLE, LLE, and SLE calculations. This model is simple and flexible in modeling the
thermodynamic phase equilibrium of binary and multi-component systems. The advantage of this
model, compared to other predictive methods such as UNIFAC, is its simplicity in defining a
molecule with only four segment numbers, no matter how complex the chemical structure of a
molecule is.
The VLE and SLE predictive ability of the NRTL-SAC model has been verified in some recent
studies. Chen and Crafts used the NRLT-SAC model to find the segment numbers of
paracetamol and sulfadiazine [12]. In another study they showed this model can be used in VLE
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calculation of common solvents [2]. Sheikholeslamzadeh and Rohani found the conceptual
segment numbers of 3-pentadecylphenol, lovastatin, and valsartan in single and binary solvents
[13]. Sheikholeslamzdeh and Rohani have also studied different systems of solvents in binary,
ternary, and quaternary mixtures to verify the applicability of the NRTL-SAC model in
predicting the VLE and VLLE behaviour of those systems [14]. They showed the NRTL-SAC
model best describes such a complex system of solvents in good agreement with the
experimental data. The results showed the NRTL-SAC model could give better results in ternary
and quaternary mixtures than the UNIFAC model. Mota et al. used the NRTL-SAC model to
estimate the segment numbers of budesonide, allopurinol, and furosemide in different solvents
[15].
In this work the NRTL-SAC model is written in separate programs for VLE, LLE, and SLE
prediction of multi-solvent systems with seven model pharmaceutical molecules. A new
optimization procedure is developed to calculate the best solvent or mixture of solvents to
maximize the yield of crystallization in a cooling-antisolvent mode. It should be noted that in the
current study, the process modeling and optimization are based on initial and final points of the
operation only. The path of cooling or addition of antisolvent is not considered here and in
addition, the initial and final operating points of crystallization are at equilibrium. It is worth
noting that throughout this work, the component refers to a solid, solute, or solvent under study.
A model molecule (an active pharmaceutical ingredient, API, or any chemical compound) can be
in the form of a solute (dissolved in a solvent or a solvent mixture) or in the form of a solid (a
crystallized or amorphous form of a solute).
4.2. Thermodynamic background
As it was mentioned in chapter 2, the group-contribution models divide the contribution of the
activity coefficient to two parts, the combinatorial and residual parts. The combinatorial part
includes the contribution of the chemical structure and the size (volume and surface of the
molecule) of the component. The residual part includes the contribution of the group size and
binary interaction between pairs of the functional groups. The thermodynamic model of NRTLSAC has been reviewed in previous chapters.
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4.2.1. VLE, LLE, and SLE prediction
For any component in equilibrium with itself in a multi-phase system, its fugacity in each phase
is equal to the corresponding value in other phases [16]:
f «

f ¬



i

f 

1, 2, … , N

4

1

N is the total number of solvents present in the system. For a vapour-liquid and solid-liquid
equilibrium system, equation 4-1 can be written in the following forms [18]:
SLE : x γ P )O

VLE : x γ P )O

LLE : x γ «

4

f )

y PO=O φ

x γ ¬

2

4

4

3

4

Where x and y are the mole fractions of component i in liquid and vapour phases, respectively.
P )O is the saturation pressure of component i inside the system at any arbitrary temperature and

total pressure PO=O and f ) is the fugacity of component i in the system. φ is the fugacity

coefficient of component i in the vapour phase, which can be equal to unity for low to moderate

pressures. The gaseous mixture is assumed ideal (Lewis-Randall rule) that is possible for low
and moderate pressures. According to equation (4-4), the γ « and γ ¬ are activity coefficients of

component i in two liquid phases of α and β, respectively. Each of equations 4-2 to 4-4 is written

for each phase equilibrium calculation in conjunction with the mass balance for the whole
system. The resulting model equations will enable us to solve the mole and phase fractions in the
system under study.
In order to predict the solid-liquid equilibrium in multi-solvent systems, the activity coefficient
of solute in solution has to be known. The following equation gives the mole fraction of solute at
equilibrium condition [16]:
lnx)

∆GCHI
V

®B



¯



°

B

lnγ)

4

5

Where x) refers to the solute mole fraction, ∆H@A) is the heat of fusion, and TU is the melting

temperature of the solid at normal conditions, which can be measured using characterization
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methods (DSC and TGA) [13]. The γ) is evaluated by activity coefficient thermodynamic

models such as NRTL-SAC model.

4.2.2. Optimization method and procedure
In order to examine the best solvent or mixture of solvents for the crystallization process of a
certain component, a new optimization algorithm was developed with the following objective
functions:
J T, y

J# T, y

SO>

S±>

SO> S±>
SO>

MO> M±>
M)
4

7

4

6

Where J T, y is the yield of the solute precipitation based on the mass of solvent (or mixtures

of solvents). The solubility of the model molecules (Sinitial or Sfinal) are in mass of solute per mass
crystallization and the mass of solvent mixture, M) . In equation (4-6) the Minitial and Mfinal denote

of solute-free solvent. This objective is a function of solubility at both initial and final states of
the initial and final mass of dissolved solute in the solvent of mass Ms. J# T, y is the
crystallization yield based on the initial mass of solute. The main difference between the two

objective functions is their dependency on solvent mass which is used in crystallization. For each
of the above objective functions, there are many constraints which should be met in order to run
the crystallization process safely and reliably. The optimization procedure with detail
formulations in single, binary, and ternary systems are demonstrated in appendix A.
The solvents which were used in the current study with their segment numbers, Antoine
coefficients, and normal boiling points are listed in Table 4-1. There is also a column which
shows the class number of each solvent used in our study, based on the recommendation of U.S.
Food and Drug Administration (FDA) for industries [18]. The solvents are divided to three
classes, with the less recommended solvent for crystallization as class 1 and the favourable
solvent as class 3. As an example, benzene is listed as class 1 due to its carcinogenic nature.
There are many solvents in classes 2 and 3, which can be used in the pharmaceutical industries,
but caution should be taken in separation and purification processes in the downstream of
crystallization process.
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Table 4-1. Segment numbers, Antoine coefficients of vapour pressure, and normal boiling points
of solvents studied in the current work [19] with the class number assigned to each solvent by
Food and Drug Administration (FDA) [18]
Solvent

X

Y-

Y+

Z

A

B

C

Tb [K]

Class

acetic acid

0.048

0.222

0.195

0.206

4.682

1642.540

-39.764

390.58

3

acetone

0.131

0.109

0.513

0.000

4.424

1312.253

-32.445

329.03

3

acetonitrile

0.018

0.131

0.883

0.000

4.279

1355.374

-37.853

354.62

2

anisole

0.536

0.010

0.653

0.000

4.177

1489.756

-69.607

426.24

3

benzene

0.615

0.000

0.281

0.000

4.018

1203.835

-53.226

352.83

1

1-butanol

0.425

0.004

0.000

0.490

4.546

1351.555

-93.340

390.64

3

2-butanol

0.343

0.069

0.000

0.393

4.329

1158.672

-104.683

372.31

3

n-butyl acetate

0.317

0.030

0.330

0.000

4.268

1440.231

-61.362

398.81

3

MTBE

0.483

0.105

0.142

0.000

4.039

1149.261

-43.150

327.71

3

carbon tetrachloride

0.739

0.027

0.142

0.000

4.023

1221.781

-45.739

349.44

1

chlorobenzene

0.727

0.024

0.484

0.000

4.111

1435.675

-55.124

404.37

2

chloroform

0.393

0.000

0.167

0.000

4.208

1233.129

-40.953

334.02

2

cumene

1.161

0.000

0.000

0.000

4.054

1455.811

-65.948

425.04

3

cyclohexane

0.892

0.000

0.000

0.000

4.140

1316.554

-35.581

353.60

2

1,2-dichloroethane

0.394

0.000

0.691

0.000

4.585

1521.789

-24.670

356.56

1

1,1-dichloroethylene

0.529

0.000

0.208

0.000

4.097

1099.400

-35.950

304.29

1

1,2-dichloroethylene

0.188

0.000

0.832

0.000

4.147

1205.400

-42.550

333.20

2

dichloromethane

0.459

0.000

0.427

0.038

4.537

1327.016

-20.474

312.97

2

1,2-dimethoxymethane
N,Ndimethylacetamide
N,Ndimethylformamide

0.277

0.030

0.077

0.057

4.037

1068.350

-50.409

315.06

2

0.160

0.778

0.193

0.000

6.095

2725.960

28.209

419.07

0.180

0.752

0.254

0.000

3.931

1337.716

-82.648

422.97

dimethyl sulfoxide

0.000

1.114

0.000

0.000

4.491

1807.002

-60.995

463.35

3

1,4-dioxane

0.154

0.086

0.401

0.000

4.581

1570.093

-31.297

374.01

2

ethanol

0.251

0.030

0.000

0.630

5.247

1598.673

-46.424

351.12

3

ethyl acetate

0.339

0.058

0.441

0.000

4.228

1245.702

-55.189

349.81

3

ethylene glycol

0.000

0.343

0.000

0.852

5.337

2161.910

-64.720

469.80

2

diethyl ether

0.387

0.028

0.177

0.000

4.022

1062.640

-44.930

309.14

3

ethyl formate

0.256

0.305

0.000

0.000

4.133

1123.943

-54.903

326.86

3

formamide

0.000

0.089

0.341

0.252

7.585

3881.305

27.655

484.04

2

formic acid

0.000

0.090

0.000

0.420

2.001

515.000

-139.408

396.75

3

n-heptane

1.152

0.000

0.000

0.000

4.028

1268.636

-56.199

371.13

3

n-hexane

1.000

0.000

0.000

0.000

4.003

1171.530

-48.784

341.47

2

isobutyl acetate

0.620

0.183

0.541

0.000

4.537

1625.875

-32.494

390.87

3

isopropyl acetate

0.552

0.154

0.498

0.000

4.552

1490.877

-34.098

361.64

3

methanol

0.090

0.139

0.000

0.594

5.204

1581.341

-33.500

337.37

2

2-methoxyethanol

0.082

0.095

0.180

0.361

5.064

1853.556

-30.838

396.87

2
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Table 4-1. Continued
Solvent

X

Y-

Y+

Z

A

B

C

Tb [K]

Class

methyl acetate

0.239

0.000

0.338

0.000

4.204

1164.426

-52.690

329.69

3

3-methyl 1-butanol

0.419

0.000

0.538

0.314

5.080

1932.043

-28.698

408.99

3

methyl butyl ketone

0.673

0.224

0.469

0.000

5.667

2011.668

-45.364

400.33

2

methyl cyclohexane

1.053

0.000

0.246

0.000

3.948

1270.763

-51.734

373.62

2

methyl ethyl ketone

0.261

0.095

0.463

0.000

3.989

1150.207

-63.904

352.22

3

methyl isobutyl ketone

0.673

0.224

0.469

0.000

3.953

1254.095

-71.537

388.79

3
NA

isobutanol
N-methyl-2pyrrolidone

0.566

0.000

0.067

0.485

4.431

1236.991

-101.528

380.68

0.252

0.790

0.281

0.000

12.657

4112.280

-66.866

391.76

nitomethane

0.122

0.000

1.032

0.051

4.405

1446.196

-45.633

373.91

2

n-pentane

0.898

0.000

0.000

0.000

3.989

1070.617

-40.454

308.83

3

1-pentanol

0.458

0.024

0.000

0.491

4.324

1297.689

-110.669

410.77

3

1-propanol

0.374

0.013

0.000

0.530

5.314

1690.864

-51.804

370.00

3

isopropyl alcohol (IPA)

0.332

0.000

0.000

0.636

4.861

1357.427

-75.814

355.06

3

n-propyl acetate

0.514

0.134

0.587

0.000

4.144

1283.861

-64.378

374.20

3

pyridine

0.135

0.000

0.305

0.000

4.163

1371.358

-58.496

387.93

2

sulfolane

0.209

0.089

0.000

0.249

4.533

2255.469

-61.757

559.33

2

tetrahydrofurane

0.235

0.040

0.320

0.708

4.121

1202.942

-46.818

338.71

2

tetrahydronaphtalene

0.924

0.000

0.865

0.000

4.127

1690.912

-70.229

479.98

2

toluene

0.604

0.000

0.304

0.000

4.142

1377.578

-50.507

383.13

2

1,1,1-trichloroethane

0.548

0.000

0.287

0.000

5.886

2210.179

34.902

340.59

1

trichloroethylene

0.552

0.000

0.262

0.000

3.553

974.538

-85.811

360.06

2

m-xylene

0.758

0.021

0.316

0.000

4.134

1462.266

-58.045

411.76

2

2

water

0.000

0.000

0.000

1.000

6.210

2354.731

7.559

371.65

NA

trimethylamine

0.403

0.030

0.000

0.000

4.016

970.297

-34.060

275.66

NA

1-octanol

0.867

0.000

0.000

0.534

6.477

2603.359

-48.799

450.75

NA

n-octane

1.253

0.000

0.000

0.000

4.049

1355.126

-63.633

398.34

NA

4.2.3. Mathematical formulation of the model
In this section, the mathematical formulation of the optimization procedure and the algorithm to
find the constituents mole fractions for single, binary, and ternary solvent mixture is
demonstrated.
Single solvent
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For safety reasons, we enforce the program to choose the upper limit of crystallization
temperature to be less than the melting point of the solid. Therefore, the mathematical
representation of the problem for single solvent optimization is:
min JA T u
TO> , T±>

Subject to

³TO> , T±> ´

³TO> , T±> ´

TO> ¸ T±>

1, 2

4

8

5 µ TU{>O¶

10 µ T)=>·{O )O

TO> and T±> are the initial and final temperatures of the crystallization operation. The vapour
pressure of a pure component (Antoine equation) is found from:
logP )O 

A

B
 C

T )O

i

1, 2, … , N

P bar¢, T K¢

4

9

The values of constants in equation (4-2A) for all the solvents were found from National Institute
of Standards and Technology source [18] and are listed in Table 4-1.
Binary solvents
For the case of binary solvent calculation, in addition to the constraints that are implemented in
the single solvent case, there are additional nonlinear constraints. The initial and final operation
temperatures are calculated based on the bubble point and freezing point of the solvent mixture.
According to the results by Sheikholeslamzadeh and Rohani the NRTL-SAC model can be best
used to predict the VLE behaviour of multicomponent systems [14]. Therefore, we adopted the
NRTL-SAC model to predict the bubble point temperature of the solvent mixture besides the
SLE calculations. The VLE calculations for binary and multi-solvent systems were coded using
methods described elsewhere [16]. In addition to the initial and final temperatures as
optimization variables, initial and final mole fractions of solvents (or their volume ratio) are also
included in the optimization procedure. Therefore, we need to have a framework to relate the
mole fractions of solvents and solute together. For a system of N solvents and a solute, the
procedure for finding the mole fractions of the constituents of the solution is a trial-and-error
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method. If we assume the mole fraction of a solute and solvent z = 1, …, N in the solution is
xsolute and xzs, respectively, then the ratio of mole fractions of two solvents is:
x )
, R#
x# )

R

x# )
, … , R u
xn )

xu )
x )

4

10

And the following relations are obtained for each solvent’s mole fraction:
x )

R x# )

R # xn )

x# )

R R # R n … R u x )
R # R n … R u x )

4

4

11

12

.
.
.
xu )

R u x )

4

13

The sum of the mole fractions of all the components is unity, therefore:
x )  x# )  xn )    xu )  x )  x)=>AO{

1

4

14

With the substitution of equations 4-11 to 4-13 in equation 4-14, we get the following:
x ) R R # … R u  R # R n … R u  …  R u  1  x)=>AO{

1

4

15

Or in compact form:
x

)

u u

¹ R   x )  x)=>AO{

 º

1

4

16

First the solute mole fraction is guessed and with the known values of solvent molar ratios (or
volume ratios) the mole fraction of the last solvent is found. The other solvent mole fractions
will be found using equations 4-11 to 4-13. The trial and error calculation is repeated until the
error between two consecutive mole fractions for each component in the solution is minimized.
The procedure to find the solubility of a solute in a system of N solvents is described elsewhere
[15]. This procedure is inside the optimization loop used in the present work. The optimization
problem for binary solvent case is:
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min JA T, R

u

TO> , T±> , R O> , R ±>

1, 2

Subject to

30= C µ »O> µ t¼½¾TU{>O¶

15= C µ »±> µ t¼½¾TU{>O¶

0 À ÁmÂ,Ã I , mÂ,C I Å À 1000
m

Ä,Ã

I

m

Ä,C

I

T±> µ TO>

TO> µ T )O  PO=O , x, ) , x#, ) 

T±> µ T )O  PO=O , x,@ ) , x#,@ ) 

4

17

5 , 65= C¿

5 , 20= C¿

10

10

Where x, ) and x#, ) are initial solvent mole fractions which are functions of temperature. x,@ )

and x#,@ ) are the final solvent mole fractions, which are functions of final temperature of the

crystallizer. T )O is the bubble temperature of the system of solvents at total pressure of PO=O and

mole fractions of components. Therefore it can be seen that another trail-and-error procedure
should be performed with the optimization for each combination of solvents, simultaneously.
This procedure will be repeated for each possible combination of solvents and finally the values
of optimization will be compared and the maximum yield will be picked as the optimal solvent
combination. If each combination of solvents is denoted by SU, in which m and n are solvent

IDs (which was defined for all the solvents in the program environment), then the optimized
value of operating conditions for each combination will be contained in each element of the
following matrix (matrix in matrix):

OMA

É0
È
È
0
È
ÈÊ
Ç0

R

TO>
R O>

T±>
S
R ±> ,#

0

Ë

…



T
R O>
R O>

T
R O>
R O>

T±>
S Î
R ±> ,
Í
Ê
Í
T±>
S Í
R ±> U, Í
Ì
0
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4

18

OYA

0

ÐÊ

0

S,#
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…

S,
Ê
Ñ
SU,
0 A

u

1,2

4

The OM is the optimization matrix that is made by optimizing
is the matrix of objective functions for u

19
UÒ
#

combination of solvents. OYA

1,2. It should be noted that both matrices are upper

diagonal and the elements of the same solvent are zero. In this study the total number of non-zero
elements of the matrix for the binary solvent was 1891 (which is calculated from

Ó#ÒÓ
#

).

Ternary and quaternary solvents
When the number of solvents in a crystallization process gets larger, the number of combinations
will grow largely. As an example, if one has to examine all the possible combinations of a
Ó#ÒÓÒÓ

ternary solvent mixture from a list of 62 solvents, the total number of 37820 (

n!

) cases

should be considered for optimization. For each case the optimization procedure consists of
linear and nonlinear constraints in addition to VLE and SLE calculations. This procedure is
computationally very intensive. Therefore, we selected a subset from all 62 solvents for each
model molecule to reduce the CPU time. The selection of solvents for ternary calculation was
based on the optimal group of solvents which were found for binary combinations. Additional
solvents which have different segment numbers from the selected binary solvents were also used
for ternary calculation. The additional solvents were selected from the solvents with similar
segment numbers and a less hazardous class of solvents.
For the quaternary solvent optimization, the computational time for all the possible combinations
is much higher (there is a total number of 557845 cases for quaternary system). In the case of
three or four solvent mixtures, the mathematical formulation for optimization is almost the same
as previously described. The difference is in the number of mole fractions present in calculation
of VLE and SLE. Also the nonlinear constraints of the framework will be changed according to
the number of components present in the system. Therefore, the optimization formulation for a
system of N solvents and a solute can be given by:

min JA T, R

TO> , T±> , Õ

u

1, 2

4
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Subject to

30= C µ »O> µ t¼½¾TU{>O¶
15= C µ »±> µ t¼½¾TU{>O¶

0ÀÖ

5 , 65= C¿

5 , 20= C¿

xu, ) xu,@ )
x, ) x,@ )
,
,
…
,
,
× À 1000
x, )
x,@ )
x#, ) x#,@ )

T±> µ TO>

TO> µ T )O PO=O , x, ) , x#, ) , … , x, ) 

T±> µ T )O PO=O , x,@ ) , x#,@ ) , … , x,@ ) 

In which R

10

10

R , R # , … , R   and accounts for initial and final ratio of solvents. The above

operation will be performed for all of the combinations of solvents of interest. The mole fractions

of solvents in the nonlinear constraint are found from the following:
x )

x# )

Ê

R

R R # … R u
S
R R # … R u    R u  1

R

4

R # R n … R u
S
R # R n … R u    R u  1

xu )

R
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R u
S
R # R n … R u    R u  1

For each optimization, the above mole fractions will be initialized and a trial-and-error procedure
is performed to stabilize the final results for each multi-solvent system and its corresponding
SLE containing the solute. If we assume the case of ternary solvent mixture, then we will have a
three-dimensional upper diagonal matrix which contains all the operating points of each ternary
solvent combination at optimal condition. Each non-zero element represents a 2 Ò 3 matrix that

consists of the operating points. As it is shown in equation 4-15A, ØÙÚ is the matrix which
corresponds to all binary combinations with the k OÜ -solvent (the third solvent in a ternary solvent

system):
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1,2

N is the total number of solvents that are added to the binary combination. R O>  and R ±> 
are the initial and final ratios of the iOÜ solvent ratio (m

mJ I

JßÂ

I

). For the quaternary system of

solvents the condition will be more complex, as the matrix of operating conditions will be four

dimensional. For this case, each element inside ØÙÚ,à is a three-dimensional sub-matrix which

contains just the values of three-solvent-combinations for the first solvent picked in fourdimensional matrix. The matrix is shown in equation 4-24.
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4.3. Results and discussion
The selected model molecules are listed in Table 4-2 [12, 13-15]. The physical properties of
model molecules with their four conceptual segment numbers which were used in our study are
also shown in Table 4-2. First, the result of optimization for single solvent case will be
discussed. Then, binary and ternary systems of solvents will be presented. As it was mentioned
earlier, the computation time for finding the best solvent mixture in binary and higher number of
solvent mixtures is prohibitively high. Therefore, the quaternary case is not presented in the
current study since the marginal improvement in the objective functions was found to be
negligible despite the enormous increase in the computational time. The chemical structures of
the model molecules used in this study are shown in Figure 4-2. For all of the computation
works, a computer with 2.67GHz Core (2) Duo processor was used. The computations were
primarily conducted in Matlab environment. It should be noted that the molar ratios which are
mentioned later are the division of the two solvents’ molar contents in a mixture (equation 5-3A).
This has not to be treated as the mole fractions of solvents in the mixture.

Table 4-2. Segment numbers and physical properties of selected components from the literature
Model molecule

Melting

Heat of

Entropy of

temperature [K]

fusion

change

[kJ/mol]

[J/mol-K]

X

Y-

Y+

Z

Lovastatin [13]

445.50

43.14

96.84

1.175

0.000

0.548

0.882

Valsartan [13]

380.65

31.65

83.15

0.000

0.946

0.000

0.539

Paracetamol [12]

443.20

27.60

62.28

0.416

0.016

0.168

1.861

Budesonide [15]

534.00

34.70

64.98

1.000

0.178

0.005

1.079

Allopurinol [15]

653.50

38.50

58.91

0.016

0.002

1.169

0.000

Furosemide [15]

534.30

48.70

91.15

0.600

0.127

0.010

1.620

Sulfadiazine [12]

538.80

31.20

57.91

0.757

0.000

0.000

1.940
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(a)

(b)

(c)

(d)

(e)

(f)

(g)
Figure 4-1. Chemical structure of model molecules used in current study, a: lovastatin, b:
valsartan, c: paracetamol, d: budesonide, e: allopurinol, f: furosemide, g: sulfadiazine

4.3.1. Single solvent screening
According to the description in previous parts, the study on solvent screening was conducted
using single, binary and ternary solvent mixtures. The first category deals with solvent selection
from single solvents. The selections were made among 62 solvents commonly used in research
centers and industries [2]. For each of the objective functions that was defined in previous
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sections, the optimization was performed to find the suitable solvent for crystallization process.
In Table 4-3 the optimal solvent for the single solvent crystallization process of each component
is given. It should be noted that the initial and final temperatures for all of the simulations in
single solvent case were chosen as 40oC and 20oC, respectively. The operating temperatures for
the process were selected to satisfy the safety of the crystallization process.

Table 4-3. The optimal single solvent for each of model components with their starting and
ending operating temperature at 40oC and 20oC, respectively
Model molecule
Solvent

Based on J

¶

Solvent

0.14

Chloroform

Yield

(¶ )=>·{O)

Based on J#

Yield

(¶ O> )=>AO{ Ò 100)
¶

Lovastatin

DMFa

Valsartan

Water

3.01

Pyridine

83.64

Paracetamol

Methanol

0.23

Pyridine

61.88

Budesonide

Ethyl formate

0.13

Pyridine

61.00

Allopurinol

Acetonitrile

Sulfolane

63.55

Furosemide

Ethyl formate

0.03

Formic acid

72.29

Sulfadiazine

DMSOb

0.16

Formic acid

61.86

9.60 Ò 10up

70.51

a: N,N-dimethyl formamide, b: Dimethyl sulfoxide
It can be seen from Table 4-3 that for each pharmaceutical model molecule, there is a solvent
that for all of 7 solutes, the solvent which yielded the highest value for objective J was different

which can produce the maximum yield based on one of the objective functions. It is worth noting
from that of the other objective, J# , which is because of the definition of two objective functions.
For the first objective, in addition to maximizing the yield (amount of crystallized solid), the

minimum consumption of solvent is also included, While the second objective function aims to
maximize the product yield with respect to the initial solute used for crystallization process. This
is more clearly illustrated in Figure 4-2. This figure shows the solubility curves of valsartan in
pyridine and water. From Table 4-3 it is seen that water will maximize the first objective
function, while pyridine optimizes the second objective function. In order to maximize the
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second objective, the final solubility should be as low as possible, while the initial solubility has
minor effect in optimizing this objective function. This shows that one may find some solvents
with near-to-zero solubility at final stage of crystallization and hence, optimize the yield based
on second objective function. However, for the first objective function, in addition of the final
solubility, the initial solubility and solvent usage (mass) also play an important role. The final
selection of the solvent can be better done by considering other parameters such as
environmental and hazardous conditions made by using specific solvent. For example, the
solvent cost is one of the important issues when dealing with the large scale production of
pharmaceuticals or specialty chemicals. If this is the case, the first objective can help an engineer
decide the favourable solvent for the process. On the other hand, if the price of solvent is not
crucial and the chemical is much more expensive, the yield based on the second objective can
help finding the best solvent.

9
8

Pyridine
Water

Solubility, g/g solvent

7
6
5
4
3
2
1
0
15

20

25

30
35
Temperature, oC

40

45

50

Figure 4-2. The obtained solubility curves for valsartan in pyridine and water from NRTL-SAC
model
In order to have a comparative study on the values of two objective functions for the
crystallization of the model molecules in 62 solvents, we used a scatter chart as is shown in
Figure 4-3, which is the single solvent solubility for sulfadiazine. The x-axis represents the
solvent identification number (i.e., the ID for water is 59) and y-axes on the right and left
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illustrate the yield based on the second and first objective functions, respectively. As it is evident
from the figure, for all of the solvents, the second objective function is in the range of 45-62%,
while the first objective function has a value of nearly zero for about 45 solvents. It means that
despite having a reasonable value for the second objective function, many of the solvents could
not give favourable results for the first objective function. Therefore, three solvent candidates
with the most favourable yields for both objective functions can be selected as N,Ndimethylacetamide, DMF, and DMSO. From the three solvents, the DMSO can be the best
¶

solvent, with the yield for the first and second objective functions being equal to 0.16¶ )=>·{O and

47.55%, respectively. However, if one based the selection on the first objective function only,
the DMF would be considered as the optimal single solvent.

0.5

Yield [g solute/g solvent]

0.45

80

Second objective

0.4

70

0.35

60

0.3
50
0.25
40
0.2
30

0.15
0.1

20

0.05

10

Yield % [g precipitate/g initial solute]

90
First objective

0

0
1

11

21

31

41

51

61

71

Solvent ID

Figure 4-3. Comparative illustration of yields for two objective functions for sulfadiazine

4.3.2. Binary solvent screening
In the case of binary solvent screening, the first objective function was used for all possible
combinations of solvents (which is 1891 binary combinations). For the binary solvent case,

87

always one can find a second solvent which leads to complete crystallization, which maximizes
the second objective function. The results of optimal process conditions at initial and final part of
the process when using the first objective function are given in Table 4-4. For each component
there are two solvents which will result in the maximum crystallization of solute per mass of
solvent. In the first column the two selected optimal solvents are shown with their molar and
volume ratios given in the third and fourth columns. The solvent selections and conditions for
each model molecule is discussed. The maximum yield of crystallization for all of the
components based on the first objective function and the corresponding value in terms of second
objective function is shown in Table 4-4. As it was mentioned, the second objective function can
be maximized with some different combinations of solvents, while the first objective is much
restrictive to solvent selections. It should be noted that the value of zero for molar or volume
ratio of solvents in Table 4-4 means that part of crystallization runs with the pure second solvent.
The same thing applies when the ratio is a large number that corresponds to negligible second
solvent. The optimal solvents with the operating conditions for crystallization of each model
component are discussed below.
Lovastatin. In this case, the initial and final temperatures exactly lie on the limits of constraints
for temperature. After optimizing all the possible solvent combinations, dimethyl sulfoxide
(DMSO) and ethyl formate were found as optimal solvent mixture. In Figure 4-4, the solubility
of lovastatin in the mixture of cumene and acetonitrile is demonstrated. As it is evident from the
results, for all the temperatures, the molar ratio of cumene:acetonitrile with the value of 0.35 will
yield the maximum solubility. For the case of crystallization with these solvents, the initial and
final state and temperature can be found from Figure 4-4. This procedure was conducted for all
the binary combinations of solvents to maximize the crystallization yield of lovastatin. From the
results shown in Table 4-4, the volume ratio of DMSO:ethyl formate at the beginning of the
crystallization is 0.47 and the final value is 32.43. This means the crystallization process should
be started with nearly half of DMSO with one unit of ethyl formate at 65oC to dissolve as much
lovastatin as possible. However, at the end of the process at 15oC, the DMSO has to be added to
the vessel to achieve the final ratio of solvents and as a result, maximizing the crystallization
yield. The temperature ranges are exactly the values which were initially set for the
crystallization without any change. This shows that the bubble point of the solvent mixture from
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the start to final part of the process and melting point of solute are higher than the operating
¶

Solubility [g/g solvent mixture]

temperatures. The optimum value of yield for lovastatin is 1.08¶ )=>·{O.
0.2
0.15
0.1
0.05
0
340

320

Temperature [K]

300

0

2

1

3

4

5

Cumene/Acetonitrile molar ratio

Figure 4-4. Solubility of lovastatin in the mixture of cumene and acetonitrile in the temperature
range of 300-340K.

Valsartan. The two optimal solvents for this component are n-heptane and water with the molar
ratio of 0.00 and 28.57 at the beginning and end of crystallization, respectively. From Table 4-4,
it can be seen that the volume ratio of n-heptane to water at both conditions shows that one of the
solvents has a high solubility (water) and the other has a very poor solubility (an anti-solvent).
Paracetamol. For this model molecule, the initial and final states of solvent mole and volume
fractions are at the extreme values, like the valsartan case. The optimum solvents for paracetamol
are cumene and methanol. As the solubility of paracetamol in methanol is very high, specifically
at higher temperatures, the initial condition of the crystallizer should be with pure methanol at
the highest possible temperature. The final state is reached by adding cumene to achieve the
volume ratio of 83.31 (cumene:methanol) to crystallize the solute. This high volume ratio of
cumene to methanol shows the huge addition of cumene as an antisolvent. Also, the temperature
should be selected as low as possible at the final stage.
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Budesonide. The solvents suitable for the highest yield for this component are cyclohexane and
ethyl formate. The procedure of the crystallization is the same as paracetamol, but with different
solvent ratios at the initial and final stages of operation.
Allopurinol. This component generally has a very low solubility in most solvents. Because of
having N-H bonds in its chemical structure, two solvents having the amine and nitrile group were
found as optimum solvents for the crystallization process. Trimethylamine is the best one to
dissolve allopurinol, while the acetonitrile at high concentration is a poor solvent. Therefore, at
the initial stage of the process, a combination of both solvents was identified for the maximum
dissolution. The mixture of two solvents has a high concentration of both nitrile and amine
groups, which may be of help in attracting and dissolving the solid molecule. Other solvents
were not able to dissolve this component compared with the mentioned two solvents. It is worth
noting that the boiling point of trimethylamine and acetonitrile are very low and as a result, the
initial temperature was adopted 39oC for the initial operation.
Furosemide. The optimal binary solvents for this component were found to be ethyl formate and
formic acid as solvent and antisolvent, respectively. The results show that at the end of
crystallization process, the volume fraction of solvent should reach to zero, as the antisolvent
will crystallize almost all of the furosemide dissolved in the solution. The yield of this process is
¶

0.13¶ )=>·{O which is very high. Trying other combinations of solvents resulted in lower yields.

On the other hand, as the first objective function was defined based on the moles of solute per
mole of solvent mixture, the lower molecular weight of mixture of solvents corresponds to the
less mass of solvents consumed. The molecular weight of formic acid and ethyl formate are low
and hence, this makes crystallization operation economical.
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Table 4-4. Optimal conditions of operation for cooling and antisolvent crystallization for the first objective function (J )
Model
component

Lovastatin

Valsartan

Paracetamol

Initial condition

Solvents
(first: second)
DMSO
Ethyl formate
n-heptane
Water
Cumene
Methanol

Molar

Volume

Final condition

Temperature
o

Molar ratio (r1)

Volume ratio
(r1’)

Temperature (oC)

ratio (r1)

ratio (r1’)

( C)

0.54

0.47

65

36.90

32.43

15

0.00

0.00

65

28.57

233.79

19

0.00

0.00

65

24.18

83.31

20

0.00

0.00

64

32.14

42.98

19

4.52

2.67

39

312.44

184.72

20

64.74

138.61

64

0.00

0.00

15

0.08

0.13

65

117.86

179.34

15

Cyclohexane
Budesonide

Ethyl formate
Acetonitrile

Allopurinol

Trimethyl
amine

Furosemide

Sulfadiazine

Ethyl formate
Formic acid
Cyclohexane
DMSO
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Sulfadiazine. In this case, DMSO is found to be the best solvent and cyclohexane as an
antisolvent. The reason why DMSO was picked for the crystallization can be the sulphide groups
which are similar in both solute and solvent. The cyclohexane is a relatively non-polar solvent
which is a poor solvent for this component.

Table 4-5. Optimum yield of first objective function (J1) for model components with its
corresponding yield based on second objective and the CPU time allocated for calculation for
binary solvent optimization
Component

Yield based on J
¶

)
¶ )=>·{O

(

Lovastatin

Yield based on J#

CPU time (hr)

96.58

14.79

¶

¶ O> )=>AO{

(

1.08

Ò 100)

Valsartan

14.24

100.00

2.94

Paracetamol

0.97

100.00

15.41

Budesonide

0.48

3.31

95.17

0.42

Furosemide

9.67 Ò 10up

100.00

0.13

62.14

1.00

Sulfadiazine

0.64

99.42

6.78

Allopurinol

4.3.3. Ternary solvent screening
As it was mentioned in previous sections, the computation time will increase rapidly as the
number of solvents under study increases. From Table 4-5, it can be seen that the required time
to optimize the 62 binary combinations of solvents for the model molecules vary from 1-25hr
CPU time. On the other hand, careful study of all common 62 solvents reveals that around half of
them have similar segment numbers. Therefore, 30 solvents from the pool of 62 solvents were
chosen for ternary solvent optimization. The optimum solvents in binary case are also included
in this subset. The optimum solvent mole and volume ratios are listed in Table 4-6 for each
model molecule. It should be noted that ri and ri’ refer to the ratios of mole or volume of solvent
ith to (i+1)th in each part of crystallization. The results of optimization for the solvents in ternary
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case for the first objective function are shown in Table 4-6. This table shows three solvent
combinations for each model molecule with their initial mole and volume ratios at the beginning
and end of crystallization.
Lovastatin. DMSO is selected as the first solvent, which is similar in the binary case as the
initial solvent for crystallization. The other two solvents screened here are different from that of
the binary case. However, the combination of the two other solvents (cyclohexane and
trimethylamine) is in such a way that the yield is nearly the same in both conditions, which
shows that DMSO has a major effect in crystallization of this component.
Valsartan. For this model molecule, n-heptane and water solvents are the same as in the binary
case. Water is selected as the initial solvent for crystallization. The molar and volume ratios of
two other solvents to water are zero. Ethyl formate is in very small amount with respect to nheptane at the end of the process, which shows the ternary optimization of solvents is nearly the
same as binary case.
Paracetamol. For this component, methanol is the major solvent initially (the same as binary
case), however methanol content is nearly zero at the final part of crystallization. The final part
of crystallization runs with the cumene as the antisolvent with a small amount of water.
Budesonide. As it is evident from Table 4-6, and using equation 4-4A to 4-6A (in appendix A),
the mole fraction of ethyl formate and formic acid are 0.96 and 0.04, respectively. This shows
that a minute amount of formic acid is added to ethyl format at initial part of crystallization. To
increase the yield, formic acid should be added to the system in large amount as is shown in
Table 4-6. Here, the temperature range of crystallization is also bounded nearly to the two limits.
The only difference between this case and the binary case is that formic acid is used as an
antisolvent. The reason for this is the presence of DMSO in the system, which interacts with
other solvents to behave like the cyclohexane interaction in the binary case.
Allopurinol. The solvent combination for ternary system has a higher yield in first objective
function (nearly 15% higher than the binary case). Acetonitrile and trimethylamine are selected
in both binary and ternary systems, however cyclohexane was added at the end of the
crystallization process to crystallize as much solute as possible in the ternary solvent case.
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Furosemide. Ethyl formate is selected in ternary system in initial part of crystallization. While
the final part of crystallization runs with 1,4-dioxane instead of formic acid in the binary solvent
combination. It seems that the yield of the first objective function has changed slightly, while the
second objective for the ternary optimization changed significantly.
Sulfadiazine. DMSO has poor dissolving power for sulfadiazine and that’s why it has been
selected in both binary and ternary systems as a crystallizing anti-solvent agent at the final part
of crystallization process. However, dichloromethane has also been selected in combination with
DMSO in ternary system at the final part of the process. The initial part of crystallization runs
with trimethylamine for the ternary case which has an excellent dissolving characteristic for
sulfadiazine.
The results of yield optimization based on both objective functions are summarized in Table 4-7.
There are some additional points which must be mentioned based on the calculations of the
ternary solvent case:
•

From Table 4-8, the yield based on optimization of the first objective function does not
change significantly compared to the binary case. It is seen that the maximum yield for a
specific component for binary and ternary and also higher combinations is nearly the
same.

•

For nearly all the seven model molecules, the optimum solvents from binary and ternary
mixtures were nearly the same. The solvents which were picked up in the ternary case
were almost from the list of solvents in binary case (Table 4-4).

•

In order to find an optimal solvent or a solvent mixture for a model molecule, the
selection should be made from the pool of binary solvents. As the cost of solvent
recovery and filtration increases with the presence of more solvents. In addition, the yield
change from the binary to ternary solvent systems is not significant.
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Table 4-6. Optimal solvent mole ratios, volume ratios, and temperature for the start and final part of crystallization
Initial condition
Model
molecule

Lovastatin

Valsartan

Paracetamol

Solvents
(first:second:th
ird)
DMSO
Cyclohexane
Trimethyl
amine
Ethyl formate
n-heptane
Water
Water
Cumene

Final condition

Molar ratio
(r1,r2)

Volume ratio (
r1’,r2’)

Temperature (oC)

Molar ratio (r1,r2)

Volume ratio (
r1’,r2’)

Temperature (oC)

2.28, 3.29

1.50, 4.03

65

0.00, 3.364

0.00, 4.12

19

0.00, 0.00

0.00, 0.00

65

0.01, 381.91

0.00, 312.50

15

7.66, 0.00

1.00, 0.00

65

0.00, 19.76

0.00, 68.09

19

0.00, 28.00

0.00, 59.93

64

32.56, 0.00

42.98

15

0.00, 17.55

0.00, 10.38

40

5.63, 0.04

11.66, 0.03

20

0.16, 101.30

0.12, 95.94

65

0.18, 0.00

0.16, 0.00

15

9.83, 344.48

7.91, 475.93

65

25.53, 0.00

20.54, 0.00

20

Methanol
DMSO
Budesonide

Ethyl formate
Formic acid

Allopurinol

Furosemide

Cyclohexane
Acetonitrile
Trimethyl
amine
DMSO
Ethyl formate
1,4-dioxane

Sulfadiazine

DMSO
Trimethyl
amine
Dichloro
methane
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Table 4-7. Optimal values of yield of crystallization for ternary mixture of solvents based on the
first objective function and the second objective function
Yield based on J

Yield based on J#

(¶ )=>·{O)

(¶ O> )=>AO{ Ò 100)

CPU time (hr)

99.96

46.92

Valsartan

14.25

100.00

12.34

Paracetamol

0.97

100.00

76.20

Budesonide

0.49

13.29

96.42

1.31

Furosemide

0.0014

99.84

0.14

99.88

4.00

Sulfadiazine

0.66

99.98

42.78

Component

Lovastatin

Allopurinol

¶

¶

1.10

4.4. Conclusion
In this work the optimal solvent screening for the crystallization of seven pharmaceutical
molecules based on a modified optimization algorithm and the NRTL-SAC thermodynamic
modeling of VLE and SLE of 62 common industrial solvents was successfully accomplished.
The algorithm showed good predictive capability in VLE, LLE, and SLE systems. Two different
objective functions were defined for the optimization. The results of single, binary, and ternary
solvent screening calculations are shown in Table 8. It is evident that, in general, the best choice
to maximize the crystallization yield of a batch cooling-antisolvent process is a binary solvent
system. As an example, the crystallization yield of valsartan and paracetamol increased by 4 and
3 times with respect to the single optimal solvent, respectively. The additional computational and
complexities created do not justify ternary solvent systems. The ternary solvent systems only
affect the second objective function, which for some cases such as furosemide results in an
improved yield. It should be noted that for some optimization cases, the high dilution condition
was happened at either or both ends of crystallization, which shows the possibility of applying
other process methods, such as evaporative crystallization. This work shows the capability of the
thermodynamic model in conjunction with the proposed optimization procedure to yield the best
combination of solvents for optimal performance of a crystallization process, specifically in a
pharmaceutical industry.
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Table 4-8. Optimal yield values for single, binary, and ternary solvent combinations
Component

Single

Binary

Ternary

J1

J2

J1

J2

J1

J2

Lovastatin

0.14

70.51

1.08

96.58

1.10

99.96

Valsartan

3.01

83.64

14.24

100.00

14.25

100.00

Paracetamol

0.23

61.88

0.97

100.00

0.97

100.00

Budesonide

0.13

61.00

0.48

100.00

0.49

99.84

Allopurinol
Furosemide
Sulfadiazine

9.60 Ò 10

up

63.55

0.03

72.29

0.16

61.86

9.67 Ò 10
0.13

62.14

0.0014
0.14

99.88

0.64

99.42

0.66

99.98

up

95.17

96.42
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Chapter 5

Modeling and Optimal Control of Solution Mediated Polymorphic
Transformation of L-Glutamic Acid
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5.1. Introduction
Crystallization process is an important unit operation in the chemical and pharmaceutical
industries. This process involves transport phenomena in which the driving force is
supersaturation that causes the diffusion of mass from the solution to the solid phase [1]. The
difference between the activity of a component in the bulk of a solution and the surface
(saturation point) is the driving force for transport of material. The supersaturation is mostly
achieved by cooling, evaporation, or anti-solvent addition [2]. Advances in technologies of
manufacturing pharmaceutical drugs have had much effect on reducing the time of production
and increasing the safety and profitability of the drugs [3]. Many chemicals and pharmaceuticals
have the ability to crystallize in different lattice shapes that is called polymorphism. The
polymorphs of a substance have the same properties in the solution and gaseous phase, but they
have different behaviour in solid state. There are some properties which make the polymorphs
differ from each other. These include solubility, dissolution rate, bioavailability, colour,
viscosity, density, crystal shape, and mechanical properties [4]. For a pharmaceutical product,
the desired polymorph, the size and the shape of the crystals are important [5]. The efficiency
and performance of many downstream unit operations (such as filtration, drying and milling) in
the particulate industries depend on the quality of the solids produced in the crystallization
operation. Most crystallization processes (especially for the pharmaceuticals) are performed in
batch units. Although the industrial batch processes for crystallization of components are wellunderstood, there are still some factors to study which can affect the size distribution of particles
and the polymorphic distribution of the product [6].
The modeling theory for crystallization processes and generally, particulate systems, was first
proposed by Hulburt and Katz [7]. The methodology pursued and developed by Randolph and
Larson [8]. The theory of particulate processes and population balance equations with their
analytical solutions was extensively studied by Ramkrishna [9]. Analytical solutions of
population balance equation (PBE) are limited to simple problems. For more complex systems
where there are more than one form of crystal (such as polymorphic systems) and in the presence
of dissolution process, the analytical solutions do not exist. There are some numerical methods of
PBE solutions, namely method of moments (Hulburt and Katz [7], Randolph and Larson [8],
Ramkrishna [9], and Marchisio et al. [10]), method of classes (Marshal et al. [11] and Hounslow
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et al. [12]), orthogonal collocation [13], Monte Carlo simulation [14], and finite element method
[15]. From the mentioned methods, method of moments (MoM) and method of classes (MoC)
are easier and faster than other methods which can be used to optimize and control the
crystallization systems. The ease of using the MoM is of importance when dealing with
polymorphic transformation systems.
The method of moments reduces the PBE to a set of ordinary differential equations in terms of
moments. The main drawback of this method is that it cannot generate the crystal size
distribution [1]. Another important note about this method is its inability in solving
crystallization systems in which the kinetic rates are non-linear and size-dependent. Some of the
moments of a population density can be approximated experimentally through the use of sensors
such as focused beam reflectance measurement, FBRM [16]. In the current work we used the
method of moments with the dissolution term added to incorporate the transformation of the
metastable to stable form. The entire concentration-temperature (C-T) surface was divided to
sub-regions and a slightly different model was applied to each region. Because of the rapid
calculation of the proposed method, the optimal control and real-time optimization of such
systems can be very efficient.
In the method of classes, the PBE is transformed into a finite set of ODEs which are produced by
discretization sizing technique [17]. The main difference of this method with the method of
characteristic is the basis of formulation. In method of classes, the ODEs which are generated
from the PBE are in terms of number of particles in each class over the size domain, while in the
method of characteristic the ODEs are based on number density function. The advantage of using
number of particles instead of number density function is the faster numerical processing for the
class method [17].
In the current work, we also have used both methods of moment and classes to get particle
moments, CSD, and concentration evolution over time. In order to speed up the calculation of
ODE sets for the class method, we used MOM and MOC in successive procedure. The output of
the MOM method which consists of birth, growth, and dissolution rates is used as input for the
MOC method. In this way all the variables which make the conventional MOC a very timeintensive method, will be firstly calculated using method of moments, coupled with the mass
balance for the whole system.
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5.2. Process modeling and simulation
The mathematical framework of a crystallizer consists of the population balance equation, mass,
and energy balances [7]. The general one-dimensional form of the population balance equation
for a batch and perfectly mixed system that includes the dissolution term is:
∂f t, L ∂ G t, Lf t, L¢

∂L
∂t

∂ D t, Lf t, L¢
∂L

BAW>{O=, t, LδL

Lä 

5

where i refers to each polymorph in the system. f t, L, G t, L, D t, L, BAW>{O=, , and

1
are

referred to number density function, growth rate, dissolution rate, nucleation rate of polymorph i,
and Dirac delta function, respectively. For the current study we have made some assumptions in
order to simplify the modeling. The breakage and agglomeration of particles were not taken into
account in the system and the volume of the batch is kept constant. The birth term is multiplied

by the Dirac delta function ( ) to impose the nucleation process for particles of size (Lä ). The
term for dissolution rate Dt, L is added to equation 5-1, as the process under study represents a

polymorphic transformation system. It should be noted that for a polymorphic system, depending
on where the process concentration is located on the concentration-temperature (C-T) diagram
(Figure 5-1), the dissolution term has to be added or removed from the equation 5-1.
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Figure 5-1. The schematic representation of the polymorphs solubility and three distinct regions
in between the curves for an arbitrary component; (Region A) nucleation and growth of stable
and metastable forms, (Region B) nucleation and growth of stable form and dissolution of the
metastable form, (Region C) dissolution of both forms.
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In addition to the PBE we need to have mass and energy balance in order to complete the model
description. The mass balance for the batch crystallization system will be:
dCt
dt

3

ρW αå  : G t, LL f t, LdL  3
∞







#

ρW αå  : D t, LL# f t, LdL

5

∞







2

C, ρW , and αå  refer to solute concentration, particle density, and volume shape factor of


polymorph i, respectively. We added the second term on the right side of equation 5-2 to include
the effect of dissolution of polymorphs. The energy balance for a jacketed vessel is:
dTt
ρ) C)
dt

3

∆HWæç)O>>O=, ρ αå  : G t, LL# f t, LdL
∞



 3

W





∆H?))=>AO=, ρW αå  : D t, LL# f t, LdL


∞



UA∆T>U

5

3

ρ) , C) , ∆HWæç)O>>O=, , ∆H?))=>AO=,, UA, and T>U are the solution density, specific heat of the
solution, heat of crystallization, heat of dissolution of polymorph i in solution, overall heat

transfer coefficient, and log-mean temperature of the crystallizer, respectively. In the current
study the temperature of the system can be controlled using a cascade controller. Therefore, the
system temperature is adjusted to the proposed trajectory and the equation 5-3 need not be
solved.
5.2.1. Numerical solution of the model
In order to distinguish the seeded and newly nucleated crystals, we divide the particles into two
parts:
•

Seeded particles with a growth governing process (although in rare cases the nucleation
can also occur on the surface of particles [18]).

•

Newly nucleated particles at high supersaturation levels and then grown in size.

With multiplication of the equation 5-1 by the Lj and after rearrangements, the following
formulation will be derived for each polymorph in the system:
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dµ 
dt
dµ 
dt

BAW>{O=,

jG µ u

jD µ u

j

5

4

1, 2, … ,5

5

5

Equation 5-4 and 5-5 are written for j = 0 to 5 to cover the zeroth to the fifth moment of each
polymorph i present in the system. µ  is the jth moment of polymorph i. Based on the moments

of polymorphs, the mean size of particles of each polymorph can be estimated [1]:
aLéU, b

ê LU f t, LdL

5

∞

ê L f t, LdL
∞

6

aLé, b is the number-averaged and aLép,n b is the volume-averaged mean size for each polymorph.
Having the initial conditions, such as the seed size distribution, concentration, and temperature,

equation 5-4 to 5-5 with mass balance will be solved for each polymorph over time. The seed
size distribution in our study is assumed as [19]:
f 0, L

f){{?, L

ε

√2πσ){{?,

exp 

L

µ){{?, #

2σ){{?, #

"

5

7

In which σ){{?, and µ){{?, are the standard deviation and average size of the seed of polymorph

i and is a constant which is used to set the mass of each polymorph seed. Also the mass of each
polymorph at the start of the process can be evaluated from:
m){{?,

ρ){{?, αå : f){{?, t, LLn dL

5

∞



8

ρ){{?, and f){{?, are the density and number density of polymorph i in the seed. The Dormand-

Prince method (Matlab, 2008) was used to solve the ODE set. The moments for each polymorph
are written for the nucleated particles and seeds, separately. For a system of two polymorphs
(which is the dominant case in crystallization systems), there would be a total of 25 ODEs that
need to be solved, simultaneously. The initial conditions for each set of equations are the
moments of particles for each polymorph (from 0th to 5th moments of seeds), initial temperature,
and concentration.
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Two important evaluated parameters from solving the equations of moment and mass balance for
the polymorphic system are birth and growth rates throughout the process. In order to get the
crystal size distribution of the particles in the slurry for each time step, we used the method of
classes for each polymorph, including the effect of growth and dissolution on the whole model
framework. The conventional method of classes (MOC) can be used for any type of
crystallization system, no matter what type of growth function is applied to the model. Although
we can apply the MOC for any type of system, but the time-demanding nature of the method is
the main drawback. This will be a significant issue when this method has to be used as a model
for control and optimization purposes (i.e., optimal control). To overcome this issue, we
combined the method of moments for the polymorphic system to the method of classes. In this
way the results of MOM will be successively used by MOC to generate CSD of polymorphs
throughout the process time, which we named it as the method of moment and classes (MOMC).
The upcoming formulas were written for all of the polymorphs present in the system. Let us
divide the whole length domain (x-dimension) by m classes and time domain by n. the smallest
value for the length domain is L* (that is the size of particles generated through birth process),
which we assume zero for numerical calculations. The increment of length for each class of
particles is:


L

Lu

5

9

Each class of particles has the average size of:
Lé

L  Lu
2

5

10

In order to discretize the PBE through the length domain, the equation based on number density
function has to be changed to the total number per class version. The number of particles at each
class of length
Nì





is:

: f t, LdL

u

5

11
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By substitution of equation (5-11) into equation (5-1), the following will be generated for each
class:


1 dN t, L Vt
∂ G t, Lf t, L¢
 :
dL
dt
Vt
∂L
u

BAW>{O= or 0



:

u

5

∂ D t, Lf t, L¢
dL
∂L
12

The nucleation term is non-zero for the first class. If we assume the value of number density at
each node (such as j) is the arithmetic average of the average number density of its neighbours,
then:
f t, L 

ééééééééé
féééééééééééé
í t, Lîu   fí t, Lî 
2

5

13

And each term on the right side of equation (5-12) can be substituted with the average value of
number of particles in the class:
f t, L 

NuJ
u


2

NJ

u

5

14

Which gives the general discretized form of PBE equation for each class of j:
1 dNJ Vt
Vt dt

Guì
N
2 u uJ

Gì
Dïì
NJ 
N
2 
2 ï ïJ

Dì
N
2  J

5

15

The above formula is written for m-2 classes, except the first and last classes. For the two
remaining classes (boundaries) we have the following notes:
•

First class; There is no flow of particle from the previous class, and in addition, the
1 dNJ Vt
Vt
dt

Gì
D#ì
NJ 
N
2 
2 # #J

nucleation will only occur here, thus:

•

1 dNdJ Vt
dt
Vt

Dì
N  BAW>{O=
2  J

GUì
GUuì
NUJ 
N
2 U
2 Uu UuJ

DUì
N
2 U UJ

Final class; There is no flow out of this class, and therefore:
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Or in matrix notation:
òòòòóñ Vtb
1 dað
Vt
dt
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Figure 5-2. A sample class (jth class) and its neighbour segments; the arrows represent (1) the
growth of particles from a class of lower average size, (2) crystal growth from the main class, (3)
dissolution from a class higher in average size, (4) crystal dissolution from the main class
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In above notations the class size is set constant throughout the length domain. As it was shown
earlier, the birth and growth rates for the whole dynamic process can be found from the MOM
outputs. Then the values for each time step are used to accelerate the MOC method to generate
the CSD of particles. The schematic diagram of the MOC method for polymorphic system is
shown is Figure 5-2. Based on the initial, boundary conditions, the kinetic parameters of growth,
nucleation, dissolution, and simulation parameters (i.e., time and length domain step
changes),the model will evaluate all the moments, concentration, birth, growth rates, and CSD
over time. In order to solve the ODE set, which contains nucleation, growth, and dissolution
parameters the method of Runge-Kutta with the order of (4,5) has been used as the starting
solution. In order to prevent failure of the mentioned method in some points, the backward
numerical differentiation (Gear’s method) has been added to the program to resolve those points.
The output of the MOM method is the initial points for the MOC method of the polymorphic
time increments, there are t Ò ½ ODE sets that have to be solved. Using MOM as a preliminary
crystallization. As the method was clarified before, based on m segments in size domain and n

method for MOC can speed up the CPU time, significantly. The flowchart for the algorithm of
MOMC method is shown in Figure 5-3.
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Figure 5-3. Algorithm for solving polymorphic transformation using MOMC method
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5.2.2. Objective functions for the optimal control of the process
For the optimal control of a polymorphic transformation crystallization system, we defined three
objective functions which are of importance in industry:
•
•
•

J , maximize the mass of stable polymorph at the final batch time

J# , maximize the average size of particles for the stable form at final batch time
Jn , maximize the mass of metastable form at the final batch time

The optimization procedure involves the discretization of the time domain to a finite time steps
(ù ú a0, ùû b) and then, implementing the constrained NLP to optimize each segment of the control

vector. In order to perform the dynamic optimization, we used the Karush-Kuhn-Tucker (KKT)
method followed by conversion of constrained optimization function to a set of unconstrained
non-linear problems. This algorithm is efficient for the polymorphic transformation system, in
which there are highly non-linear functions of growth, dissolution, and nucleation with mass
balance equation. The mathematical formulation of the optimal control for the process is:
Maximize J > xt, ut, τ

5

21

5

22

5

24

Subject to:
dx
dt

yt

f > xt, ut, π

gxt, ut, π

dut
ü À R Um
R U À ü
dt

UU À ýù À UUm

u±>

Fixed value

5

5

5

23

25

26

where l and i denote the objective function number and the polymorph, respectively. ut is the

control vector (such as operating temperature or anti-solvent flow rate) and xt is the state

variables, which consists of moments, solute concentration, etc. y(t) is any measurement vector
such as mass or volume of polymorphs during the process time.

denotes all the parameters that

are used in kinetic rates. Rmin and Rmax are the minimum and maximum cooling rates. u±> is the
final value of the control vector, which enforces the optimization procedure to bound the control
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at the final batch time. The initial guess for temperature profile is a linear cooling, which for
most cases provides a good start for dynamic optimization procedure.
5.3. The model compound and the simulation using the conventional cooling policies
One of the interesting model compounds to study in the field of polymorphic transformation is Lglutamic acid, which has a stable ( ) and a metastable ( ) form [20]. Scholl et al. conducted
extensive experiments on polymorphic transformation of L-glutamic acid and found the kinetic
parameters representing the important behaviours during the process [21]. Cornel et al. studied
the effect of process parameters (such as stirring rate and impurity) on the transformation rate of
metastable to stable at 45oC [22]. Ono et al. used the Raman spectroscopy to quantify the fraction
of stable to metastable during crystallization of L-glutamic acid at different temperatures [18].
They concluded that the temperature has a strong effect on transformation process. The kinetic
parameters which are used in our study have been found by Scholl et al [21]. Also the data on the
solubility of two forms were found from literature and fitted [20]. All possible cases of
crystallization scenarios based on the initial concentration of solute and its position with respect
to the solubility of two polymorphs, have been studied. For all the cases the volume of system is
kept constant and the temperature profile is changed. The following are the nucleation, growth,
and dissolution kinetic equations implemented in our model [21]:
Bα
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k ¶α Sα
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ln# Sα
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B, G, and D are birth, growth, and dissolution rates, respectively. In the above equations,
supersaturation is defined as the ratio of solute concentration to the solubility concentration at a
given temperature. The kinetic parameters which were used in this study are shown in Table 5-1
[21, 23].
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Table 5-1. Kinetic parameters with their values and units
Symbol
k α

Value

8.0 Ò 10

K α

1.0 Ò 10u

K ¶α

9.0 Ò 10u#

k ¶α

k ?α
k β

K β
k )β

2.5 Ò 10u

#
tn 
t

t


3.5 Ò 10u
5.4 Ò 10p
1.5 Ò 10

6.0 Ò 10p

K )β

1.0 Ò 10un

K ¶β

1.6 Ò 10u

k ¶β

Unit

#
tn 
#
t# 

6.5 Ò 10u

t


Case 1. Supersaturation with respect to both forms (Region A in Figure 5-1)
This case has been studied by Cornel et al., experimentally [22]. In their study they performed
different cases of polymorphic transformation with initial concentration high enough to start
nucleation and growth of both polymorphs. All experiments were conducted at constant
temperature of 45oC. In order to examine the behaviour of the crystallization process, we
assumed that both stable and metastable forms were present, initially. The seed size distribution
of both polymorphs is given by equation 5-7, with parameters given in Table 5-2. The product
quality indices are of high importance in the particulate industry, such as the ratio of the mass of
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the two forms and the ratio of the seeded volume to the newly nucleated volume for each
polymorph.
Table 5-2. Seed size distribution parameters for stable (α) and metastable (β) forms used in
equation 5-7

Polymorph

µ m

ε
1 Ò 10

Stable

50 Ò 10uÓ

1 Ò 10

Metastable

σ m

2 Ò 10uÓ

30 Ò 10uÓ

2 Ò 10uÓ

α·

0.031
0.48

ρW 

kg

mn

1540
1540

In this case study we examined the effect of cooling profile on the supersaturation profile. The
cooling profile was implemented from the following relation [24, 25]:
Tt

T=

T=

T@  N

t

t ¦OWÜ

Q

P

5

32

where T= , T@ , t ¦OWÜ, and P are initial temperature, final temperature, batch time, and a power

number of cooling policy. The value of P can be changed according to the desired policy which

will be implemented on the system. It should be noted that the cooling policy from equation 5-20
is not necessarily give the optimal trajectory. The three following values of P were selected to
cover three common cooling conditions:
•
•
•

P

P

P

0.1, corresponds to an approximation of natural cooling,
1.0, which represents the linear cooling, and

3.0, that can be considered as a non-linear approximate optimal cooling.

The initial solute concentration and temperature are 43g solute/kg solvent and 45oC, respectively.
According to the results shown in Figure 5-4a, the solute concentration drops rapidly using the
natural cooling. Therefore most of the supersaturation is consumed initially, yielding a rich
content of fine particles. For the higher values of P, the concentration curve shows a sudden
decrease at around 0.25 h, and then, there is a moderate supersaturation until nearly the end of
the process. Therefore, the profile with higher value of P will result in a better quality of product.
It should be noted that for all three conditions we assumed simultaneous nucleation and growth
of both polymorphs (region A in Figure 5-1).
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Figure 5-4. (a) Supersaturation profile, (b) Three cooling policies implemented on the crystallization system, (c) the ratio of the stable
to metastable masses, and (d) mass of metastable form of L-glutamic acid over time (for the case 1)
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Figure 5-4c shows that the ratio of the stable to the metastable form for all of the three cooling
policies drops in the first 0.1 h of the process and then increases until the end of the batch time.
However, the values of this ratio are lower than unit for the whole process and for all of the three
cooling policies. The decrease in the ratio in the first part of the process is due to the rapid
growth and nucleation of metastable form in comparison to the stable form. The cooling policy
with P = 3.0 has the highest value of ratios and favours the production of the stable form. From
Figure 5-2d it can be seen that the mass of the metastable form is increased for all of the three
policies, however, for P = 0.1 the increase in metastable production is the highest. Under these
conditions, if the objective is to produce the maximum amount of metastable form, the cooling
policy of P = 0.1 should be selected to favour the formation of that form.
Case 2. Supersaturation with respect to the stable form and undersaturation with respect
to the metastable form
If the initial solute concentration lies in between the solubility curves of the stable and
metastable forms, then the metastable form dissolves. This increases the solute concentration and
thus, the supersaturation with respect to the stable form is raised. The metastable form dissolves
and the stable form is produced. The transformation from the metastable to the stable form will
last until all of the metastable form is dissolved. In this case, we considered three scenarios:
•

Un-seeded condition,

•

Seeded with only the stable form, and

•

Seeded with both polymorphs.

Case 2.1. Un-seeded condition (Region B in Figure 5-1)
At 45oC the solubility of the stable and metastable forms are 16.46 and 23.01 g solute/kg solvent,
respectively. In order to start the crystallization process with an un-seeded condition, there
should be a large supersaturation initially and maintained during the process. Therefore we
selected the initial supersaturation with respect to the stable form as much as possible to induce
the nucleation of this form. It should be noted that the process operating point at start is in region
B of the Figure 5-1. Because of the small distance of the starting point of the process to the
metastable solubility curve, it is more likely that the C-T operating curve crosses the metastable
solubility curve and produces the metastable form to some extent. The batch time for the un115

seeded case was set to 15 h. This is because of the kinetic behaviour of nucleation for L-glutamic
acid which enforces the nucleation to start with much delay. Based on the Figure 5-5, the
supersaturation is a strong function of the cooling rate. For the sudden drop in temperature at the
early stages of the process, there is a sudden increase in supersaturation and then a decrease,
instantaneously. However, the supersaturation profiles for other cooling rates are different. As
the power number for cooling policy (P, equation 5-20) increases, the average supersaturation is
higher and thus, the product quantity and quality will be changed.
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Figure 5-5. Time evolution of supersaturation with respect to the solubility of the stable form
(top) and average size of the stable form based on number-weighted definition (bottom) in case
of un-seeded operation.
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For the natural cooling profile, the average size of the stable form increases until nearly 4 h of
the process, as the supersaturation is high in the early stages of the operation. The average size
(number-weight) remains constant from the 5 h of the process until the end of the batch. This
behaviour is also the same for the case of linear cooling, however in the first 4 h of the process,
the average size is nearly zero. For the case of P = 3.0, the size remains nearly zero for the first
7.5 h of the operation. The second part of the process (for P = 3.0) shows the growth in size.
During this second period, the temperature is suddenly reduced to 25oC. Because of this sudden
change, the nucleation occurs rapidly followed by growth and an increase in the size of the stable
form. It is worth noting that the average size of the particles is based on the number of particles
present in the system, which is different from the volume average size. This type of size was
considered here, as the dominant process is nucleation, instead of the growth. All of the three
curves of average sizes in Figure 5-5 show a maximum point during the process. This happens
because of the rate of change of the first moment of particles is faster with respect to the zeroth
moment of particles at a specific time of the process. However, after that time, the size of
particles tends to be constant. The mass of the stable form produced minus the mass of the
metastable form for a range of cooling policies from a near-to-flat cooling policy during the
considered batch time (P = 4.0) to a sudden drop at initial (P = 0.01) is illustrated in Figure 5-6.
The batch time for all of the power numbers is 2 h.
Based on the results shown in Figure 5-6, two conclusions can be drawn:
•

For small P values up to 0.2, the stable form production is inversely related to the initial
concentration of batch system and this behavior will be reversed for power numbers
higher than 0.2.

•

For each initial concentration, there is an optimum point at which the difference between
the stable and metastable form masses is maximized. For three different initial
concentrations (while all other process and seeding parameters are kept constant), the
optimum power number is related to the initial concentration and its value ranges from
0.17 to 0.47 for initial concentration from 17 to 21 g solute/kg solvent.

It can be concluded that in order to achieve as much stable form as possible for the cooling
policies given by equation 5-20, one has to select a near-to-natural cooling policy. However this
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case is only valid when the process is conducted in an un-seeded manner and the batch time is
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Figure 5-6. Difference of the mass of stable form produced from the metastable in a wide range
of cooling policies for three different initial concentrations
Case 2.2. Seeded only with the stable form (Region B in Figure 5-1)
Here, we seed the crystallizer with the stable polymorph in the absence of the metastable form.
The initial solute concentration for all conditions was set to 20 g solute/kg solvent, 45oC as the
initial temperature, and 20oC as the final temperature. The seed parameters were taken from
Table 5-1, except the average size (µ) and ε which were varied over three values. At first, the ε
was adjusted so as to maintain the same mass of 0.6 g seeds/kg solvent for all three conditions
and µ was changed from 50 to 150µm. The operation time for this case was set to 5 h and the
linear cooling policy was adopted for all of the three seed conditions. We studied the effect of
changing the seed size on the process performance. From Figure 5-7 it is found that no
metastable form is produced during the process because of undersaturation with respect to
metastable form, while the mass of the stable form increases during the run. It should be noted
that the mass of the stable form at the end of the batch for all three seed sizes was almost the
same (12.48 g/kg solvent), which implies the independency of product mass with seed size. This
fact is in agreement with the findings by Cornel et al [22]. For the seeds of higher mean size, the
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precipitation process will be more rapid than the seeds with smaller mean size. As a result, the
supersaturation will be higher for the case of smaller seed size.
The effect of changing the seed mass of the stable form on the process output is shown in Figure
5-8. The seed parameters are the same as the ones in Table 5-1 except for the ε, which defines
the mass of seed. The average size of the seed in three conditions was 50µm. The initial
concentration, initial and final temperature, and other conditions were the same as above.
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Figure 5-7. Concentration evolution (top) and supersaturation (bottom) over time for three
different seeding average sizes (µm)
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Figure 5-8. Supersaturation profile (top) and average size of particles (bottom) for three different
masses of stable form seeds
As the mass of seeds increases, the concentration of solution is dropped more rapidly. This is
because of the presence of more particles that are used as precipitation sites for crystallization
from the solution. Therefore, as it is depicted in Figure 5-8, the supersaturation for the case of
seed mass of 0.6 g/kg solvent has the highest value, while the curve shows the lower values for
the higher mass of seeds. Because finally the concentration is the same for three cases, the same
mass of crystals will be precipitated on the seed surfaces. As a result, at lower seed loading (or
the lower numbers of particles) results in larger average size (Figure 5-8).
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Case 2.3. Seeded with both polymorphs (Region B in Figure 5-1)
In the final case we studied the effect of the presence of stable and metastable form seeds
together. In order to see the effect of dissolution and cooling policy on the product quality, three
cooling scenarios were selected. The seeding for all three cooling policies was the same, with the
average seed size of 40µm and standard deviation of 2µm. Initial solute concentration for all
conditions was set to 20 g solute/kg solvent, 45oC as initial temperature, and 20oC as final
temperature. The seeding mass of metastable and stable forms was 2.39 and 0.03 g seed/kg
solvent, respectively. The reason for setting much higher value for metastable seeding mass
compared with the stable form is the dissolution process of the metastable form, which will be
transferred to the stable form (depending on cooling policy adopted). The process variables are
shown in Figure 5-9.
Figure 5-9a illustrates the average size of the metastable form (L1,0) for the cooling scenarios.
The natural cooling policy (P = 0.1) results in the largest mean size over the entire process (this
is due to the short batch time employed). The sharp increase in the average size is a result of fast
cooling process, which enforces the C-T curve to cross the metastable solubility curve, and
results in the formation of metastable polymorph. The next highest average size is for linear and
non-linear (P = 3.0) scenarios. It is seen that the size of metastable form for these two procedures
lies on each other until nearly 0.5 h after the start of the process. The reason for this behaviour is
that the metastable solubility curve has an approximately equal distance with the C-T curve for
both forms and thus, the same undersaturation. However, after this time, the size of the
metastable form differs for the two policies, as the cooling path shows its effect on the process
output.
Figure 5-9b shows the average size of the stable form over process time. Due to the reduction in
size of metastable form and its dissolution, the stable form will nucleate and grow. It is
interesting to see that the rapid cooling makes the stable form grow in size for nearly 2.5 h of the
process and then increase very slightly. For the case of linear cooling, the size of stable form
rapidly grows (even higher than P = 3.0) and then, approaching a constant value. The last cooling
policy (P = 3.0) shows a near-to-linear growth of stable form, and decreases in slope in the last 1
h of the process. This behaviour is a result of keeping a high and nearly constant supersaturation
throughout the run.
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In Figure 5-9c the supersaturation curves for three methods are displayed. As it is expected for
the rapid cooling policy, the supersaturation sharply increases, and then decreases. The linear
cooling has a lower slope in the C-T curve, but still has high supersaturation in the first 2.5 h of
the process. However, for P = 3.0, because of (1) lower slope in temperature profile and (2)
dissolution of the metastable form at early stage of the process, the supersaturation is maintained
at a nearly constant level. After the whole dissolution of the metastable form, and on the other
hand, cooling of the process (the decrease in temperature starts nearly 2 h after the start of the
process), again the supersaturation is increased. The supersaturation level is nearly constant and
high with an average value of 1.3.
Finally, in Figure 5-9d the masses of the stable and metastable forms over time for three cooling
policies are illustrated. The rapid cooling leads to a high production of metastable form
compared with the other two cooling methods. The final mass of the stable form for the linear
and non-linear cooling (P = 3.0) is almost the same, while the rapid cooling gives the lowest
mass of the stable form and results in highest mass of the metastable form. The initial mass of
the stable seed form is nearly zero, while the mass of the metastable form seed is around 2.4 g
seed/kg solvent. At the end of the batch process, the rapid cooling gives nearly three times of the
metastable product mass as it was seeded, initially. For the other two procedures, almost all of
the metastable form is transformed to the stable form.
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Figure 5-9. Polymorphic transformation in the presence of stable and metastable form seeds using three cooling policies, (a) average size of
metastable, (b) average size of stable form, (c) supersaturation with respect to stable solubility, (d) mass of stable and metastable form
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5.4. Optimal control for polymorphic transformation in the presence of dissolution process
With the conventional cooling discussed above, some cooling policies resulted in higher masses
of the stable or metastable form, while the average size of products was not favourable. On the
other hand, some policies achieved a low mass of product with a desirable average size.
However, using an optimal control policy with the objectives defined in section 1.3, it is possible
to compromise between the yield of the desirable form and its quality in terms of the average
crystal size. All cases are for the seeded crystallization with both the stable and metastable forms
with the initial concentration between the two solubility curves. The initial solute concentration,
initial, and final temperature were selected as 20 g solute/kg solvent, 45oC, and 20oC
respectively. The batch time was selected as 4 h for all of the conditions. The Rmin and Rmax were
taken as 0.0 and 2.0oC/min, respectively. The initial mass of the stable and metastable forms
were 0.03 and 2.39 g seed/kg solvent and the average size of the stable and metastable form
seeds was 40µm with the standard deviation of 2µm.
Figure 5-10 shows the optimal cooling curves in addition of the three conventional cooling
policies. Figure 5-10a shows the six cooling policies for the crystallization process. For the first
objective function (J1, maximizing the mass of the stable form at the end of the batch), the curve
of cooling is nearly a combination of the two non-linear and linear curves. The optimal cooling
curve for the second objective function (J2, maximizing the average size of the stable form at the
end of the process) lies nearly on the cooling policy of P = 3.0 until 2 h of the process start. The
slope will be higher as the process continues to the end of the batch time. The optimal curve for
the third objective function (J3, maximizing the mass of metastable form at the end of the
process) is very different from other cooling policies. Until 1 h into the process, the curve is
nearly the same as the non-linear mode (P=3.0). From the 1 h to the 2 h of the process, the
temperature suddenly drops to the value of 20oC and is kept constant at this temperature until the
end of the process.
The average size of the stable form is illustrated in Figure 5-10b. This shows that the optimal
cooling policy will reach even larger final product size of particles in comparison to the nonlinear cooling. It is worth noting that other values of P higher and lower that P = 3.0 were tried to
confirm that the optimal policy has the highest value of mean size. Figures 5-10c and 5-10d
show the mass of the stable and metastable forms, respectively. It can be seen from Figure 5-10d
124

that the optimal cooling policy for the third objective function, J3, produces the highest mass of
the metastable product, even higher than the rapid cooling. The numerical values of the objective
functions for the optimal and regular policies are shown in Table 5-3.

Table 5-3. Optimal values of mass of stable, metastable, and the size of stable form with their
values of conventional cooling policies
cooling Linear

cooling Non-linear

Objective

Natural

function

(P = 0.1)

(P = 1.0)

cooling (P = 3.0)

8.71

13.02

13.41

13.85

65.54

98.60

148.50

153.83

5.87

1.62

0.67

7.80

¶

¶ )=>·{O

J1 (

)

J2 (µm)
¶

J3 (¶ )=>·{O)

Optimal cooling

Table 5-4 shows the results of simulation for each of the previous cases when the methods of
MOC and MOMC are applied. From the results that are depicted in this table, the MOMC could
best simulate the polymorphic transformation process within the less CPU time than the method
of classes and also, gives the same results.

125

160
A vera g e size (L1 0 , m icrom e te r)

45

140

T e m p e ra tu re (o C )

40

120

35

P = 0.1
P = 1.0
P = 3.0
Optimal condition

100

30
25
20
15
0

Optimal curve (J1)
Linear cooling
Natural cooling
Non-linear cooling (P = 3.0)
Optimal curve (J2)
Optimal curve (J3)

0.5

1

1.5

2
Time (h)

2.5

3

3.5

80
60
40
20
0

4

0.5

1

1.5

2
Time (h)

M a s s o f sta b le fo rm (g /k g s o lv e n t)

14
12
10

4
2
1

4

3

3.5

4

10

6

0.5

3.5

12

P = 0.1
P = 1.0
P = 3.0
Optimal condition

8

0
0

3

(b)
M ass of m etastable form (g/kg solvent)

(a)

2.5

1.5

2
Time (h)

2.5

3

3.5

4

(c)

8
6

P = 0.1
P = 1.0
P = 3.0
Optimal condition

4
2
0
0

0.5

1

1.5

2
Time (h)

2.5

(d)

Figure 5-10. Optimal trajectory of (a) temperature for different objective functions, (b) average size of stable form (J2), (c) mass of
stable form (J1), and (d) Mass of metastable form (J3)
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Table 5-4. Important results of the crystallization process using the two methods of MOC and
MOMC
MOC method (case 1)

MOMC method (case I)

Number of size
intervals

100

[-]

300

300

[-]

Number of time
intervals

100

[-]

400

500

[-]

CPU time

290.84

Second

7.18

7.24

Second

Mass balance
error

1.38e-11

gr/kg

3.55e-14

1.03e-13

gr/kg

MOC method (case 2.1)

MOMC method (case 2.1)

Number of size
intervals

100

[-]

300

300

[-]

Number of time
intervals

100

[-]

400

500

[-]

CPU time

237.73

Second

12.16

12.89

Second

Mass balance
error

1.46e-12

gr/kg

8.01e-013

1.46e-12

gr/kg

MOC method (case 2.2)

MOMC method (case 2.2)

Number of size
intervals

100

[-]

300

300

[-]

Number of time
intervals

100

[-]

400

500

[-]

CPU time

290.84

Second

13.48

14.14

Second

Mass balance
error

1.38e-11

gr/kg

2.65e-14

1.03e-13

gr/kg

MOC method (case 2.3)

MOMC method (case 2.3)

Number of size
intervals

100

[-]

300

300

[-]

Number of time
intervals

100

[-]

400

500

[-]

CPU time

237.73

Second

13.76

14.42

Second

Mass balance
error

1.46e-12

gr/kg

6.11e-13

1.46e-12

gr/kg
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5.5. Conclusion
In this study, modeling of a batch polymorphic crystallization process of L-glutamic acid with
the dissolution term of the metastable form was developed. The model was solved using the
method of moments. The polymorphic transformation process was studied for solutions
supersaturated with respect to both forms and undersaturation with the metastable form. The
effect of cooling policies and seed average size and loadings were studied. The method is so
flexible that can handle any kind of process conditions and seeding parameters. The optimal
control policy was used with three single-objective functions. The optimal profiles show a better
performance in comparison with the conventional cooling policies. Because of changing the
stability of the polymorphic forms beyond a specific temperature in enantiotropic systems
(transition temperature), the modeling and optimal control of such processes is of importance and
interest. Finally, the novel method of MOMC was developed with the combination of two
methods of MOC and MOM. The resulted method showed efficiency in calculation time required
for process modeling. The MOMC method could generate the crystal size distribution of the
crystallization system during the progress of time.
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Chapter 6

Experimental Studies on Crystallization of Polymorphic
Transformation of L-Glutamic Acid
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6.1. Introduction
In the previous chapters, the main focus was on the solubility of different pharmaceuticals in
pure and mixed solvents and also, the crystallization process in solvent screening and
polymorphic transformation systems. In chapter 2, the solubility of pharmaceutical component in
pure and mixed solvents using thermo-gravimetric method was shown. In this chapter, the
experiments on monitoring of the nucleation and polymorphic transformation of L-glutamic acid
are discussed.
It is known that the nucleation in a solution can occur only if there is a high supersaturation. As it
is mentioned previously, the solubility of a solid in a solvent can be measured by different
methods, such as the thermo-gravimetric method which we used in this project. The metastable
zone width however, can't be detected by such methods. At each concentration, there is a region
between the saturated and supersolubility curve know as metastable zone width (MSZW). The
schematic representation of the MSZW is shown in Figure 6-1. The MSZW is dependent on
various process parameters, such as concentration, presence of impurities, cooling rate, and
agitation rate [1]. There are some techniques that have been employed to detect the onset of
nucleation, such as electrical conductivity [2], turbidity [3], ultrasound [4], and focus beam
reflectance measurement (FBRM) [1, 6].
Since a few years ago, the use of in-situ spectroscopic measurements has been started in many
applications of crystallization [6-9]. From the above mentioned methods, the FBRM is an
accurate method in detecting the nucleation process. Thus, we used Lasentec FBRM for our
studies in nucleation and also, polymorphic transformation. The FBRM shows the counts of the
particles dispersed in a solvent as a unit of no. / volume (Figure 6-2). The real time measurement
data is sent to the central computer (HEL pc) for recording and further processing.
In addition to the experiments for the nucleation detection and kinetics, the polymorphic
transformation study was performed with the help of FBRM. For L-glutamic acid, the two
polymorphs have different shapes: stable form is needle like and metastable form is prismatic.
Because of the difference between the particle shapes, the FBRM can qualitatively detect any
significant change in the particle shape distribution and thus, detect polymorphic transformation
process. It should be noted that the detection depends on the crystalline shape of the polymorphs
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of a compound. This gives us the ability to detect the polymorphic transformation using FBRM,
however, there are many other chemicals which have polymorphs that can't be detected using
FBRM technology.
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Figure 6-1. The solubility and nucleation curves for an arbitrary component
Figure 6-2 demonstrates the user interface program for the FBRM probe.

Figure 6-2. FBRM user interface program
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6.2. Nucleation onset and rate detection
The approach to estimate the nucleation kinetics of a solid in a solution from MSZW
experiments was introduced by Nyvlt [10]. He assumed that the nucleation rate at the onset of
nucleation process corresponds to the supersaturation rate. Based on this assumption, the rate of
supersaturation generation can be formulated as a function of the cooling rate:
?2
?O

CR

?9Iª
?B

6

1

Where S, CR, and Csat are referred to supersaturation, cooling rate, and saturation concentration
at a given temperature. Based on the works by Nyvlt, the rate of nucleation can be shown as:
J

k  ∆CU

6

2

Where Jn is the nucleation rate in mass of solid / mass of solvent. He showed that by plotting the
log(MSZW) versus log(CR), one can find the two important parameters of nucleation equation
(m and kn):
logCR

mlogMSZW  logk   m

1log r

dC)O
s
dT

6

3

The two parameters of m and kn that are found from the above equation will be used in the
nucleation rate equation for modeling and prediction purposes.
6.2.1. Experimental procedure
In order to find the nucleation rate of L-glutamic acid at different temperatures, we prepared five
different sets of experiments which were run by an automated program that was built in Matlab
environment. The saturation temperatures chosen for the experiments performed were: 55, 50,
45, and 40oC. Four cooling rates of 0.5, 0.4, 0.3, and 0.2oC/min were selected for nucleation
experiments. In all of the experiments, the stirring rate was adopted as 250 rpm. The stirrer was a
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45o pitch blade made of teflon coated material. The stirring rate was controlled by WinISO
software which is the interface between the operator and the equipment.
First, the required amount of solvent and solid are added together at a temperature higher than
the saturation temperature in the 1-L crystallization vessel which was equipped with a
cooling/heating jacket. The automated process is programmed in the following manner:
1. After the required amount of solid and solvent are added to the vessel, the program starts
to heat the solution 5oC higher than the corresponding saturation temperature of the
solution.
2. After reaching the specified temperature, the FBRM is used to ensure the complete
dissolution of the solids. The temperature will be cooled down with the specified rates
(such as 0.5oC per min) until the nucleation is detected.
3. After the nucleation (or cloud point) is detected by the FBRM, the temperature is kept
constant for 1 hour while the nucleation and growth proceed.
4. The temperature is raised with the same rate of the cooling process until it reaches to the
point mentioned in step 1.
5. The process for other cooling rates will be done (steps 1-4) until all the four cooling rates
are tested for the solution.
6. At this point, the program calls the pump to add required solvent to the vessel to dilute
the solution to the lower saturated temperature.
7. Steps 1-4 are repeated for the new saturation temperature.
8. Step 6 is performed for all of the four saturated temperatures.

It should be noted that all of the above steps were performed three times to get the average
values of saturation and nucleation points.

6.2.2. Results and discussion

In all of the experiments, the beta form (stable form) of the L-glutamic acid were used. The
results of the saturation and cloud points for different experiments are shown in Figures 6-3. As
it can be seen in this figure, the higher cooling rate results in a wider MSZW. For the lower
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saturation temperature, the MSZW is wider and the slope of the nucleation curve is decreased.
Using the results of Figure 6-3, the MSZW as a function of the cooling rate can be found. As it
can be seen from Figure 6-3a, the solubility curve is measured for four different solution
concentrations. The solubility points were found using the heating of the nucleated solution until
28

T = 55oC
T = 50oC

Concentration [g / g solvent]

26

T = 45oC

24

T = 40oC

22
20
18
16
14
12

10

30

50

70

Temperature [oC]

(a)
Concentration [g / g solvent]

28

Saturation curve
Cooling rate = 0.5oC/min
Cooling rate = 0.4oC/min
Cooling rate = 0.3oC/min
Cooling rate = 0.2oC/min

26
24
22
20
18
16
14
12
10

20

30

40

50

60

Temperature [oC]

(b)
Figure 6-3. (a) Measured saturated and nucleation points of solutions of different with the (b)
solubility and nucleation curves for each cooling rate
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the point where all of the nucleated particles disappear. The metastable points for each solution
concentration is found from cooling the saturated solution with different cooling rates. One
example of this procedure is shown in Figure 6-4. As it is shown in this figure, the process starts
from the highest temperature (normally 5oC above the saturation point) and maintained at that
temperature for an hour or more to ensure total dissolution. After reaching to the complete
dissolution, the temperature is decreased with a specified rate until the cloud point is found.
Thereafter, the temperature is maintained constant for about 1 hour while the nucleation is
happening. The temperature again is raised with the same rate to the previous starting value for
dissolution of the nucleated particles. This cycle is repeated three times for a specific solution
concentration and cooling rate. The arithmetic average of the resulted values are shown in Figure
6-3b.
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Figure 6-4. A schematic diagram of cyclic automated operation for the saturation temperature of
40oC

It can be seen from Figure 6-3b that as the cooling rate for a given solution concentration
decreases, the metastable zone width is decreased. As the cooling rate decreases, the time
required for the saturated solution to start nucleating is decreased. As the cooling rate goes up,
the solution takes some time to respond to the changes in temperature and thus, the MSZW is
wider for higher cooling rates. It is worth noting that for some cooling rates that are very high,
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the time required for the onset of nucleation is enough to cross the melting point of the solvent.
That's why we didn't cool the solution beyond the 0.5oC/min.
For each of the saturation points, we examined four cooling rates and therefore, the plot of
logarithm of MSZW versus logarithm of cooling rate can be constructed (Figure 6-5). The four
plots in Figure 6-5 show the data points with their regressed curves. If we compare equation (62) with the fitted curves of the diagrams in Figure 6-5, we can find the values of parameters m
and kn. Table 6-1 contains the calculated values of m and kn for different saturated temperatures.
Table 6-1. Kinetic data on the nucleation of L-glutamic acid from FBRM measurement

55

2.955

dC)O
dT

50

2.820

0.71

45

2.624

0.58

40

2.468
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Saturation
o

temperature [ C]

m

kn
2.78 Ò 10up

0.79

3.84 Ò 10up
4.32 Ò 10up
5.84 Ò 10up

It can be seen from Table 6-1 that the parameter m (the power in equation (6-2)) corresponds to
the saturation temperature. It is important to note that the two parameters of nucleation have
strong dependency on temperature. Therefore, the two following equations are derived from
Table 6-1:
m

k

0.033T  1.142
0.001

2 Ò 10u T

6

4

6

5

If one has to find the overall nucleation kinetic equation for the process, the parameters from
equations (6-4) and (6-5) can be put into equation (6-2) to get:
J

0.001

2 Ò 10u T∆C.nnBï.p#
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Figure 6-5. Diagrams of the plot of logarithm of cooling rate versus logarithm of MSZW for four different saturation temperatures at
constant stirring rate (250rpm)
139

6.3. Polymorphic transformation process

Pure L-glutamic acid (beta form, 99% purity) and monosodium salt of L-glutamic acid (higher
than 99%) were purchased from Sigma Aldrich and used as received without further purification.
The other form of L-glutamic acid (alpha form) is not common in commercial usage and
therefore, we produced it with the method reported in the literature [11, 12]. In order to produce
the alpha form, we employed the pH-shift reaction to precipitate the crystals. The monosodium
salt was dissolved in a specified volume of ultrapure water and after complete dissolution at
around 5oC, the fuming hydrochloric acid (37-38%) was added to the solution drop wise. after
complete addition, the precipitated crystals were filtered and dried. To ensure the production of
the alpha form, XRPD was employed.
In order to check if the FBRM can clearly detect the shape of the two forms of L-glutamic acid,
we made 11 samples of different mass ratios of alpha to beta forms of the component. The
samples contained the pure forms of the polymorphs, as well. The mass of the samples were
chosen to be the same. All of the samples were added to the saturated solutions of L-glutamic
acid to prevent further dissolution. The results of the FBRM measurement after stabilizing, are
shown in Figure 6-6.
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Figure 6-6. Particle size distribution for five different samples of alpha to beta L-glutamic acid
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As it is evident from the Figure 6-6, the samples with the less amount of beta form exhibit the
higher counts in larger class chord length (100-250µm). On the other hand, the samples with
higher amount of beta form compared to the alpha form show finer chord lengths of particles,
specifically in the range of 1-100µm. This confirms the fact that the metastable form has the
needle like shape and therefore, the higher chord length. With this ability of qualitatively
detecting the polymorphic forms of L-glutamic acid, we performed the polymorphic
transformation of the alpha to beta form. The polymorphic transformation experiments were
done at constant temperature of 45oC. At first the saturated solution of beta L-glutamic acid at
45oC was prepared and kept constant at that temperature for 2 hours to ensure complete
dissolution. We added the pure alpha form into the solution around 90 min into the run. This is to
ensure no solid is dispersed in the solution. Once the solid is added to the vessel, as expected, the
number of the counts in the class of 100-250µm started rising and maintained in the range of
3000-4000 counts/s.
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Figure 6-7. Four distinct regions of crystallization of L-glutamic acid: (a) complete dissolution
of stable form, (b) Addition and dissolution of metastable form, (c) Polymorphic transformation,
dissolution of metastable form and formation of stable form, and (d) complete dissolution of
metastable form and formation of stable form
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This region is denoted by B in Figure 6-7. After nearly 300 min from the start of the process, the
counts for the range of 100-250 µm fell gradually until the complete dissolution within 100 min.
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Figure 6-8. X-ray powder diffraction of the polymorphs of L-glutamic acid

It is seen that while the number of particles in the range of 100-250µm started to decrease, the
counts in the range of 1-22µm (mostly the beta form) started increasing. The polymorphic
transformation process happens in region C of the Figure 6-7. Once the whole metastable form is
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disappeared, there will be just the stable form and thus, we see the crystallization (growth) of the
stable form and increasing the counts of the particles (region D in Figure 6-7).
In another experiment, we did a rapid cooling of the solution of alpha form to transform to beta
form. The polymorphic transformation of L-glutamic acid was performed starting at 80oC. First
we dissolved 2.5gr of solid in 200ml of ultrapure water and we let the solids to dissolve
completely in the solvent. The complete dissolution was verified by FBRM probe. After reaching
to this point, the cooler started cooling down to 45oC with a ramp of 1.5oC/min. Soon after
reaching to 45oC, a sample from the solution was filtered and the dried by vacuum drying at
60oC. Other samples of the solution were filtered and dried in 1h, 2.5h, and 5h of the process.
The dried solids were characterized by x-ray powder diffraction (XRPD) and the results show the
polymorphic transformation during the course of the process (Figure 6-8).
The XRPD results in the range of 2-theta between 5-30o is shown in Figure 6-8a. The
characteristic peak is between 2-theta of 10-11o. Figure 6-8b magnifies the mentioned range to
show the change in the intensities for the two forms in more detail.
6.4. Conclusion
In this chapter, we examined two important aspects of crystallization, nucleation and
polymorphic transformation. In both experiments the FBRM spectroscopy was employed to
detect the onset of the nucleation and particle chord length in different classes. In the nucleation
experiments, the solutions at different saturation temperatures were subjected to different cooling
rates to determine the cloud points and then, finding the kinetic parameters of nucleation. We
could find the overall nucleation rate equation for the range of temperature that the experiments
were done. The polymorphic transformation of the L-glutamic acid at 45oC was performed and
qualitatively detected using FBRM probe. The use of FBRM for detection of the polymorphic
transformation was validated using 11 samples of different metastable to stable forms. This study
proved the ability of FBRM probe in detection of nucleation, polymorphic crystallization
processes, and other related applications.
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Chapter 7

Conclusions and Future Works
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This project successfully addressed the two main challenges that a pharmaceutical and in
general, chemical industry is facing. The first challenge is to have a powerful, accurate, and also
flexible thermodynamic model in predicting the phase behaviours of systems exhibiting
equilibrium between phases. The main focus was to model the solid-liquid equilibrium condition
in systems containing a pharmaceutical component in a pure or mixed solvent. Another issue that
this project aimed to solve was to model the crystallization systems consisting of polymorphic
transformation process. This type of phenomenon has been discussed in the industrial
crystallization audience since a few years ago and thus, finding a reliable and fast method of
solving the process variables in dynamic mode will help the researchers and industry in
predicting the behaviour of such systems and optimizing the operating conditions. The main
contribution of this project can be devided into two streams: 1) Applying a new thermodynamic
model to a wide variety of industrial applications and verifying the different phase behaviors of
the systems involved in pharmaceutical industry and 2) introducing a new combined numerical
method of MoMC which could result in a faster and more accurate process simulation of
polymorphic transformation systesm and then be used in dynamic optimization of the process. In
this chapter the brief overview of the important findings in each of the previous chapters is
discussed and finally, the future possible works in the two main streams of research in this
project will be demonstrated.
7.1. Solid solubility prediction and measurement
The two models of NRTL-SAC and UNIFAC were selected for predicting the solubility of three
chemical components in pure and mixed solvents. In order for us to use the NRTL-SAC model,
we had to find the four characteristic parameters of each of those components to be used for
prediction purposes. Therefore, we selected a portion of the experimental data on different pure
and mixed solvents for nonlinear parameter estimation. Then, the NRTL-SAC model was used to
predict the rest of the experimental data and thus, validate the method. The common and
powerful model of UNIFAC was also employed to compare the results with the NRLT-SAC
model. It is worth noting that for the valsartan, the UNIFAC model could not be used, as the
functional groups in the chemical structure of the component have not been defined yet. The
overall ability of the NRTL-SAC model in prediction of the solubility in different conditions,
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directed us to further study the method in modeling other phase behaviour systems which was
the subject of chapter 3.
7.2. VLE, and VLLE prediction for industrial solvent systems
Using the two models of activity coefficient prediction mentioned in section 7.1, we could
successfully implement the NRTL-SAC model for six different binary, ternary, and quaternary
systems of industrial solvents. The results from the model prediction when compared to the
UNIFAC model and experimental data, showed a satisfactory application of the proposed model.
The results of this chapter, especially the bubble point calculation were used as a constraint
nonlinear function in chapter 4.
7.3. Solvent screening process
We developed a novel algorithm of finding the best combination of solvents in binary and
ternary mixture of solvents for a given crystallization process. The single solvent investigation
was also performed using the NRTL-SAC method as a thermodynamic framework for prediction
purposes. The resulted package showed its strength in modeling complex and time-intensive
process of solvent screening for seven selected model components. It should be noted that the
outcomes from chapters 2 and 3 were all used to support the calculation procedure in this
chapter.
7.4. Polymorphic transformation process modeling and optimal control
In this chapter we developed a novel method of combining methods of moment and classes
together to take advantage of both methods. The resulting method could be used to generate CSD
in addition to the moments of particles and other necessary variables in the system. The MoMC
method was used in order to model the batch cooling crystallization of a polymorphic
transformation system in different conditions and with a variety of seed sizes and masses. The
method was also applied to an optimal control procedure to get the optimal trajectory in the
course of crystallization for three important objective functions used in the pharmaceutical
industry. The outcome of this chapter was to build a comprehensive model to include all possible
scenarios that happen in the crystallization of a polymorphic transformation system. The optimal
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control method that applied to the model, showed an improvement in the performance of the
crystallizer for different objective functions.
7.5. Experimental results for crystallization of L-glutamic acid
In chapter 5, we used the dynamical model of the polymorphic crystallization system to predict
the behaviour of the system in different conditions. The experimental part of the crystallization
process, including the nucleation detection, nucleation kinetic study, and polymorphic
transformation process were all performed in chapter 6. The use of particle chord length
measurement probe (FBRM) in detecting the onset of nucleation and disappearance (saturation
point) was shown. The FBRM also showed its capability in detecting the qualitative
transformation from metastable to stable form of L-glutamic acid at constant temperature. The
polymorphic transformation of this model compound was also detected by offline method of
XRPD using different samples from the system at various times of the process.
7.6. Future Works
The results from this project showed that there are more works that are needed to be performed
in the mentioned areas of solution thermodynamics and polymorphic crystallization. For the first
part of study, the use of the NRTL-SAC model was comprehensively studied. However, there are
some points which need to be addressed in solubility prediction of pharmaceutical components:
•

The presence of impurities in the solvent or solid, which may affect solid solubility

•

The presence of two liquid phases with a solid dissolved in the liquid phase

In chapter 3, six important solvent systems that are common in industry were modeled using the
NRTL-SAC model. There are some works that can be done in this field, such as:

•

The study on other systems that exhibit azeotropic behaviors using this model and other
activity coefficient based methods
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In the solvent screening process, there are many factors that can affect the objective functions
defined in chapter 4. Therefore, the study of those factors can be beneficial to improve the
accuracy of the model:
•

Some solvents and solids that are used in our study may react with each other at some
conditions (e.g., temperature). Therefore, having a precise knowledge of the reaction
between the combinations of solvents can be included in the program and may
significantly help the researchers in doing the experimental work safely and without loss
of materials.

•

In the current study, the path of crystallization from the initial to final conditions is not
studied. As it was stated in chapter 4, the assumption was made to consider just two
points of operation (initial and final state). However, in order to have a deeper
understanding of the process, one can include the population balance equations with
required nucleation and growth kinetics in the calculation. It should be noted that in order
to achieve this, a wide range of experimental data on kinetics of nucleation and growth
are needed for each system of solvents.

•

In addition to the two objective functions that are used in our project, one can define
other cost functions to be optimized.

In chapter 5, we studied the polymorphic transformation of L-glutamic acid using method of
moments and also the novel method of MoMC. A few assumptions were made for making the
calculation process easier and faster. In some crystallization processes, the agglomeration and
breakage are common and thus, neglecting their effect on process modeling can result in large
deviations from reality. Therefore, including the effect of other processes, such as breakage and
agglomeration in the mode, can give a more accurate result for some systems.
The objective functions that were defined for optimal control procedure come from industrial
point of view for crystallization processes. There are other objective functions, such as PSD
distribution, which can be studied using the novel method of MoMC, as this is very fast in
calculation compared to the other common methods, such as MoC.
In the area of experimentation, there are some works that need to be done in the field of
polymorphic crystallization process and optimal control. Some examples include the use of
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Raman to detect online composition of polymorphs during the process or application of FBRM
combined with Raman to detect the polymorphic transformation with more accuracy.
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Appendixes
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In the appendix, the codes that were used in all parts of the project are included. It should be
noted that depending on the objective in the project, a few parts of the codes needs to be
changed. These changes are not including the main program, but rather contain the parameter
values, the number of components in the system, and other minor changes. Therefore, the
mentioned codes can be successfully used for the purposes of fluid phase behaviour calculation
and crystallization of different polymorphic systems in dynamic mode.A. Matlab codes for

thermodynamic models
A.1. NRTL-SAC model
function Solubility = Sol(T,y,r,delta_S_R,T_melting,MW)
N = numel(r(1,:));
Tau = [0,1.643,1.643,6.547;1.834,0,0,-2;1.834,0,0,2;10.949,1.787,1.787,0];
binary parameters for conceptual segments)
alpha = [0,.2,.2,.2;.2,0,0,.3;.2,0,0,.3;.2,.3,.3,0];
x(1) = .5;
if (N>=3)
F(1:N-2) = 1;
for i=1:N-2
for j=i:N-2
F(i) = F(i)*y(j);
end
end
else
F = 0;
end
SUM_SOLVENT = sum(F) + 1;
x(N) = (1-x(1))/SUM_SOLVENT;
if (N>=3)
for i = N-1:-1:2
x(i) = x(i+1)*y(i-1);
end
end
Error = 1;
counter = 0;

while(Error>0.000000001)
R(1:N) = 0;
for j=1:N
for i=1:4
R(j) = R(j) + r(i,j);
end
end
phi(1:N) = 0;
for j=1:N
for i=1:N
phi(j) = phi(j) + (R(i)*x(i));
end
phi(j) = R(j)*x(j)/phi(j);
end
L_Gamma_C(1:N)=0;
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%----- Tau (NRTL

for i=1:N
for j=1:N
L_Gamma_C(i) = L_Gamma_C(i) - R(i)*(phi(j)/R(j));
end
L_Gamma_C(i) = L_Gamma_C(i) + log(phi(i)/x(i)) + 1;
end
%------------ Residual part
%------------ local binary quantities
------------for i=1:4
for j=1:4
G(i,j) = exp(-alpha(i,j)*Tau(i,j));
end
end
%----------Activity coefficient of segment species m (Gamma(m)) ------Sum = 0;
for i=1:4
for j=1:N
Sum = Sum + x(j)*r(i,j);
end
end
X(1:4)=0;
for j=1:4
for z=1:N
X(j) = X(j) + (x(z)*r(j,z))/Sum;
end
end
for j=1:N
for i=1:4
XX(i,j) = r(i,j)/R(j);
end
end
Sum_1(1:4) = 0;
Sum_2(1:4) = 0;
Sum_3(1:4) = 0;
Sum_1_I(1:4,1:N)
Sum_2_I(1:4,1:N)
Sum_3_I(1:4,1:N)
SUM_I(1:4,1:N) =
SUM_I_1(1:4,1:N)

%-------

x(j)

%----- x(j,I)

= 0;
= 0;
= 0;
0;
= 0;

for j=1:4
for i=1:4
Sum_1(j) = Sum_1(j) + X(i)*G(i,j)*Tau(i,j);
Sum_2(j) = Sum_2(j) + X(i)*G(i,j);
end
end
SUM(1:4,1:4) = 0;
SUM_1(1:4,1:4) = 0;
for j=1:4
SUM(j) = X(1)*G(1,j) + X(2)*G(2,j) + X(3)*G(3,j) + X(4)*G(4,j);
%----- SUM(m , m')
SUM_1(j) = X(1)*G(1,j)*Tau(1,j) + X(2)*G(2,j)*Tau(2,j) + X(3)*G(3,j)*Tau(3,j) +
%----- SUM_1(m , m')
X(4)*G(4,j)*Tau(4,j);
end
for j=1:4
for i=1:4
Sum_3(j) = Sum_3(j) + X(i)*G(j,i)/SUM(i)*(Tau(j,i)- SUM_1(i)/SUM(i));
end
end
L_Gamma_m_lc = (Sum_1./Sum_2 + Sum_3);

for k=1:N
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for j=1:4
for i=1:4
Sum_1_I(j,k) = Sum_1_I(j,k) + XX(i,k)*G(i,j)*Tau(i,j);
Sum_2_I(j,k) = Sum_2_I(j,k) + XX(i,k)*G(i,j);
end
end
end

for i=1:N
for j=1:4
SUM_I(j,i) = XX(1,i)*G(1,j) + XX(2,i)*G(2,j) + XX(3,i)*G(3,j) + XX(4,i)*G(4,j);
%--SUM_I(component,m')
SUM_I_1(j,i) = XX(1,i)*G(1,j)*Tau(1,j) + XX(2,i)*G(2,j)*Tau(2,j) +
SUM_I(component,m')
XX(3,i)*G(3,j)*Tau(3,j) + XX(4,i)*G(4,j)*Tau(4,j); %--end
end
for k=1:N
for j=1:4
for i=1:4
Sum_3_I(j,k) = Sum_3_I(j,k) + XX(i,k)*G(j,i)/SUM_I(i,k)*(Tau(j,i)SUM_I_1(i,k)/SUM_I(i,k));
end
end
end
L_Gamma_m_lc_I = (Sum_1_I./Sum_2_I + Sum_3_I);
L_Gamma_R(1:N) = 0;
for j = 1:N
for i = 1:4
L_Gamma_R(j) = L_Gamma_R(j) + r(i,j)*(L_Gamma_m_lc(i) - L_Gamma_m_lc_I(i,j));
end
end
Gamma = exp(L_Gamma_C + L_Gamma_R);
Ln_x = delta_S_R.*(1 - T_melting./T) - log(Gamma(1));
x_new(1) = exp(Ln_x);
x_new(N) = (1 - x_new(1))/SUM_SOLVENT;
if (N>=3)
for i = N-1:-1:2
x_new(i) = x_new(i+1)*y(i-1);
end
end
Error = abs(x(1) - x_new(1));
x = x_new;
counter = counter + 1;
if counter> 2000
x = 0;
break;
end
end
M_solution = 0;
for i=1:(numel(x)-1)
M_solution = M_solution + x(i+1)/sum(x(2:end))*MW(i+1);
end
Solubility = x(1)/(1-x(1))*MW(1)/M_solution;
if (Solubility<0)
Solubility = NaN;
end
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A.2. UNIFAC model
function L_Gamma = UNIFAC_new(T,x,a,R,Q,v,K)
NC = nnz(x);
r(1:NC) = 0;
q(1:NC) = 0;
for i=1:NC
for j=1:K
r(i) = r(i) + R(j)*v(j,i);
q(i) = q(i) + Q(j)*v(j,i);
end
end
L(1:NC) = 0;
Phi(1:NC) = 0;
Teta(1:NC) = 0;
SUM_Phi = 0;
SUM_Teta = 0;
SUM_L = 0;
for i=1:NC
L(i) = 5*(r(i) - q(i)) - (r(i) - 1);
SUM_Phi = SUM_Phi + x(i)*r(i);
SUM_Teta = SUM_Teta + x(i)*q(i);
SUM_L = SUM_L + x(i)*L(i);
end
for i=1:NC
Phi(i) = x(i)*r(i)/SUM_Phi;
Teta(i) = x(i)*q(i)/SUM_Teta;
end
%-------------- Combinatorial part of Gamma

-------------

L_Gamma_C(1:NC) = 0;
for i=1:NC
L_Gamma_C(i) = log(Phi(i)/x(i)) + 5*q(i)*log(Teta(i)/Phi(i)) + L(i) - Phi(i)/x(i)*SUM_L;
end
%---------------------------------------------------------TETA(1:K) = 0;
SUM_TETA = 0;
X(1:K) = 0;
SUM_X(1:K) = 0;
SUM_X_mixture = 0;
SAI(1:K,1:K) = 0;
SUM_SAI(1:K) = 0;
SUM_SAI_SAI(1:K) = 0;
for i=1:K
for j=1:NC
SUM_X(i) = SUM_X(i) + v(i,j)*x(j);
SUM_X_mixture = SUM_X_mixture + v(i,j)*x(j);
end
end
for i=1:K
X(i) = SUM_X(i)/SUM_X_mixture;
SUM_TETA = SUM_TETA + Q(i)*X(i);
end
for i=1:K
TETA(i) = Q(i)*X(i)/SUM_TETA;
end
for i=1:K
for j=1:K
SAI(i,j) = exp(-a(i,j)/T);
end
end
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for i=1:K
for j=1:K
SUM_SAI(i) = SUM_SAI(i) + TETA(j)*SAI(j,i);
end
end
for i=1:K
for j=1:K
SUM_SAI_SAI(i) = SUM_SAI_SAI(i) + TETA(j)*SAI(i,j)/SUM_SAI(j);
end
end
L_Gamma_R_K(1:K) = 0;
for i=1:K
L_Gamma_R_K(i) = Q(i)*(1 - log(SUM_SAI(i)) - SUM_SAI_SAI(i));
end
%-------------------- For calculation of Ln_Gamma in component i for
%-------------------- subgroup j
TETA_Component(1:K,1:NC) = 0;
SUM_TETA_Component(1:NC) = 0;
X_Component(1:K,1:NC) = 0;
SUM_X_mixture_Component(1:NC) = 0;
SUM_SAI_Component(1:K,1:NC) = 0;
SUM_SAI_SAI_Component(1:K,1:NC) = 0;
for i=1:NC
for j=1:K
SUM_X_mixture_Component(i) = SUM_X_mixture_Component(i) + v(j,i);
end
end
for j=1:K
for i=1:NC
X_Component(j,i) = v(j,i)/SUM_X_mixture_Component(i);
end
end
for i=1:NC
for j=1:K
SUM_TETA_Component(i) = SUM_TETA_Component(i) + Q(j)*X_Component(j,i);
end
end
for i=1:NC
for j=1:K
TETA_Component(j,i) = Q(j)*X_Component(j,i)/SUM_TETA_Component(i);
end
end
for i=1:NC
for j=1:K
for z=1:K
SUM_SAI_Component(j,i) = SUM_SAI_Component(j,i) + TETA_Component(z,i)*SAI(z,j);
end
end
end
for i=1:NC
for j=1:K
for z=1:K
SUM_SAI_SAI_Component(j,i) = SUM_SAI_SAI_Component(j,i) +
TETA_Component(z,i)*SAI(j,z)/SUM_SAI_Component(z,i);
end
end
end
L_Gamma_R_K_Component(1:K,1:NC) = 0;
for i=1:NC
for j=1:K
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L_Gamma_R_K_Component(j,i) = Q(j)*(1 - log(SUM_SAI_Component(j,i)) SUM_SAI_SAI_Component(j,i));
end
end
L_Gamma_R(1:NC) = 0;
for i=1:NC
for j=1:K
L_Gamma_R(i) = L_Gamma_R(i) + v(j,i)*(L_Gamma_R_K(j) - L_Gamma_R_K_Component(j,i));
end
end

L_Gamma = exp(L_Gamma_R + L_Gamma_C);

A.3. Bubble point calculation for the NRTL-SAC model
function out = BUBBLE_NRTLSAC(P_tot,x,r,Antoine)
N
A
B
C
G

=
=
=
=
=

numel(x);
Antoine(1:N,1);
Antoine(1:N,2);
Antoine(1:N,3);
gamma(x,r);

for i=1:N
T_sat(i) = B(i)/(A(i) - log10(P_tot)) - C(i);
end
T_sol = 0;
for i=1:N
T_sol = T_sol + x(i)*T_sat(i);
end

T0 = T_sol;
options=optimset('Display','iter');
T = fsolve(@(T)fun(T,Antoine,x,G,P_tot),T0,options);
for i=1:N
P_sat(i) = 10^(A(i) - B(i)/(T + C(i)));
end
for i=1:N
y(i) = x(i)*G(i)*P_sat(i)/P_tot;
end
out = [T,y];

A.4. Dew point calculation
function out = DEW(P_tot,y,r,Antoine)
N = numel(y);
A = Antoine(1:N,1);
B = Antoine(1:N,2);
C = Antoine(1:N,3);
for i=1:N
T_sat(i) = B(i)/(A(i) - log10(P_tot)) - C(i);
end
T_sol = 0;
for i=1:N
T_sol = T_sol + y(i)*T_sat(i);
end
for i=1:N
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P_sat(i) = 10^(A(i) - B(i)/(T_sol + C(i)));
end

P_sat_new = 0;
for i=1:N
P_sat_new = P_sat_new + P_tot*(y(i)*P_sat(1)/(P_sat(i)));
end
T = B(1)/(A(1) - log10(P_sat_new(1))) - C(1);
for i=1:N
P_sat(i) = 10^(A(i) - B(i)/(T + C(i)));
end
for i=1:N
x(i) = y(i)*P_tot/P_sat(i);
end
G = gamma(x,r);
P_sat_new = 0;
for i=1:N
P_sat_new = P_sat_new + P_tot*(y(i)*P_sat(1)/(G(i)*P_sat(i)));
end
T_old = B(1)/(A(1) - log10(P_sat_new)) - C(1);
error_1 = 1;
while (error_1>0.00000001)
gamma_old = gamma(x,r);
error_2 = 1;
for i=1:N
P_sat(i) = 10^(A(i) - B(i)/(T_old + C(i)));
end
while (error_2>0.000000001)
for i=1:N
x(i) = y(i)*P_tot/(gamma_old(i)*P_sat(i));
end
%--- x's are normalized
S = sum(x);
for i=1:N
x(i) = x(i)/S;
end
%---------------------gamma_new = gamma(x,r);
error_2 = sum(abs(gamma_new - gamma_old));
gamma_old = gamma_new;
end
G = gamma(x,r);
P_sat_new = 0;
for i=1:N
P_sat_new = P_sat_new + P_tot*(y(i)*P_sat(1)/(G(i)*P_sat(i)));
end
T_new = B(1)/(A(1) - log10(P_sat_new)) - C(1);
error_1 = abs(T_new - T_old);
T_old = T_new;
end
T = T_new;
out = [T,x];
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A.5. Bubble point calculation for the UNIFAC model
function out = Bubble_UNIFAC(P_tot,x,Antoine,a_parameter,R,Q,v,K)
N
A
B
C

=
=
=
=

numel(x);
Antoine(1:N,1);
Antoine(1:N,2);
Antoine(1:N,3);

for i=1:N
T_sat(i) = B(i)/(A(i) - log10(P_tot)) - C(i);
end
T_sol_old = 0;
for i=1:N
T_sol_old = T_sol_old + x(i)*T_sat(i);
end
error = 1;
j = 1;
while(error > 0.00000001)
G = UNIFAC_new(T_sol_old,x,a_parameter,R,Q,v,K);
for i=1:N
P_sat(i) = 10^(A(i) - B(i)/(T_sol_old + C(i)));
end
for i=1:N
y(i) = x(i)*G(i)*P_sat(i)/P_tot;
end
Sum = 0;
for i=1:N
Sum = Sum + x(i)*G(i)*P_sat(i)/P_sat(j);
end
P_sat(j) = P_tot/Sum;
T_sol_new = B(j)/(A(j) - log10(P_sat(j))) - C(j);
error = abs(T_sol_new - T_sol_old);
T_sol_old = T_sol_new;
end
out = [T_sol_old,y];

B. Matlab codes for solvent screening
B.1. Optimization for single solvent
clc
clear all
load('solvent_segment_number');
load('solid');
P_tot = 1.013;
count = 1;
for j=2:9
for i=1:62
T_sat(i) = r_solvent(i,7)/(r_solvent(i,6) - log10(P_tot)) - r_solvent(i,8);
T_max(i) = 40 + 273.15;
T_min(i) = 20 + 273.15;
if(T_max(i) >= solute(j,1) - 5 || T_min(i) >= solute(j,1) - 5 || T_max(i) > T_sat(i) - 10
|| T_min(i) > T_sat(i) - 10)
Mass_per_solvent_1(j,i) = 0;
Mass_per_solvent_2(j,i) = 0;
else
Mass_per_solvent_1(j,i) = (Sol(T_max(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]) - ...
Sol(T_min(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]))/...
Sol(T_max(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]);
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Mass_per_solvent_2(j,i) = (Sol(T_max(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]) - ...
Sol(T_min(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]));
S_1(j,i) = Sol(T_max(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]);
S_2(j,i) = Sol(T_min(i),0,[solute(j,4:7)'
r_solvent(i,1:4)'],solute(j,3),solute(j,1),[solute(j,8) r_solvent(i,5)]);
end
if (Mass_per_solvent_1(j,i)<0)
Mass_per_solvent_1(j,i) = 0;
elseif (Mass_per_solvent_2(j,i)<0)
Mass_per_solvent_2(j,i) = 0;
end
[C_1,I_1] = max(Mass_per_solvent_1(j,:));
[C_2,I_2] = max(Mass_per_solvent_2(j,:));
Max_1(j,:) = [C_1,I_1];
Max_2(j,:) = [C_2,I_2];
count = count + 1
end
count = 1;
end
i = 1;
for T = 273+15:273+50
SS_1(i) = Sol(T,0,[solute(3,4:7)' r_solvent(51,1:4)'],solute(3,3),solute(3,1),[solute(3,8)
r_solvent(51,5)]);
SS_2(i) = Sol(T,0,[solute(3,4:7)' r_solvent(59,1:4)'],solute(3,3),solute(3,1),[solute(3,8)
r_solvent(59,5)]);
i = i + 1;
end
T = 15:50;
plot(T,SS_1);
hold on
plot(T,SS_2,'--');

B.2. Optimization for binary solvent combination
clc
clear all
load('solvent_segment_number');
load('solid');
P_tot = 1.013;
starting_solvent = 1;
ending_solvent = 62;
solute_ID = 9;
tic;
for i = starting_solvent:ending_solvent-1
for j = i + 1:ending_solvent
x0 = [273+40;1;273+20;1];
lb = [273.15+30;0;273.15+15;0];
ub = [273.15+min(solute(solute_ID,1)-273.15-5,65);1000;273.15+min(solute(solute_ID,1)273.15-5,20);1000];
A = [-1,0,1,0]; b= 0;
[x,fval] = fmincon(@(x)(1).*binary(x,solute_ID,i,j),x0,A,b,[],[],lb,ub,@(x)binary_const(x,P_tot,[r_solvent(i,1:4)'
r_solvent(j,1:4)'],[r_solvent(i,6:8);r_solvent(j,6:8)]));
Initial_Temperature(i,j) = x(1);
Final_Temperature(i,j) = x(3);
Initial_Solvent_Ratio(i,j) = x(2);
Final_Solvent_Ratio(i,j) = x(4);
Yield_per_Solvent(i,j) = fval;
end
end
toc;
CPU_time = toc/3600;

161

function F = binary(y,solute_ID,solvent_1_ID,solvent_2_ID)
load('solvent_segment_number');
load('solid');
F = (Sol(y(1),y(2),[solute(solute_ID,4:7)' r_solvent(solvent_1_ID,1:4)'
r_solvent(solvent_2_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent(solvent_1_ID,5) r_solvent(solvent_2_ID,5)])...
- Sol(y(3),y(4),[solute(solute_ID,4:7)' r_solvent(solvent_1_ID,1:4)'
r_solvent(solvent_2_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent(solvent_1_ID,5) r_solvent(solvent_2_ID,5)]));
end

B.2.1. Constraints for binary solvent combination
function [c,ceq] = binary_const(x,P_tot,r,Antoine)
c(1) = x(1) - 10 - BUBBLE_NRTLSAC(P_tot,[x(2)/(1+x(2));1/(1+x(2))],r,Antoine);
c(2) = x(3) - 10 - BUBBLE_NRTLSAC(P_tot,[x(4)/(1+x(4));1/(1+x(4))],r,Antoine);
ceq = 0;
end

B.3. Optimization code for ternary solvent combination
clc
clear all
load('solvent_segment_number_1');
load('solid');
P_tot = 1.013;
% solvent_1_ID = 5;
% solvent_2_ID = 6;
starting_solvent = 1;
ending_solvent = 30;
tic;
% count_first_solvent = 1;
% count_second_solvent = 1;
z = 1;
for solute_ID = 9:9
for i = starting_solvent:ending_solvent - 2
for j = i + 1:ending_solvent - 1
for k = j + 1:ending_solvent
x0 = [273+40;1;1;273+20;1;1];
lb = [273.15+30;0;0;273.15+15;0;0];
ub = [273.15+min(solute(solute_ID,1)-273.155,65);500;500;273.15+min(solute(solute_ID,1)-273.15-5,20);500;500];
A = [-1,0,0,1,0,0]; b= 0;
[x,fval] = fmincon(@(x)(1).*ternary(x,solute_ID,i,j,k),x0,A,b,[],[],lb,ub,@(x)ternary_const(x,P_tot,[r_solvent_1(i,1:4)',
r_solvent_1(j,1:4)',
r_solvent_1(k,1:4)'],[r_solvent_1(i,6:8);r_solvent_1(j,6:8);r_solvent_1(k,6:8)]));
Initial = Sol(x(1),[x(2),x(3)],[solute(solute_ID,4:7)' r_solvent_1(i,1:4)'
r_solvent_1(j,1:4)'
r_solvent_1(k,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent_1(i,5) r_solvent_1(j,5) r_solvent_1(k,5)]);
Final = Sol(x(4),[x(5),x(6)],[solute(solute_ID,4:7)' r_solvent_1(i,1:4)'
r_solvent_1(j,1:4)'
r_solvent_1(k,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent_1(i,5) r_solvent_1(j,5) r_solvent_1(k,5)]);
Initial_Temperature(i,j,k,z) = x(1);
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%

Final_Temperature(i,j,k,z) = x(4);
Initial_Solvent_Ratio_1(i,j,k,z) = x(2);
Initial_Solvent_Ratio_2(i,j,k,z) = x(3);
Final_Solvent_Ratio_1(i,j,k,z) = x(5);
Final_Solvent_Ratio_2(i,j,k,z) = x(6);
Yield_per_solvent_1(i,j,k,z) = -fval;
end
count_first_solvent = count_first_solvent + 1;
end
end
toc;
CPU_time(z) = toc/3600;
z = z + 1;
tic;

end
for solute_ID = 1:1
[c,i] = max(Yield_per_solvent_1);
[t,j] = max(c);
[y,k] = max(t);
Index(solute_ID,:) = [ i(:,j(:,:,k(:,:,:,solute_ID),solute_ID),k(:,:,:,solute_ID),solute_ID)
, j(:,:,k(:,:,:,solute_ID),solute_ID) , k(:,:,1,solute_ID) ];
max_solubility(solute_ID) =
Yield_per_solvent_1(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID);
Initial_Temp(solute_ID) =
Initial_Temperature(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID);
Final_Temp(solute_ID) =
Final_Temperature(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID);
Initial_Sol_Ratio(solute_ID,:) =
[Initial_Solvent_Ratio_1(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)
Initial_Solvent_Ratio_2(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)];
Final_Sol_Ratio(solute_ID,:) =
[Final_Solvent_Ratio_1(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)
Final_Solvent_Ratio_2(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)];
Initial_Volume_Ratio(solute_ID,:) =
[Initial_Solvent_Ratio_1(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)*r_so
lvent_1(Index(solute_ID,1),5)/r_solvent_1(Index(solute_ID,2),5)*r_solvent_1(Index(solute_ID,2),10
)/r_solvent_1(Index(solute_ID,1),10)
Initial_Solvent_Ratio_2(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)*r_sol
vent_1(Index(solute_ID,2),5)/r_solvent_1(Index(solute_ID,3),5)*r_solvent_1(Index(solute_ID,3),10)
/r_solvent_1(Index(solute_ID,2),10)];
Final_Volume_Ratio(solute_ID,:) =
[Final_Solvent_Ratio_1(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)*r_solv
ent_1(Index(solute_ID,1),5)/r_solvent_1(Index(solute_ID,2),5)*r_solvent_1(Index(solute_ID,2),10)/
r_solvent_1(Index(solute_ID,1),10)
Final_Solvent_Ratio_2(Index(solute_ID,1),Index(solute_ID,2),Index(solute_ID,3),solute_ID)*r_solve
nt_1(Index(solute_ID,2),5)/r_solvent_1(Index(solute_ID,3),5)*r_solvent_1(Index(solute_ID,3),10)/r
_solvent_1(Index(solute_ID,2),10)];
end
for i=1:1
V_initial(i,:) = [Initial_Volume_Ratio(i,1)*Initial_Volume_Ratio(i,2)*1000./(1 +
Initial_Volume_Ratio(i,2)*Initial_Volume_Ratio(i,1) + Initial_Volume_Ratio(i,2))
Initial_Volume_Ratio(i,2)*1000./(1 + Initial_Volume_Ratio(i,2)*Initial_Volume_Ratio(i,1) +
Initial_Volume_Ratio(i,2)) 1000./(1 + Initial_Volume_Ratio(i,2)*Initial_Volume_Ratio(i,1) +
Initial_Volume_Ratio(i,2))];
V_final(i,:) = [Final_Volume_Ratio(i,1)*Final_Volume_Ratio(i,2)*1000./(1 +
Final_Volume_Ratio(i,2)*Final_Volume_Ratio(i,1) + Final_Volume_Ratio(i,2))
Final_Volume_Ratio(i,2)*1000./(1 + Final_Volume_Ratio(i,2)*Final_Volume_Ratio(i,1) +
Final_Volume_Ratio(i,2)) 1000./(1 + Final_Volume_Ratio(i,2)*Final_Volume_Ratio(i,1) +
Final_Volume_Ratio(i,2))];
end

function F = ternary(y,solute_ID,solvent_1_ID,solvent_2_ID,solvent_3_ID)
% load('solvent_segment_number');
load('solvent_segment_number_1')
load('solid');
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F = Sol(y(1),[y(2),y(3)],[solute(solute_ID,4:7)' r_solvent_1(solvent_1_ID,1:4)'
r_solvent_1(solvent_2_ID,1:4)'
r_solvent_1(solvent_3_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent_1(solvent_1_ID,5) r_solvent_1(solvent_2_ID,5) r_solvent_1(solvent_3_ID,5)])...
- Sol(y(4),[y(5),y(6)],[solute(solute_ID,4:7)' r_solvent_1(solvent_1_ID,1:4)'
r_solvent_1(solvent_2_ID,1:4)'
r_solvent_1(solvent_3_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent_1(solvent_1_ID,5) r_solvent_1(solvent_2_ID,5) r_solvent_1(solvent_3_ID,5)]);
end
function F = ternary_1(y,solute_ID,solvent_1_ID,solvent_2_ID,solvent_3_ID)
load('solvent_segment_number');
load('solid');
F = (Sol(y(1),[y(2),y(3)],[solute(solute_ID,4:7)' r_solvent(solvent_1_ID,1:4)'
r_solvent(solvent_2_ID,1:4)'
r_solvent(solvent_3_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent(solvent_1_ID,5) r_solvent(solvent_2_ID,5) r_solvent(solvent_3_ID,5)])...
- Sol(y(4),[y(5),y(6)],[solute(solute_ID,4:7)' r_solvent(solvent_1_ID,1:4)'
r_solvent(solvent_2_ID,1:4)'
r_solvent(solvent_3_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent(solvent_1_ID,5) r_solvent(solvent_2_ID,5) r_solvent(solvent_3_ID,5)]))...
/ Sol(y(1),[y(2),y(3)],[solute(solute_ID,4:7)' r_solvent(solvent_1_ID,1:4)'
r_solvent(solvent_2_ID,1:4)'
r_solvent(solvent_3_ID,1:4)'],solute(solute_ID,3),solute(solute_ID,1),[solute(solute_ID,8)
r_solvent(solvent_1_ID,5) r_solvent(solvent_2_ID,5) r_solvent(solvent_3_ID,5)]);
end

B.3.1. Constraints for ternary solvent combination
function [c,ceq] = ternary_const(x,P_tot,r,Antoine)
c(1) = x(1) - 10 BUBBLE_NRTLSAC(P_tot,[x(2)*x(3)/(1+x(2)*x(3)+x(3)),x(3)/(1+x(2)*x(3)+x(3)),1/(1+x(2)*x(3)+x(3))],
r,Antoine);
c(2) = x(4) - 10 BUBBLE_NRTLSAC(P_tot,[x(5)*x(6)/(1+x(5)*x(6)+x(6)),x(6)/(1+x(5)*x(6)+x(6)),1/(1+x(5)*x(6)+x(6))],
r,Antoine);
ceq = [];
end

C. Matlab codes for MOMC of polymorphic transformation
C.1. Batch crystallization simulation for polymorphic system
function ANS =
batch_crystal(T_F1,T_F2,S,U,U_1,a,m,L0,LN,Ostwald_Factor,seed_constant_stable,seed_constant_unsta
ble,seed_STD_stable,seed_STD_unstable,...
seed_ave_size_stable,seed_ave_size_unstable,rho_stable,rho_unstable,rho_solvent,kv_stable,kv_unst
able,C_0,T_0,batch_time,...
KB1,KB2,KBB1,KBB2,KB_1,KBB_1,KD,ID,KD_1,KG1,KG2,KG_1,G_1)
%-----------------------------------------------------------------% ANS(t,1) = zeroth momemnt metastable
% ANS(t,2) = first momemnt metastable
% ANS(t,3) = second momemnt metastable
% ANS(t,4) = third momemnt metastable
% ANS(t,5) = zeroth momemnt stable
% ANS(t,6) = first momemnt stable
% ANS(t,7) = second momemnt stable
% ANS(t,8) = third momemnt stable
% ANS(t,9) = concentration
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%
%
%
%

ANS(t,10) = fourth momemnt metastable
ANS(t,11) = fourth momemnt stable
ANS(t,12 - m+11) = number of particles in each interval for metastable
ANS(t,m+12 - 2*m+11) = number of particles in each interval for metastable

%-----------------------------------------------------------------

%
%
%
%
%

a = length(Temperature);
m = 500;
L0 = 0;
%--- [micrometer]
LN = 150*10^-6;
%--- [micrometer]
ostwald_factor = 0;

%-- seeding parameters
% lamda = [8.227*10^7 , 3.877*10^8 , 3.731*10^8 ; 2.483*10^10 , 1.63*10^10 , 1.501*10^10];
% sigma = [8.608 , 12.127 , 12.115 ; 27.289 , 27.989 , 28.131]*10^-6;
% miu = [214.977 , 127.269 , 127.427 ; 155.069 , 155.017 , 155.007]*10^-6;
CSD_Alpha(1,:) =
seed_csd(seed_constant_unstable,seed_STD_unstable,seed_ave_size_unstable,m,L0,LN)';
CSD_Beta(1,:) = seed_csd(seed_constant_stable,seed_STD_stable,seed_ave_size_stable,m,L0,LN)';
%----------------------------------%
%
%
%
%

rho_crystal = 1540;
alpha_v = .031;
rho_crystal_1 = 1540;
alpha_v_1 = .48;
rho_solvent = 990;

phi = (LN-L0)/m;
f0 = CSD_Beta(1,:);
f0_1 = CSD_Alpha(1,:);
L=(L0+phi/2):phi:(LN-phi/2);
%----------For the stable polymorph
%---- Initial conditions
miu_0 = trapz(L,f0);
miu_1 = trapz(L,f0.*L);
miu_2 = trapz(L,f0.*L.^2);
miu_3 = trapz(L,f0.*L.^3);
miu_4 = trapz(L,f0.*L.^4);
miu_5 = trapz(L,f0.*L.^5);
%----------- For the metastable polymorph
%---- Initial conditions
miu_0_1 = trapz(L,f0_1);
miu_1_1 = trapz(L,f0_1.*L);
miu_2_1 = trapz(L,f0_1.*L.^2);
miu_3_1 = trapz(L,f0_1.*L.^3);
miu_4_1 = trapz(L,f0_1.*L.^4);
miu_5_1 = trapz(L,f0_1.*L.^5);
Mass_of_Alpha_seed = rho_unstable/rho_solvent*kv_unstable*1000*miu_3_1;
Mass_of_Beta_seed = rho_stable/rho_solvent*kv_stable*1000*miu_3;
%----------For the first polymorph
N0 = [ miu_0_1 miu_1_1 miu_2_1 miu_3_1 miu_0 miu_1 miu_2 miu_3 C_0 miu_4_1 miu_4 0 0 0 0 0 0 0 0
0 0 miu_5_1 miu_5 0 0];
t_final = batch_time*3600;
delta_t = t_final/a;
result(1,1:15) = [N0(1:11),N0(22),N0(23),0,0];
MIU_OF_PARTICLES(1,:) = N0;
CSD_stable(1:m,1) = f0';
CSD_metastable(1:m,1) = f0_1';
z = 2;

165

for i=1:a
if (i<=S)
T(i) = T_0 - (T_0 - T_F1)*(delta_t*i/(delta_t*S))^U;
else
T(i) = T_F1 - (T_F1 - T_F2)*(delta_t*(i-S)/(t_final - delta_t*S))^U_1;
end
end
T = [T_0 T];
Supersaturation_stable(1) = result(1,9)/solubility(T(1));
Supersaturation_metastable(1) = result(1,9)/solubility_1(T(1));
Number_ave_size_stable(1) = result(1,6)/result(1,5)*10^6;
Number_ave_size_metastable(1) = result(1,2)/result(1,1)*10^6;
Volume_ave_size_stable(1) = result(1,11)/result(1,8)*10^6;
Volume_ave_size_metastable(1) = result(1,10)/result(1,4)*10^6;
Mass_stable_form_produced(1) = Mass_of_Beta_seed;
Mass_unstable_form_produced(1) = Mass_of_Alpha_seed;
tic;
for i=2:a+1
kb1 = KB1;
kb2 = KB2;
kbb1 = KBB1;
kbb2 = KBB2;
kb_1 = KB_1;
kbb_1 = KBB_1;
kd = KD;
id = ID;
kd_1 = KD_1;
kg1 = KG1;
kg2 = KG2;
kg_1 = KG_1;
g_1 = G_1;

tspan = 0:delta_t/3:delta_t;
if (result(end,9) >= (1 + Ostwald_Factor)*solubility_1(T(i)))
kd_1 = 0;
kd = 0;
kb1 = 0;
kb2 = 0;
kbb1 = 0;
kbb2 = 0;
kg1 = 0;
elseif (result(end,9) > solubility_1(T(i)) && result(end,9) < (1 +
Ostwald_Factor)*solubility_1(T(i)))
kd_1 = 0;
kd = 0;
elseif (result(end,9) > solubility(T(i)) && result(end,9) <= solubility_1(T(i)))
if (result(end,1)<=0 || result(end,2)<=0 || result(end,3)<=0 || result(end,4)<=0 ||
result(end,10)<=0)
N0(1) = 0;
N0(2) = 0;
N0(3) = 0;
N0(4) = 0;
N0(10) = 0;
N(22) = 0;
N0(12) = 0;
N0(13) = 0;
N0(14) = 0;
N0(15) = 0;
N0(16) = 0;
N(24) = 0;
kd_1 = 0;
kb_1 = 0;
kg_1 = 0;
kd = 0;
Number_ave_size_metastable(z) = 0;
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Volume_ave_size_metastable(z) = 0;
else
kb_1 = 0;
kg_1 = 0;
kd = 0;
end
else
kb1 = 0;
kb2 = 0;
kbb1 = 0;
kbb2 = 0;
kg1 = 0;
kg2 = 0;
kb_1 = 0;
kg_1 = 0;
end
options=optimset('Display','iter');
t N] = ode45(@(t,N)
batch_sim1(t,N,T(i),rho_stable,kv_stable,rho_unstable,kv_unstable,rho_solvent,kb1,kb2,kbb1,kbb2,k
b_1,kbb_1,kd,kd_1,kg1,kg2,kg_1,g_1),tspan,N0,options);
for q=1:numel(N)
if N(q)<0
N(q) = 0;
end
end
N = real(N(end,:));
N0 = N;
MIU_OF_PARTICLES(z,:) = N;
%------------------------------------------------------------result(z,1) = N(1) + N(12);
result(z,2) = N(2) + N(13);
result(z,3) = N(3) + N(14);
result(z,4) = N(4) + N(15);
result(z,5) = N(5) + N(17);
result(z,6) = N(6) + N(18);
result(z,7) = N(7) + N(19);
result(z,8) = N(8) + N(20);
result(z,9) = N(9);
result(z,10) = N(10) + N(16);
result(z,11) = N(11) + N(21);
result(z,12) = N(22) + N(24);
result(z,13) = N(23) + N(25);
%------------------------------------------------------------B_stable(z) = Birth(kb1,kb2,T(i),result(end,9),kbb1,kbb2,result(end,4));
B_metastable(z) = Birth_1(kb_1,T(i),result(end,9),kbb_1);
Dissolution_stable(z) = Dissolution(kd,T(i),result(end,9));
Dissolution_metastable(z) = Dissolution_1(kd_1,T(i),result(end,9));
Growth_stable(z) = growth(kg1,kg2,T(i),result(end,9));
Growth_metastable(z) = growth_1(kg_1,g_1,T(i),result(end,9));
G_stable(z) = Growth_stable(end) - Dissolution_stable(end);
G_metastable(z) = Growth_metastable(end) - Dissolution_metastable(end);
Supersaturation_stable(z) = result(end,9)/solubility(T(i));
Supersaturation_metastable(z) = result(end,9)/solubility_1(T(i));
Number_ave_size_stable(z) = result(end,6)/result(end,5)*10^6;
Number_ave_size_metastable(z) = result(end,2)/result(end,1)*10^6;
Volume_ave_size_stable(z) = result(end,8)/result(end,7)*10^6;
Volume_ave_size_metastable(z) = result(end,4)/result(end,3)*10^6;
result(z,14) = B_metastable(z)/G_metastable(z);
result(z,15) = B_stable(z)/G_stable(z);
Number_stable = f0.*phi;
Number_metastable = f0_1.*phi;
NUM_STABLE(z,1:m) = Number_stable;
NUM_UNSTABLE(z,1:m) = Number_metastable;
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[t F] =
ode45(@(t,f)CSD(t,f,Growth_stable(z),Dissolution_stable(z),B_stable(z),m,phi),tspan,Number_stable
,options);
[t F_1] =
ode45(@(t,f)CSD(t,f,Growth_metastable(z),Dissolution_metastable(z),B_metastable(z),m,phi),tspan,N
umber_metastable,options);
if (result(end,1)<=0 || result(end,2)<=0 || result(end,3)<=0 || result(end,4)<=0 ||
result(end,10)<=0)
ff_1 = 0;
%
ff = 0;
ff = F(end,:)./phi;
elseif (result(end,5)<=0 || result(end,6)<=0 || result(end,7)<=0 || result(end,8)<=0 ||
result(end,11)<=0)
ff = 0;
%
ff_1 = 0;
ff_1 = F_1(end,:)./phi;
else
%
ff = 0;
%
ff_1 = 0;
ff = F(end,:)./phi;
ff_1 = F_1(end,:)./phi;
end
CSD_stable(1:m,z) = ff;
CSD_metastable(1:m,z) = ff_1;
f0 = CSD_stable(1:m,z);
f0_1 = CSD_metastable(1:m,z);
Mass_stable_form_produced(z) = rho_stable/rho_solvent*kv_stable*1000*result(end,8);
Mass_unstable_form_produced(z) = rho_unstable/rho_solvent*kv_unstable*1000*result(end,4);
z=z+1;
end
cputime_MOMC = toc;
Mass_balance = C_0 + Mass_of_Alpha_seed + Mass_of_Beta_seed - (Mass_unstable_form_produced(end) +
Mass_stable_form_produced(end) + result(end,9));
crystallizer_MOMC =[Mass_of_Alpha_seed ; Mass_unstable_form_produced(end) ; Mass_of_Beta_seed ;
Mass_stable_form_produced(end) ; Mass_balance ; cputime_MOMC ];
ANS = [MIU_OF_PARTICLES [crystallizer_MOMC;zeros(a-5,1)] result CSD_metastable' CSD_stable'
Mass_stable_form_produced' Mass_unstable_form_produced' T'];

C.2. Equations governing the polymorphic crystallization process
function dN =
batch_sim1(t,N,T,rho_crystal,alpha_v,rho_crystal_1,alpha_v_1,rho_solvent,kb1,kb2,kbb1,kbb2,kb_1,k
bb_1,kd,kd_1,kg1,kg2,kg_1,g_1)
dN = zeros(25,1);
%---- N(m+1) = zeroth moment for Alpha phase, metastable
dN(1) = 0;
dN(2) = -1*Dissolution_1(kd_1,T,N(9))*N(1) + 1*growth_1(kg_1,g_1,T,N(9))*N(1);
%---- First
moment for Alpha phase, metastable
dN(3) = -2*Dissolution_1(kd_1,T,N(9))*N(2) + 2*growth_1(kg_1,g_1,T,N(9))*N(2);
%---- Second
moment for Alpha phase, metastable
dN(4) = -3*Dissolution_1(kd_1,T,N(9))*N(3) + 3*growth_1(kg_1,g_1,T,N(9))*N(3);
%---- Third
moment for Alpha phase, metastable
dN(10) = -4*Dissolution_1(kd_1,T,N(9))*N(4) + 4*growth_1(kg_1,g_1,T,N(9))*N(4);
%---- Fourth
moment for Alpha phase, metastable
dN(22) = -5*Dissolution_1(kd_1,T,N(9))*N(10) + 5*growth_1(kg_1,g_1,T,N(9))*N(10);
%---- Fifth
moment for Alpha phase, metastable
dN(5) =

0;

%---- N(m+1) = zeroth moment, stable
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dN(6) = 1*growth(kg1,kg2,T,N(9))*N(5) - 1*Dissolution(kd,T,N(9))*N(5);
%---- First moment for
Beta phase, stable
dN(7) = 2*growth(kg1,kg2,T,N(9))*N(6) - 2*Dissolution(kd,T,N(9))*N(6);
%---- Second moment
for Beta phase, stable
dN(8) = 3*growth(kg1,kg2,T,N(9))*N(7) - 3*Dissolution(kd,T,N(9))*N(7);
%---- Third moment for
Beta phase, stable
dN(11) = 4*growth(kg1,kg2,T,N(9))*N(8) - 4*Dissolution(kd,T,N(9))*N(8);
%---- Fourth moment
for Beta phase, stable
dN(23) = 5*growth(kg1,kg2,T,N(9))*N(11) - 5*Dissolution(kd,T,N(9))*N(11);
%---- Fifth moment
for Beta phase, stable
%-----------------------------------------------------dN(9) = -3*1000/rho_solvent*rho_crystal_1*alpha_v_1*growth_1(kg_1,g_1,T,N(9))*(N(3)+N(14)) +
3*1000/rho_solvent*rho_crystal_1*alpha_v_1*Dissolution_1(kd_1,T,N(9))*(N(3)+N(14)) 3*1000/rho_solvent*rho_crystal*alpha_v*growth(kg1,kg2,T,N(9))*(N(7)+N(19)) +
%---- N(m+5) =
3*1000/rho_solvent*rho_crystal*alpha_v*Dissolution(kd,T,N(9))*(N(7)+N(19));
Concentration
%-----------------------------------------------------dN(12)
dN(13)
moment
dN(14)
Second
dN(15)
moment
dN(16)
Fourth
dN(24)
moment

%---= Birth_1(kb_1,T,N(9),kbb_1);
= -1*Dissolution_1(kd_1,T,N(9))*N(12)
for Alpha phase, metastable
= -2*Dissolution_1(kd_1,T,N(9))*N(13)
moment for Alpha phase, metastable
= -3*Dissolution_1(kd_1,T,N(9))*N(14)
for Alpha phase, metastable
= -4*Dissolution_1(kd_1,T,N(9))*N(15)
moment for Alpha phase, metastable
= -5*Dissolution_1(kd_1,T,N(9))*N(16)
for Alpha phase, metastable

dN(17) =
dN(18) =
for Beta
dN(19) =
for Beta
dN(20) =
for Beta
dN(21) =
for Beta
dN(25) =
for Beta

N(m+1) = zeroth moment for Alpha phase, metastable
+ 1*growth_1(kg_1,g_1,T,N(9))*N(12);
%---- First
+ 2*growth_1(kg_1,g_1,T,N(9))*N(13);

%----

+ 3*growth_1(kg_1,g_1,T,N(9))*N(14);

%---- Third

+ 4*growth_1(kg_1,g_1,T,N(9))*N(15);

%----

+ 5*growth_1(kg_1,g_1,T,N(9))*N(16);

%---- Fifth

%---- N(m+1) = zeroth moment, stable
Birth(kb1,kb2,T,N(9),kbb1,kbb2,(N(14) + N(3)));
1*growth(kg1,kg2,T,N(9))*N(17) - 1*Dissolution(kd,T,N(9))*N(17);
%---- First moment
phase, stable
2*growth(kg1,kg2,T,N(9))*N(18) - 2*Dissolution(kd,T,N(9))*N(18);
%---- Second moment
phase, stable
3*growth(kg1,kg2,T,N(9))*N(19) - 3*Dissolution(kd,T,N(9))*N(19);
%---- Third moment
phase, stable
4*growth(kg1,kg2,T,N(9))*N(20) - 4*Dissolution(kd,T,N(9))*N(20);
%---- Fourth moment
phase, stable
5*growth(kg1,kg2,T,N(9))*N(21) - 5*Dissolution(kd,T,N(9))*N(21);
%---- Fifth moment
phase, stable

C.3. CSD generation for each polymorph
function df = CSD(t,f,G,D,B,m,phi)
%--%--%--df =

the first size is L0 and the last is Ln.
if the number of class sizes are m, then each class size (phi) would
be (Ln-L0)/m
zeros(m,1);

df(1) = -(G)/(2*phi)*f(1) + D/(2*phi)*f(2) - D/(2*phi)*f(1) + B;
for i=2:m-1
df(i) = -(G)/(2*phi)*f(i) - (D)/(2*phi)*f(i) + G/(2*phi)*f(i-1) + D/(2*phi)*f(i+1);
end
df(m) = -(D)/(2*phi)*f(m) - G/(2*phi)*f(m) + G/(2*phi)*f(m-1);

C.4. Seed size distribution of both polymorphs
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function CSD = seed_csd(lamda,sigma,miu,m,L0,LN)
phi = (LN-L0)/m;
z = 1;
for L=(L0+phi/2):phi:(LN-phi/2)
CSD(z) = lamda/((2*pi)^.5*sigma)*exp(-(L - miu)^2/(2*sigma^2));
z = z + 1;
end

C.4. Birth, growth, and dissolution of the stable polymorph
function B = Birth(kb1,kb2,T,C,kbb1,kbb2,moment_2_met)
C_star = solubility(T);
B = kb1.*(abs(C./C_star)).^(7/3).*exp(-kbb1/(log(C./C_star)).^2) + kb2.*moment_2_met.*exp(kbb2./(log(C./C_star)));

function G = growth(kg1,kg2,T,C)
C_star = solubility(T);
G = kg1.*abs(C./C_star-1).^(5/6).*exp(-kg2./(abs(C./C_star-1)));

function D = Dissolution(kd,T,C)
C_star = solubility(T);
D = kd.*(abs(C./C_star-1));

C.5. Birth, growth, and dissolution of the metastable polymorph
function B = Birth_1(kb_1,T,C,kbb_1)
C_star_1 = solubility_1(T);
B = kb_1.*(abs(C./C_star_1)).^(7/3).*exp(-kbb_1./(log(C./C_star_1)).^2);
function G = growth_1(kg_1,g_1,T,C)
C_star_1 = solubility_1(T);
G = kg_1.*abs(C./C_star_1-1).^(5/6).*exp(-g_1./(abs(C./C_star_1-1)));
function D = Dissolution_1(kd_1,T,C)
C_star_1 = solubility_1(T);
D = kd_1.*(abs(C./C_star_1-1));

C.6. Solubility of both polymorphs
function C_star = solubility(T)
C_star = 7.644*10^-3.*T.^2 - 1.165*10^-1.*T + 6.222;
function C_star = solubility_1(T)
C_star = 8.437*10^-3.*T.^2 + 3.032*10^-2.*T + 4.564;

C.7. Optimal process calculation
%--------- Kinetic parameters for stable polymorph
KB1 = 5.4*10^4;
KB2 = 6*10^4;
KBB1 = 15;
KBB2 = 0.001;
KD = 0;
ID = 0;

170

KG1 = 6.5*10^-8;
KG2 = 0.16;
%--------- Kinetic parameters for metastable polymorph
KB_1 = 8*10^5;
KBB_1 = 0.1;
KG_1 = 2.5*10^-7;
G_1 = 0.09;
KD_1 = 2*10^-8;
%--------- Seeding parameters for stable poylmorph
lamda_1 = 1*10^10;
sigma_1 = 2*10^-6;
miu_1 = 40*10^-6;
k_v_stable = 0.031;
rho_stable = 1540;
%--------- Seeding parameters for metastable poylmorph
lamda_2 = 5*10^10;
sigma_2 = 2*10^-6;
miu_2 = 40*10^-6;
k_v_metastable =.48;
rho_metastable = 1540;

run_time = cputime;
%--------- Initial condition and segment numbers in length and time domain
L0 = 0;
LN = 100*10^-6;
m = 300;
a = 40;
Ostwald_Factor = 1;
rho_solvent = 996;
T_0 = 45;
t_batch = 4; %--- hours
initial_concentration = 20; %--- gr/kg
delta_t = t_batch/a;
time = 0:delta_t:t_batch;
phi = (LN - L0)/m;
L = L0 + phi/2:phi:LN - phi/2;
L = L.*10^6;
lb = [20 , 20, 0, 0, 0];
ub = [T_0, 20, a, 5, 5];
for i=1:a-1
for j=1:a
if j == i
A(i,j) = -1;
elseif j == i+1
A(i,j) = 1;
else
A(i,j) = 0;
end
end
end
for i=a:2*a-2
for j=1:a
if j == i - a + 1
A(i,j) = -1;
elseif j == i+1-a + 1
A(i,j) = 1;
else
A(i,j) = 0;
end
end
end
b = [R_max*ones(a-1,1);-R_min*ones(a-1,1)];
b = R_max*ones(a-1,1);
x0 = [T_F1, T_F2, S, U, U_1];
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[x,fval] = fmincon(@(x)(1).*objective_1(x(1),x(2),x(3),x(4),x(5),a,m,L0,LN,Ostwald_Factor,lamda_1,lamda_2,sigma_1,sigma_2
,miu_1,miu_2,rho_stable,rho_metastable,rho_solvent,...
k_v_stable,k_v_metastable,initial_concentration,T_0,t_batch,KB1,KB2,KBB1,KBB2,KB_1,KBB_1,KD,ID,KD
_1,KG1,KG2,KG_1,G_1),x0,[],[],[],[],lb,ub);
AA =
batch_crystal(x(1),x(2),x(3),x(4),x(5),a,m,L0,LN,Ostwald_Factor,lamda_1,lamda_2,sigma_1,sigma_2,m
iu_1,miu_2,rho_stable,rho_metastable,rho_solvent,...
k_v_stable,k_v_metastable,initial_concentration,T_0,t_batch,KB1,KB2,KBB1,KBB2,KB_1,KBB_1,KD,ID,KD
_1,KG1,KG2,KG_1,G_1);
Conc(1,:) = AA(:,9);
Mass_met(1,:) = AA(:,end);
Mass_st(1,:) = AA(:,end-1);
phi = (LN - L0)/m;
L = L0 + phi/2:phi:LN - phi/2;
for i = 1:a
if (i<=x(3))
T(i) = T_0 - (T_0 - x(1))*(delta_t*i/(delta_t*x(3)))^x(4);
else
T(i) = x(1) - (x(1) - x(2))*(delta_t*(i-x(3))/(t_batch-delta_t*x(3)))^x(5);
end
end
T = real([T_0 T]);
time = 0:delta_t:t_batch;
phi = (LN - L0)/m;
L = L0 + phi/2:phi:LN - phi/2;
L = L.*10^6;
figure(1)
plot(time,solubility(T),'-o',time,solubility_1(T),'--',time,Conc);
title('concentration');
figure(2)
plot(time,Mass_st,time,Mass_met,'--');
title('Mass');
figure(3)
plot(time,AA(1:end,32)./AA(1:end,31).*10^6);
figure(4)
plot(L,AA(1,end-m-1:end-2));
toc;
run_time = cputime - run_time;
run_time = run_time/60;

172

Resume

Surname: Sheikholeslamzadeh
Name: Ehsan

Objective Summary
• Chemical and environmental process design, analysis, and optimization
• Chemical waste management and recovery process design
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•
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Software and Other Skills
•
•
•
•
•
•
•
•
•

Excellent knowledge of simulation and HAZOP study software (Aspen Dynamics, Aspen Zyqad,
Aspen Hysys, Aspen Properties, Aspen B-JAC, Pro II)
Excellent knowledge of software for preparation of documents and reports (MS-Word, MSExcel, MS-PowerPoint, MS-Visio, MS-Access, Autocad P&ID and Plant3D, Minitab)
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•
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•
•
•

•
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174

Journal Publications and Conference Presentations
•

•
•

•
•

•

•

•

Sheikholeslamzadeh E., Rohani S. “Solubility Prediction of Pharmaceutical and Chemical
Compounds in Pure and Mixed Solvents Using Predictive Models”. Ind. Eng. Chem. Res. 2012, 51
(1), 464–473.
Sheikholeslamzadeh E., Rohani S. “Vapour-liquid and vapour-liquid-liquid equilibrium modeling
for binary, ternary, and quaternary system of solvents”. Fluid Phase Equilib. 2012, 333, 97-105.
Sheikholeslamzadeh E., Chen C.-C., Rohani S. “Optimal Solvent Screening for the Crystallization
of Pharmaceutical Compounds from Multisolvent Systems”. Ind. Eng. Chem.Res. 2012, 51 (42)
13792-13802.
Sheikholeslamzadeh E., Rohani S. “Modeling and Optimal Control of Solution Mediated
Polymorphic Transformation of L-glutamic Acid”. Ind. Eng. Chem. Res. 2013, 52 (7) 633-2641.
Sheikholeslamzadeh E., Rohani S. “Modeling and Optimization of the Polymorphic
Transformation Process using the Novel MoMC Method”, 61st Canadian Chemical Engineering
Conference, London, ON, Canada, 2011.
Sheikholeslamzadeh E., Rohani S. “Thermodynamic Modeling and Experimental Study of
Solubility of the Chemical and Pharmaceutical Compounds”, 61st Canadian Chemical
Engineering Conference, London, ON, Canada, 2011.
Sheikholeslamzadeh E., Rahimpour M.R. “A comparison between co-current and countercurrent
flows in mega-methanol reactor”, 11th national congress of chemical engineering, Tehran,
Iran,Tarbiat moddarres university, 2006.
Sheikholeslamzadeh E., Rahimpour M.R. “Catalyst deactivation in autothermal megamethanol
reactor” 11th national congress of chemical engineering, Tehran, Iran,Tarbiat moddarres
university, 2006.

Other Activities
•
•
•

Technical program chair of the particle technology research centre (PTRC) and 61th Canadian
Chemical Engineering Conference member, London, Ontario, Canada, Oct. 2011.
Member of Canadian Society for Chemical Engineers (CSChE).
Member of CGS (chemical graduate society) of graduate students of the University of Western
Ontario

Honors
• Recipient of Western Graduate Research Scholarship and NSERC (Natural Sciences and
Engineering Research of Canada) grant, since Sep. 2009.
• Rank 3rd in the national entrance exam of M.Sc. program, Iran, 2006.
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